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Abstract 
 
Cefuroxime axetil (CFA) is a broad spectrum second generation Cephalosporin antibiotic, active 
against a wide range of common pathogens, including many β-lactamse producing strains. The 
drug is marketed as powder for oral suspension and tablet dosage forms. CFA extreme bitterness 
limits its use in a wide spectrum of patients. Administration of CFA in a suppository dosage 
form may be a useful alternative to oral route and convenient for infants, children and the elderly 
who find it difficult to swallow tablets or taste the extremes bitterness of the suspension dosage 
form. This study aims in formulating and evaluating suppositories containing Cefuroxime axetil 
for pediatric use. CFA suppositories were formulated by the fusion method using two main types 
of suppository basses; water soluble and fatty bases. PEG bases were used as the water soluble, 
while Witepsol H15 and Novata (A & BCF) were used as the fatty bases. The PEG water soluble 
bases were excluded from the study as they were found incompatible with CFA. Witepsol H15 
was used in the study formulations as it showed better CFA release and lower melting points 
when compared with those formulated by using Novata bases. Suppositories were evaluated for 
physical appearance, uniformity of weight, disintegration time, drug content, in-vitro dissolution 
study and stability studies. 
The rate and extent of CFA release from formulations prepared using fatty bases were influenced 
by the physicochemical properties such as melting range value. The drug partitioning appeared to 
favor the lipid phase and had a negative impact on CFA release characteristics. 
Sixteen formulations were prepared for the study. Surfactants and melting range modifiers (i.e. 
Tween 20, Tween 85, SLS, Lanolin Anhydrous and Lecithin S) were added in different 
percentages and combinations, and as a result they significantly increased CFA release from the 
formulations they were prepared with. 
The mechanism of drug release was evaluated using several mathematical models, including the 
Higuchi, Korsemeyer-Pappas, zero ordered, first order and Weibull models. CFA release kinetics 
were best described by the Weibull, Korsemeyer-Peppas and Higuchi model, and the values of 
the release exponent, n, revealed that the drug release was a consequence of the combined effects 
XIX 
of CFA diffusion, rate of melting of the base and partitioning of the drug which can be 
considered to be anomalous release. 
Stability studies were conducted at three conditions (i.e. 25
o
C/60%RH, 30
o
C/60% RH and 2–
8
o
C) for the selected representative formulations; indicated that they are more stable at 
refrigerator conditions (2-8
o
C) and most of them showed instability at 25
 o
C and 30
o
C storage 
conditions. 
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1.1 Rectal dosage forms 
Suppositories are solid dosage forms of varying weight and shape, intended for the 
administration of medicines via the rectum, vagina, or urethra for local or systemic drug delivery 
(David, 2008). They consist of a dispersion of an active ingredient in an inert matrix, which is 
generally composed of a rigid or semi-rigid base (Lieberman, et al, 1998). These dosage forms 
melt, soften or dissolve in the relevant body cavity prior to releasing the active ingredient (Abate, 
et al, 2005). Rectal suppositories are conventionally bullet, torpedo or conically-shaped with a 
rounded apex. Suppositories can be used to administer drugs for use as protectants or for 
palliative care of local tissues at the point of introduction or as a carrier for therapeutic agents 
where they are intended to exert localized or systemic effects (David, 2008). 
Suppositories are either used for local action or systemic action. The type of action desired and 
the type of suppository must be considered when formulating suppositories, as the base exerts a 
marked influence on the release and action of drug. If systemic actions are desired, the 
suppository should melt or dissolve rapidly and release the drug readily (Aulton, 2002). 
The use of the rectal route for drug administration is certainly not the route of first choice due to 
poor patient acceptability and psychological biases (Bergogne, Bryskier, 1999). However, the 
use of rectal delivery is often appropriate in situations where a patient is unwilling or unable to 
make use of the oral route of drug administration. This may occur in cases where the 
administration of a drug via the oral route results in intolerance, nausea and vomiting or 
associated gastric pain (Bolognia, et al, 1996). In addition, in cases where patients are 
uncooperative, unconscious or lack lucidity or when access to the intravenous route is 
compromised, as is the case, for example, with children or patients in intensive care units. Rectal 
dosing may also be of value in achieving appropriate therapeutic outcomes for patients needing 
multiple drug therapy or continuous intravenous fluid infusion, where treatment is difficult or 
when there are few undamaged veins available for catheterization (Bergogne, Bryskier, 1999). 
The abundant supply of blood vessels and rapid diffusion of drugs through the rectal mucosa 
permits rapid absorption of many drugs which make the rectum a convenient route for systemic 
administration of drug. Many classes of medicaments appear to be well absorbed (e.g. 
antinauseants, tranquilizers, vasodilators, vasoconstrictors, bronchodilators, sedatives, analgesic 
etc.). 
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Local medication of the anal region is employed most often in the treatment of hemorrhoids; 
however these are used for other conditions such as bacterial infection and chronic inflammation 
(e.g. Local anesthetics, astringents, antiseptics and various anti- bacterial agents) (Aulton, 2002). 
The ideal suppository should be easy to administer without pain on insertion and should remain 
at the administration site for a reasonable period of time. Conventional solid suppositories often 
give patients a feeling of alien discomfort and subsequently their refusal to use such delivery 
devices may lead to poor patient compliance. Furthermore, if the solid suppositories lack 
sufficient muco-adhesivity, they may traverse up the rectal cavity and reach the end of the colon, 
with the result that the drug delivered in this area may be absorbed into the venous blood system, 
thereby increasing the potential for the compound to undergo hepatic first-pass metabolism, the 
avoidance of which is one of the potential advantages of suppository use (De Boer G.A., et al, 
1982). 
Antibiotics are usually administered either orally or by a parenteral route, the latter being used 
for drugs that are poorly or not bioavailable by the oral route or when clinical situations require 
rapid or higher antibiotic concentrations to be achieved in the body. The rectal route of antibiotic 
administration is seldom mentioned in experimental and clinical pharmacokinetic studies and the 
characteristics of administration of antibiotics by suppository are poorly documented. 
There are signiﬁcant differences between countries in terms of the acceptability of suppositories 
by patients, but, in some populations, rectal drug delivery could represent a convenient, 
alternative route of antibiotic administration when other routes are not available. (Bergogne, 
Bryskier, 1999) 
1.2 Advantages and disadvantages of rectal dosage forms 
Rectal dosage forms have the following advantages (David, 2008): 
 They may be successfully employed to provide a local effect for the treatment of 
infection and inflammation, e.g. hemorrhoids, proctitis. 
 They are used to promote evacuation of the bowel (by irritating the rectum), to   relieve 
constipation or to cleanse the bowel prior to surgery. 
 They may be employed to provide systemic drug absorption in situations where oral drug 
absorption is not recommended. Examples of such applications include: 
– patients who are unconscious, e.g. in intensive care or who are postoperative 
– patients who are vomiting, e.g. gastrointestinal infection, migraine 
 4 
– gastro irritant drugs, e.g. non-steroidal anti-inflammatory agents, particularly in 
chronic usage 
– drugs that are prone to degradation in the stomach 
– drugs that are erratically absorbed from the upper gastrointestinal tract 
 They may be employed to provide local treatment of diseases of the colon, e.g. Crohn’s 
disease, ulcerative colitis. 
 Their administration is easily performed by the patient. 
Disadvantages of rectal dosage forms include: 
 In certain countries, especially the USA and the UK, the rectal dosage forms are 
generally unpopular, especially for systemic administration of therapeutic agents, 
whereas the opposite is true in European countries. 
 Specialist advice is required concerning the administration of dosage forms. 
 The absorption of therapeutic agents from the rectum is slow and prone to large 
intrasubject and intersubject variability. The presence of feces within the rectum 
considerably affects both the rate and extent of drug absorption. 
 Rectal administration of therapeutic agents may result in the development of local side-
effects, in particular proctitis. 
 The industrial manufacture of suppositories is more difficult than for other common 
dosage forms. 
1.3 Physiology and anatomy of the rectum  
 A diagrammatic representation of the gastrointestinal tract, featuring the rectum, is shown in 
Figure (1.1). The main physiological features of the rectum that are related to drug delivery and 
hence to the formulation of rectal products are as follows (David, 2008): 
 The length of the rectum is about 15–20 cm. The rectum is joined to the sigmoid colon at 
the top and to the anus. 
 The rectum is divided into two sections: (1) the anal canal; and (2) the ampulla. The 
ampulla is the larger of the two sections (approximately four times larger than the anal 
canal). Feces are stored in the ampulla and excreted through the anus (a circular muscle) 
via the anal canal. 
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 There are three separate veins in the rectum: upper haemorroidal vein that drains into the 
portal vein, which flows to the liver, middle and lower haemorroidal veins that drain 
directly into the general circulation (Figure1.2). 
 The wall of the rectum is composed of an epithelial layer that is one cell thick. Two 
cellular types exist: (1) cylindrical cells; and (2) goblet cells – the latter are responsible 
for the secretion of mucus. There are no villi (or microvilli). 
 When empty the rectum contains about 3 ml of mucus, spread over a rectal surface area 
of approximately 300 cm
2
. 
 The pH within the rectum is essentially neutral with minimal buffering capacity 
(approximately 7.5 for mucous layer). Therefore, due to the inability of the fluids within 
the rectum to alter the degree of ionisation, the salt form of the drug is an important 
determinant of the resulting local efficacy and/or systemic absorption. The presence of 
fecal matter will markedly affect both the dissolution of the drug in the rectal fluids and 
the subsequent absorption of the drug into the systemic circulation. 
 The fate of the absorbed drug is dependent on the area of the rectum from which 
absorption has occurred. Drugs that are absorbed into the inferior and middle 
haemorrhoidal veins will enter the circulation via the inferior vena cava and will 
subsequently avoid direct exposure of the drug to, and hence metabolism by, the liver. 
Absorption into the upper (superior) haemorrhoidal vein will result in entry into the liver 
(and subsequent metabolism) via the portal vein. 
 There are no esterases or peptidases in the rectal fluid. 
 Local muscle activity within the rectal wall may influence the rate of dissolution of solid 
dosage forms within the rectum, i.e. suppositories. 
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Figure 1.1 Diagrammatic representation of the gastrointestinal tract, with particular emphasis on 
the rectum (David, 2008). 
 
 
 
Figure 1.2 Diagrammatic representation of blood flow into and from the rectum (Stephen W. 
Hoag, 2002). 
 
Since many experimental studies of rectal drug administration are performed in animals, it is 
necessary to note the differences in structure between human and animal rectums. In most animal 
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species, histological analysis reveals more goblet cells in the rectal mucosa than in the colon; in 
rats and rabbits there are many lymph nodes in the lamina propria and submucosa. 
The mucosa is also thrown into several longitudinal folds containing large veins: this structure 
seems favourable to local absorption of drugs. A rapid colorectal cell turnover has also been 
described, potentially stimulated by chemicals such as ethanol or isoenergetic carbohydrates but 
such response has not always been discussed in studies of antibiotic administration in rats or 
rabbits (Bergogne, Bryskier, 1999). 
1.4 Rectal absorption 
The mechanism of absorption of systemically active drugs from the rectum involves drug release 
from the suppository into the rectal cavity, diffusion of the drug through rectal fluids to the rectal 
mucosa, followed by absorption across the rectal tissues and subsequent transport into the 
general circulation. The mechanism of absorption is similar to that occurs in the gastrointestinal 
tract, which in turn involves two main routes of penetration, the transcellular and paracellular 
routes. The transcellular route involves absorption of drugs across epithelial cells whereas the 
paracellular route involves absorption of drugs via the interconnecting tight junctions between 
mucosal cells (Toshiaki N., Rytting J.H., 1997). The rectal absorption of drugs is governed 
largely by the general principles of transfer of drugs. Depending on their chemical structure, 
drugs may cross the rectal wall either by absorption across the epithelial cell (transcellular) or via 
the tight junctions interconnecting the mucosal cells (paracellular). (Bergogne, Bryskier, 1999) 
Following absorption from the rectum, the therapeutic agent enters the haemorroidal veins. 
Blood from the upper haemorroidal vein enters the portal vein, which flows into the liver, where 
drug metabolism occurs. Conversely, blood in the middle and lower haemorroidal veins enters 
the general circulation (David, 2008). 
1.4.1. Factors affecting drug availability from suppositories 
Several local factors may inﬂuence absorption in the rectum: the mucous layer, the variable 
volume of rectal ﬂuid, the basal cell membrane, the tight junctions and the intracellular 
compartments may each constitute local barriers to drug absorption, depending on histological 
factors and on the molecular structure of the administered drug. The pharmaceutical formulation, 
therefore, may play a major role in the rectal absorption and consequently in the systemic 
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distribution and pharmacokinetics of drugs administered via suppository (Bergogne, Bryskier, 
1999). 
Rectal absorption and systemic distribution of a rectally administered drug may be influenced 
directly by the formulation composition, in addition to physiological factors. These factors relate 
specifically to the volume and composition of the rectal fluids and the associated environment, 
the physicochemical properties of the drug substance in addition to the physicochemical 
properties of the suppository base from which the drug is to be delivered (De Boer G.A., et al, 
1982). The factors affecting rectal absorption of a drug administered in suppository formulations 
are summarised in Table 1.1   
 
Table 1.1:  Summary of the factors affecting drug availability from suppositories  
 
Physiological Factors  API Formulation Parameters 
Buffer capacity  Solubility Composition 
Rectal fluid volume  Surface properties Melting behavior 
Surface tension  Particle size Rheological properties 
Composition  Drug concentration Surface tension 
Motility of the rectal wall  
 
Partition coefficient 
pKa and the degree of 
ionization 
 
 
1.4.1.1 Physiological factors  
The diffusivity of a drug is influenced by its physicochemical nature, the physiological state of 
the colon and rectum, including the amount and nature of fluid and solids present. 
In the absence of faecal matter, an administered drug will have a greater potential to make 
contact with the mucosal surfaces of the rectum from which absorption will take place. The 
membranous wall of the rectum is covered with a continuous relatively viscous mucous blanket, 
which acts as a mechanical barrier to the free passage of a drug through the epithelial wall 
(David, 2008).  
The rectum has a relatively small surface area available for drug absorption (About 200 to 
400cm
2
) compared to the small intestine. The rapidity and intensity of the therapeutic effects of 
suppositories are related to the surface area of the rectal mucous membrane covered by the 
melted base-drug mixture (the spreading capacity of the suppositories). This spreading capacity 
may be related to the presence of surfactants in the base (David, 2008). 
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 The positioning of a suppository in the rectum is critical in terms of the potential for exposure of 
a drug to liver enzymes following absorption and subsequent metabolism. A drug that is 
absorbed into the systemic circulation via the inferior or middle rectal veins will bypass the liver, 
resulting in a higher bioavailability than one transported by the superior vein to the liver via the 
hepatic portal system, prior to its entry into the systemic circulation (De Boer G.A., et al, 1982).  
The pH of the rectal fluids also plays a significant role in drug absorption and is often a rate-
controlling step in rectal drug absorption. Rectal fluids have virtually no buffering capacity and, 
as a consequence, the characteristics of dissolved drugs will to a large extent determine the pH 
that prevails in the anorectal area following administration. It had been demonstrated that the 
intra-luminal pH of the rat colon can affect the absorption of acidic and basic drugs and that the 
unionized form of a drug is preferentially permeable. Thus the absorption of basic drug will be 
more favorable from rectal fluids, since it would be largely unionized and remain unionized at 
rectal pH, which is approximately 7.2. Therefore, it can be suggested that ionized substances that 
are lipid-insoluble will be poorly absorbed through rectal tissues (Lachman, et al, 1986). 
 
1.4.1.2 Physicochemical characteristics of the drug and base affecting absorption:  
1.4.1.2.1 Drug solubility:   
 The solubility of an API in the vehicle to be used as the suppository base determines whether the 
product that is produced is either a solution or suspension formulation and the solubility of a 
drug in the rectal fluid will determine the maximum attainable concentration possible, in the 
rectum, and consequently the driving force for the absorption process (Aulton, 2002) .  
If a drug has a high oil to water partition coefficient and the base of choice is a fatty material, the 
API will primarily be in solution in the base. Therefore the ability or tendency of the drug to 
leave the vehicle will be low and the subsequent release rate into the rectal fluids will be slow 
(Aulton, 2002).  
1.4.1.2.2 Partition coefficient   
Drug absorption from the rectum is a consequence of the partitioning of a dissolved drug from a 
molten base into the rectal fluids and from the rectal fluids to the rectal mucosa, in addition to 
the rate of solution of the drug in the body fluids. It has been suggested that penetration of a drug 
through the barrier phase or epidermal mucosa of the rectum is proportional to the permeability 
constant of the drug, which is a complex constant taking into account factors such as transfer of 
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drug from the base to the barrier phase and diffusion of a drug through the barrier membrane. 
The transfer of a medicament from a base is related to the solubility of the medicaments in that 
base, whereas diffusion through the barrier membrane is related to the lipid/water partition 
coefficient of the drug between those fluids (Abate, et al, 2005).  
 1.4.1.2.3 Particle size:   
When the formulation is composed of an API that has been dispersed in the appropriate 
formulation base/vehicle, e.g. a hydrophilic drug dispersed in a lipophilic base or vice versa, the 
rate of dissolution of the drug is inversely proportional to the particle size of the dispersed active 
agent (David, 2008). However, size reduction and the use of a smaller particle size does not 
necessarily ensure higher blood levels, as the drug release process is relatively complex and 
involves the melting and spreading of the base, in addition to the wetting, sedimentation and 
dissolution of the drug (Herman, 1995).  
 1.4.1.2.4 Surface properties:   
If wetting of the API by the vehicle or base does not occur, powder particles may agglomerate, 
which in turn may affect the uniformity of dispersion of the API, due to the increased tendency 
for the agglomerated powder to sediment prior to the setting of the suppository. In order to 
reduce the surface effects of poorly wettable API’s, the addition of a surfactant to a formulation 
will more than likely improve the wetting of the API and subsequently the facilitate dissolution 
of the drug in the suppository and in the rectal fluids (Aulton, 2002). 
1.4.1.2.5 Nature of the base: 
The base must be capable of melting, softening, or dissolving to release its API for absorption. If 
the base interacts with the API inhibiting its release, then drug absorption will be impaired or 
even prevented. Also, if the base is irritating to the mucous membranes of the rectum, then it 
may initiate a colonic response and a bowel movement that results incomplete API release and 
absorption (David, 2008). 
1.4.2 Enhancement of rectal absorption 
The rate at which the drug diffuses into the rectal mucosa is influenced by the physicochemical 
relationship that exists between a drug, the rectal fluids, the suppository base and the membranes 
of the rectal cavity. Drug absorption from a suppository formulation can be modulated by the 
incorporation of absorption or permeation enhancers into the dosage form. The derivatives of 
amino acids, surfactants, fatty acids derivatives, and carboxylic acid derivatives have been 
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reported to act as effective absorption or penetration enhancers for rectally administered 
compounds (Toshiaki, Rytting, 1997). 
The addition of adjuvant to a formulation can affect drug absorption by changing the rheological 
properties of the base at body temperature or by altering the dissolution rate of a drug in the 
rectal fluids. The safety, efficacy and compatibility of a drug and/or base with absorption 
enhancers must be established during pre formulation studies since the addition of an absorption 
enhancer may either reduce or increase drug release rates, depending on the nature of the 
enhancer, base and drug to be incorporated into a specific formulation (Lachman, et al , 1986).   
The promoting effect of sodium salts of saturated straight chain fatty acids on the rectal 
absorption of ampicillin and of ceftizoxime has been conﬁrmed in mice, rats, rabbits and dogs 
with bioavailability rates higher in mice and rabbits(76–100%) than in dogs (28.9% and 42% for 
ampicillin and ceftizoxime, respectively. The fatty acid used in the latter study and in others was 
sodium caprate, a carboxylic acid sodium salt, which improved the rectal absorption of poorly 
absorbed drugs such as lactams. Several other fatty acid salts, e.g. sodium capronate, sodium 
caprylate and sodium palmitate, also improved the absorption of ampicillin but the best 
absorption-promoting effect was exhibited by sodium caprate, with satisfactory bioavailability of 
71.3% and 64.2% for ampicillin and piperacillin, respectively. In the same study, the 
bioavailability of cephalosporin generally ranged between 60.6% (cefotiam) and 92.4% 
(cefazolin), with lower bioavailability for cefpiramide (26.2%) and cefoperazone (27.5%). It 
seems likely that the absorption-promoting effect on lactams is stronger for antibiotics of smaller 
molecular size. Various other absorption promoters have been used in experiments in animals. 
For example, Witepsol H-15, a saturated triglyceride, has been used in suppositories of 
bacampicillin and compared with the same formulation of ampicillin. For the rectal 
administration of latamoxef in rats, the release rates from suppositories containing Witepsol H-
15 only, or with the addition of Tween 80 (1%), with or without diclofenac sodium, a non-
steroidal antiinﬂammatory drug, were compared. It was shown that the latter additions 
signiﬁcantly increased the rectal absorption of latamoxef, with bioavailability as high as 72%. 
Several other studies in animals of the suppository route of administration of amino glycosides 
have used similar preparations, with triglycerides (Witepsol H-15 or H-42) for gentamicin11 or 
with medium-chain glycerides (Capmul) for gentamicin and tobramycin rectal administration, 
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resulting in enhanced absorption of amino glycosides which are otherwise poorly absorbed 
(Bergogne, Bryskier, 1999). 
1.5 Formulation of suppositories 
The typical weight range for suppositories is 1–4 grams, with the 2-gram suppository being the 
commonly used size. The smallest suppositories are mainly reserved for use in children, whereas 
the largest size may be administered to adults, e.g. glycerin suppositories that are used to relieve 
constipation in adults. Suppositories are tapered at one end (to aid insertion) and are frequently 
wider in the middle before tapering towards the other end (thereby aiding retention in the rectum 
and enabling the suppository to be pressed forward by the anal sphincter). The drug loading of 
suppositories ranges from 0.1 to 40% w/w. In general, suppositories are composed of an inert 
base into which the therapeutic agent is incorporated (dissolved/dispersed) (David, 2008). 
 
                                   
            Figure 1.3 Examples of the different shapes and sizes of suppositories (David, 2008). 
1.5.1 Suppository bases:     
Suppository bases are usually classified, according to their physical and chemical characteristics, 
into three main classes: (David, 2008) 
 Fatty or oleaginous bases, such as theobroma oil, synthetic and semi-synthetic fatty 
bases. 
 Water-soluble or water miscible bases that may consist of glycerol, gelatin and/or 
polyethylene glycol. 
 Miscellaneous bases such as hydrophilic or water-dispersible compounds that may 
include nonionic surfactants mixed with either vegetable oils or waxy solids  
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1.5.1.1 Fatty bases: 
 Cocoa butter (Theobroma Oil):  
This is a natural material that consists of a mixture of fatty acid esters of glycerol, such as stearic, 
palmitic and oleic, predominantly triesters, e.g. glyceryl tripalmitate. The presence of unsaturated 
esters (e.g. oleic acid) contributes to the low melting point of cocoa butter (30–360C), thereby 
facilitating cocoa butter melting following insertion within the rectum. The incorporation of 
lipophilic drugs into cocoa butter has been reported to lower the melting-point range of 
suppositories produced using this base, which may lead to stability problems and may result in 
suppositories that are too soft to insert. Cocoa butter is safe, non-toxic and non-irritating. 
 The major problem with the use of cocoa butter as a base for suppositories is polymorphism, i.e. 
the ability of this material to exist in different crystalline forms; this is accredited to the high 
content of triglycerides, which may lead to instability issues (notably poor setting properties or 
re-melting of the suppositories following manufacture) (David, 2008).  
Synthetic and semi-synthetic fatty bases:  
Semi-synthetic fats are usually white, brittle, solid, odorless and unctuous to touch and produce 
suppositories that are white and have an attractive, clean, polished appearance (Raymond, et al, 
2006). 
Hard fats are available in a variety of grades with different melting ranges, hydroxyl values and 
other physicochemical characteristics. The hydroxyl value is one of the physicochemical 
properties of a base that can be used to distinguish fatty bases in terms of their compatibility with 
an API and an associated extended shelf life. A high hydroxyl value indicates that the base has a 
greater ability to absorb water relative to a base with a low hydroxyl value and it has been 
suggested that these bases should not be used to manufacture formulations containing drugs that 
are readily hydrolyzed (Aulton, 2002). The water absorbing capacity of a suppository base could 
influence the formation of w/o emulsions in situ in the rectum, which must be avoided since drug 
release rates from these systems have been reported to be very slow (Aulton, 2002). A base with 
a high hydroxyl value will have a tendency to form hydrogen bonds with components of the 
formulation and the API, which in turn may result in relatively slow release rates of a drug from 
the base to the rectal mucosa. Bases with a high hydroxyl value have also been reported to be 
irritant to the rectal mucosa (Raymond, et al, 2006). 
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The use of hard fat suppository bases is preferred over the use of cocoa butter, as they do not 
exhibit polymorphism and their solidification is unaffected by overheating during the 
manufacturing process (Lachman, et al, 1986). The hard fat bases have a narrow temperature 
interval between their melting and solidification points, which is generally between 1.5°C and 
2°C and seldom over 3°C (Lachman, et al, 1986). The narrow temperature range between 
melting and solidification aids in the manufacture of uniform suppositories, as the risk of 
sedimentation of an insoluble drug dispersed in the base is usually low. In addition, hard fat 
suppository bases contract markedly on cooling thereby reducing the need for the use of a 
lubricant to facilitate removal of products from moulds following manufacture. 
As the presence of unsaturated fatty acids in the semi-synthetic bases is reduced, the bases are 
relatively resistant to oxidation when compared to cocoa butter, which contains a considerable 
amount of unsaturated oleic acid (Aulton, 2002). Semi-synthetic fatty bases have low acid and 
iodine values of < 2 and < 7, respectively, when compared to cocoa butter, which has an acid 
value of < 5 and an iodine value of 34-38. Low acid and iodine values are essential properties of 
suppository bases should a long shelf-life be required (Lachman, et al, 1986). The possibility of 
decomposition by moisture, acids and oxygen, which leads to rancidity in fats, increases with 
high iodine values (Lachman, et al, 1986). 
Examples of commercially available semi-synthetic fatty suppository bases include fractionated 
palm kernel oil, and hard fats such as Novata with different types, Massa Estarium®, 
Massupol®, Suppocire® and Witepsol®. 
1.5.1.2 Water-soluble and water-miscible bases: 
There are two main categories of suppository base in this classification: (1) glycerol–gelatin base 
which dissolves in the rectal fluids; and (2) water-miscible bases, composed of polyethylene 
glycols (PEGs) (David, 2008): 
Glycerol–gelatin: 
Glycerol–gelatin bases are mainly used for the formulation of suppositories that contain a water-
soluble APIs. These suppository bases are prepared by dissolving gelatin (about20% w/w) in 
glycerol (70% w/w) with the aid of heating (about100
o
C); the API is generally 
dissolved/dispersed in an aqueous phase (<10% w/w) and then combined with the glycerol phase 
with stirring prior to pouring into the suppository mould.  
The use of this type of base is restricted by several disadvantages, including: 
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 Physiological effect. Glycerol–gelatin suppositories will induce defecation and, hence, 
are used to relieve constipation or to facilitate bowel evacuation prior to surgery. 
 Difficult to manufacture.  
 Hygroscopic. Glycerol–gelatin bases will absorb moisture from the atmosphere and 
therefore must be carefully packaged to prevent moisture uptake and to maintain both the 
shape and mechanical properties of the suppository. This ability of glycerol–gelatin bases 
to absorb water will also occur within the rectum, leading to dehydration and irritation of 
the rectal mucosa. To minimise this phenomenon, the suppository may be moistened with 
water prior to insertion. 
 Potential interactions with APs. 
Water-miscible bases: 
The melting point of PEGs increases as the molecular weight increases, e.g. the melting points of 
PEG 1000 and PEG 8000 are 37–40oC and 60–63oC, respectively. Typically the melting point of 
PEG suppository bases is about 42
o
C; this is generally achieved and controlled using the 
appropriate mixtures of grade of this polymer.  
There are two concerns regarding the use of PEG-based suppositories. PEG is known to enhance 
the solubility of therapeutic agents and therefore this interaction between the drug and polymer 
may affect the subsequent release of the drug from the liquefied base. Secondly, the solubility of 
the drug in the solid base may change as functions of both storage conditions and time and this 
may result in crystal growth within the suppository.  
Following insertion into the rectum, these suppositories will not melt but, due to their 
hygroscopic properties, will gradually dissolve (the volume of rectal fluid is too small to allow 
rapid dissolution) and, in so doing, will enable drug dissolution to occur. This ability to absorb 
moisture may lead to patient discomfort due to the extraction of water from the rectal mucosa 
into the suppository; however, this may be minimized by the inclusion of water (> 20% w/w) and 
by moistening the suppository prior to insertion. PEG-based suppositories will require storage in 
moisture-resistant packaging. 
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1.5.2 Criteria for selecting a suitable suppository base  
The properties of an ideal suppository base: (Saritha, 2005), (Aulton, 2002) 
1- Melts at body temperature or dissolves in body fluids. 
2- Non-toxic and non-irritant. 
3- Compatible with the APIs. 
4- Releases the APIs readily. 
5- Easily molded and removed from the mould. 
6- Stable to heating above the melting point. 
7- Easy to handle. 
8- Stable on storage. 
9- If the base is fatty, it has the following additional requirements. 
– “Acid Value” is below 0.2. 
– “Saponification value” ranges from 200 to 245. 
– “Iodine value” is less than 7. 
The selection of a suitable suppository base depends on a number of physicochemical variables, 
including, but not limited to the solubility of the drug in the base and rectal fluids, in addition to 
the intended therapeutic goals following rectal administration. Table 1.2 shows the 
recommended suppository base in relation to API solubility. 
     Table 1.2: API solubility and recommended suppository base (Aulton, 2002) 
API solubility in Choice of base 
Fat 
 
Water 
Low High 
 
Fatty base 
High 
 
Low Aqueous base 
Low Low Indeterminate 
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 In order to ensure that the maximum amount of drug is released from a base, a principal of 
opposites may be applied. A water-soluble drug may be incorporated into a fatty base while a fat 
soluble drug may be best incorporated into a water soluble or miscible base. The selection of a 
suitable base shall be based on knowledge of the physicochemical properties and intrinsic 
pharmaceutical or pharmacological activity of the active ingredients to be incorporated into the 
suppository (Lachman, et al, 1986).   
The physical properties of a suppository base that may or may not be affected by the addition of 
a drug or that can influence drug release rate, as well as the stability of the final product are the 
melting characteristics, iodine value and the hydroxyl value. These parameters are widely used in 
the pharmaceutical industry for a range of applications with regard to suppository base selection 
(Leiberman, et al, 1998). 
 
 The following rules are considered: (Leiberman, et al, 1998), (Jayanti, N.D) 
1) A narrow interval between the melting point and the solidification point, especially the 
small scale (say, in a pharmacy).      
2) For a drug that can lower the melting point, high melting range bases are used (say 37 to 
41
O
C). Examples for such drugs are camphor, chloral hydrate, menthol, phenol, thymol, 
and volatile oils 
3) When large amounts of total solids, which can increase the viscosity of the melted 
suppository, are used, bases with low melting ranges, such as (30 to 34
O
C) shall be used. 
4) Bases with low acid values (below 3) and iodine values (below 7) give suppositories with 
long shelf life. 
5) For drugs intended for systemic effect, the chosen base must liquefy at or below body 
temperature, whereas only base softening or dispersion may be adequate for the delivery 
of compounds intended for local action, sustained and/or modified release of the API. 
6) Suppository bases with high melting points may be useful for delivering drugs that tend 
to lower the melting point of a base after inclusion, or for suppositories intended for use 
in warm climates. The high molecular weight PEG bases, in combination with low 
molecular weight PEG, may be appropriate. 
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7)   A suppository base with a low hydroxyl value should be selected in cases where the 
API(s) to be incorporated in the delivery system is/are sensitive to the presence of the 
free hydroxyl radicals. 
1.5.3 Additives used in the formulation of suppositories  
The formulation of successful suppositories, in addition to suppository base, may necessitate the 
inclusion of other excipients. These include: (David, 2008) 
1.5.3.1 Surface-active agents: 
Surfactants, such as Sorbian esters and polyoxyethylene sorbitan fatty acid esters, are used to 
enhance the wetting properties of the suppository base with the rectal fluid, and consequently 
enhance the drug release or dissolution rate. The use of surfactants is mainly reserved for 
formulations composed of a lipophilic suppository base and/or a lipophilic drug. 
1.5.3.2 Agents to reduce hygroscopicity: 
These agents reduce the uptake of water by fatty suppository bases from the atmosphere during 
storage, and thus enhance the chemical and physical stability of the finished dosage form. 
Colloidal silicon dioxide is an example for this category.  
Water uptake during storage of water-miscible bases will result in changes to the mechanical 
properties (softening) and shape of these dosage forms. Accordingly, protection against water 
uptake during storage is also afforded by the use of moisture-resistant packaging. 
1.5.3.3 Agents to control the melting point of the base: 
The melting point of the base may be manipulated to enhance the mechanical properties and 
physical stability of the suppository in response to the deleterious effects of storage at higher 
temperature and/or the presence of a therapeutic agent that is soluble in the suppository base. 
Examples of excipients that are commonly used to increase the melting point of suppositories 
prepared using fatty bases include: 
 beeswax (white or yellow wax) 
 cetyl esters wax stearic acid 
 stearic alcohol 
 aluminium mono- or distearate 
 colloidal silicon dioxide 
 magnesium stearate 
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 bentonite. 
Conversely there may be a requirement to reduce the melting point of the fatty suppository base, 
e.g. to enable melting within the rectum. Examples of excipients that may be used for this 
purpose include: 
 glyceryl monostearate 
 myristyl alcohol 
 polysorbate 80 
 propylene glycol. 
The melting point of PEG-based suppositories may be controlled by using different molecular 
weights and ratios of PEGs.  
 
 
1.5.3.4 Lubricants 
Lubricating the cavities of the mould is helpful in producing elegant suppositories and free from 
surface depression. The lubricant must be different in nature from the suppository base; 
otherwise it will become absorbed and fail to provide a buffer film between the mass and the 
metal. The water soluble lubricant is useful for fatty bases while the oily lubricant is useful for 
water soluble bases. 
 
Table 1.3 Lubricants for use with suppository bases: 
 
Base Lubricant 
 
Theobroma oil Soap spirit 
 
Glycerol-gelatin base liquid paraffin 
 
Synthetic fats No lubricant required 
 
Macrogols No lubricant required 
 
 
1.5.4 Preparation of suppositories:  
Suppositories may be prepared by either cold or fusion/melt molding methods (Lachman, et al, 
1986), (Abate, et al, 2005). 
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1.5.4.1 Cold Methods: 
 In these methods the API is well mixed with grated suppository base by the aid of water or wool 
fat, then the suppositories are formed either by hand molding into rods or compression molding 
through suitable openings. The rods were cut to the suitable length or weight.  
These methods are suitable for preparing small numbers of suppositories, and for heat labile 
APIs. The major disadvantage of these methods is the unavoidable air entrapment, which makes 
it impossible to control the weight, and increase the possibility for oxidation of both the base and 
the API.  
 
 
1.5.4.2 Fusion or Melt Molding: 
This is the most commonly used method for producing suppositories on both small and large 
scale. Suppository molds are available for the preparation of various types and sizes of 
suppositories. Molds are made of aluminum alloy, brass, or plastic and are available with from 
six to several hundred cavities.  
 In this method the base material is first melted, preferably on a water bath to avoid local 
overheating. 
 The drug is then dispersed or dissolved in the melted suppository base. 
 The mixture then is poured into a suppository mold, allowed to cool, and the finished 
suppositories are removed by opening the mold. 
The method of choice for commercial production involves the automated filling of molds or 
preformed shells by a volumetric dosing pump that meters the melt from a jacketed kettle or 
mixing tan directly into the molds or shells. Strips of preformed shells pass beneath the dosing 
pump and are filled successively, passed through cooling chambers, sealed, and then packaged. 
1.5.4.3 Problems in formulation: 
1- Water in suppositories: 
Formulators do not like to use water for dissolving drugs in suppositories for the following 
reasons: 
a. Water causes oxidation of fats. 
b. If the suppositories are manufactured at a high temperature, the water evaporates, the drugs 
crystallize out. 
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c. Absorption of water soluble drugs is enhanced only if the base is an oil – in – water emulsion 
with more than 50% of the water in the external phase. 
d. Drug excipient interactions are more likely to happen in the presence of water. 
e. Bacterial contamination may be a problem 
2- Hygroscopicity: 
a.  Glycerogelatin suppositories lose moisture in dry climates and absorb moisture in humid 
conditions. 
b. The hygroscopicity of polyethylene glycol bases depends on the chain length of the 
molecule. As the molecular weight of these ethylene oxide polymers increases the 
hygroscopicity decreases 
3- Drug excipient interactions 
4- Viscosity: 
When the base has low viscosity, sedimentation of the drug is a problem. 2% aluminum 
monostearate may be added to increase the viscosity of the base. Cetyl and stearyl alcohols or 
stearic acid are added to improve the consistency of suppositories. 
5- Brittleness: 
Cocoa butter suppositories are elastic, not brittle. Synthetic fat bases are brittle. This problem can 
be overcome by keeping the temperature difference between the melted base and the mold as 
small as possible. Materials that impart plasticity to a fat and make them less brittle are small 
amounts of Tween 80, castor oil, glycerin or propylene glycol 
6-Density: 
Density of the base, the drug, the volume of the mould and whether the base is having the 
property of volume contraction are all important. They all determine the weight of the 
suppository. 
7- Lubrication of moulds: 
Some widely used lubricating agents are mineral oil, aqueous solution of SLS, alcohol and 
tincture of green soap. These are applied by wiping, brushing or spraying. 
8- Volume contraction: 
On solidification the volume of the suppository decreases. The mass of the suppository pulls 
away from the sides of the mould. This contraction helps the suppository to easily slip away 
from the mould, preventing the need for a lubricating agent. Sometimes when the suppository 
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mass is contracting, a hole forms at the open end. This gives an inelegant appearance to the 
suppository. Weight variation among suppositories is also likely to occur. This contraction can 
be minimized by pouring the suppository mass slightly above its congealing temperature into a 
mould warmed to about the same temperature. Another way to overcome this problem is to 
overfill the molds, and scrape off the excess mass which contains the contraction hole. 
10- Weight and volume control: 
Various factors influence the weight of the suppository, the volume of the suppository and the 
amount of active ingredient in each suppository, they are: 
a. Concentration of the drug in the mass 
b. Volume of the mould cavity 
c. The specific gravity of the base 
d. Volume variation between moulds 
e. Weight variation between suppositories due to the inconsistencies in the manufacturing 
process. 
11- Rancidity: 
The unsaturated fatty acids in the suppository bases undergo auto oxidation and decompose into 
aldehydes, ketones and acids. These products have strong, unpleasant odors. The lower the 
content of unsaturated fatty acids in a base, the higher is its resistance to rancidity. 
1.5.5 Calculation of the mass of base required:  
One concern regarding the manufacture of suppositories is the calculation of the mass of base 
that is required. The volume of each suppository mould is known and has been calibrated. 
However, if the drug is dispersed in the molten formulation, the volume of the formulation will 
be dependent on the mass of drug present (remembering that solids displace an equal volume of 
base). To ensure that the correct volume of base is used, a calculation is performed based on the 
displacement value, i.e. the ratio of the weight of the drug to the weight of base displaced by the 
drug. The displacement factor may be visualised as the weight of drug required to displace unit 
weight of base (David, 2008).  
In practice the displacement value is calculated as follows: 
 The average weight of the suppository mould is calculated using the blank suppository 
base (the molten base is added to the correct volume, allowed to cool and then weighed). 
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 The weight of drug needed for the total number of suppositories is calculated (weight of 
drug per suppository. 
 Suppositories are then prepared by adding the mass of drug to the notional mass of 
suppository base, melting and then dispensing into the suppository moulds. The weight of 
the cooled suppositories is then determined. 
Displacement Value:  
The volume of a suppository from the particular mould is obviously uniform, but its weight will 
vary according to the density of medicaments. Consequently, products made from moulds cannot 
be prepared accurately unless allowance is made for the alteration in density of the mass due to 
added medicaments. The quantity of medicament which displaces 1 part of cocoa-butter or any 
other base (called the displacement value) is the most convenient method of making this 
allowance (Lachman, et al, 1986). 
The amount of base that is replaced by active ingredients in the suppository formulation can be 
calculated. The replacement factor, f, is derived from the following equation: 
 
  
        
      
             ………………………….. (1.1)                               
Where E=weight of pure base suppositories, G=Weight of suppositories with X% active 
ingredient. The appropriate mass of suppository base to be used for a specific batch of product is 
calculated using the following Equation: 
        
  
 
     …………………………………… (1.2) 
Where, 
              P = the amount of base required                    D = the amount of drug that is required 
             N = the number of prepared suppositories      f = displacement value  
             S = the size of the mould used 
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1.6 Quality Control of Suppositories:  
The quality control of suppositories includes the physical, chemical and physio-chemical aspects. 
1.6.1 Visual examination 
This includes odor, colour, surface condition and shape. It is important to check for the absence 
of fissuring, pitting, fat blooming, exudation, sedimentation, and the migration of the active 
ingredients. Suppositories can be observed as an intact unit and also by splitting them 
longitudinally. 
1.6.2 Uniformity of mass 
Twenty units are individually weighed and the average mass is determined. Not more than two of 
the individual masses deviate from the average mass by more than 5.0% and deviate by more 
than twice that percentage. It is used as indicator to potential problems in manufacturing process. 
(BP, 2011) 
1.6.3 Melting time 
Melting time is the time taken by an entire suppository to melt when it is immersed in a constant 
temperature bath at 37°C. 
1.6.4 Melting range (melting point, melting zone) 
It indicates the temperature at which the base starts melting and the temperature at which it is 
completely molten. A number of different techniques are used to study melting behavior, 
including the open capillary tube, the U-tube, the ascending melting point and the drop point 
methods (Loyed, 2007). 
1.6.5 Content and content uniformity testing 
In order to ensure content uniformity, individual suppositories must be analyzed to provide 
information on dose-to-dose uniformity. Testing is based on the assay of the individual content 
of drug substance(s) in a number of individual dosage units to determine whether the individual 
content is within the limits set.  
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Ten units are assayed individually. The requirements for dosage uniformity are met if the amount 
of API in each of the 10 dosage units as determined from the Content Uniformity method lies 
within the range of 85.0% to 115.0% of the label claim, and the acceptance value is not more 
than 15 (USP32, 2010). 
1.6.6 Mechanical strength/crushing test 
Suppositories can be classified as brittle or elastic by evaluating the mechanical force required to 
break them. Tests are used that measure the mass (in kilograms) that a suppository can bear 
without breaking. A good result is at least 1.8–2 kg pressure. The purpose of the test is to verify 
that the suppository can be transported under normal conditions, and administered to the patient 
(Loyed, 2007).  
 1.6.7 Disintegration test for suppositories 
The disintegration test determines whether suppositories soften or disintegrate within a 
prescribed time when placed in an immersion fluid (BP, 2011), (Loyed, 2007).  
Disintegration is considered to be achieved when:  
 The components of the suppositories have separated, e.g. melted fatty substances 
have collected on the surface of the liquid, insoluble powders have fallen to the 
bottom, and soluble components have dissolved or are distributed in one or more of 
the ways described in Methods 1 and 2; 
 There is softening of the test sample, usually accompanied by an appreciable change 
of shape without complete separation of the components. The softening process is 
such that a solid core no longer exists when pressure is applied with a glass rod. 
 Rupture of the gelatin shell or rectal capsule occurs resulting in release of the 
contents. 
 Dissolution is complete. 
For disintegration testing the Apparatus indicated in Fig.1.4 is used for water-soluble, hydro 
dispersible and fat-based suppositories, while Apparatus in Fig.1.5 may be used as alternative 
apparatus for fat-based.  
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Fig.1.4 Disintegration apparatus for hydro dispersible and fat-based suppositories (BP, 2011)    
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Figure 1.5 Alternative disintegration apparatus for fat based suppositories (Loyed V, 
2007) 
 
1.6.8 Dissolution testing 
The most frequently used techniques for the measurement of in vitro drug release from 
suppository dosage forms are those used for the assessment of drug release from solid oral 
dosage forms as described in the USP. The apparatus that has been used includes the USP 
Apparatus I or basket apparatus, USP Apparatus II or paddle apparatus and USP Apparatus IV or 
flow-though cell apparatus, or modifications thereof (USP 32, 2010).  
No single method of dissolution testing is suitable for all the various suppository formulations 
and types of suppositories (Loyed, 2007).  
The mechanism by which a drug is made available for absorption from suppositories 
manufactured using hydrophilic bases is quite different from that of suppositories manufactured 
using lipophilic bases. Drug release from hydrophilic bases such as Polyethylene glycole (PEG) 
is a result of the progressive dissolution of the base and associated excipients in the intra-rectal 
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fluids. By contrast, drug release from lipophilic suppository bases is the result of a series of 
successive steps that involve the melting of the base at or below body temperature (37° C), 
migration of the drug particles to the interface between the melted excipients and the rectal 
secretions, diffusion of drug molecules from the molten base to the rectal barrier membranes and 
subsequent absorption of the drug into general circulation (Happiness, 2006). 
A schematic diagram summarizing the aforementioned release processes of a drug from a 
lipophilic suppository formulation is depicted in Figure 1.6 
  
                    
 
Fig. 1.6 Schematic representation of a drug release process dispersed in a lipophilic suppository 
base 
 
A number of techniques have been used for the study of in vitro drug release from suppository 
dosage forms. The techniques that are in use differ mainly in the extent to which they are able to 
mimic in vivo physiological conditions. Two basic techniques have been employed, those that 
use membranes in the assessment of drug release and those that do not. Animal studies have also 
been used in conjunction with in vitro dissolution studies, in an attempt to correlate in vitro-in 
vivo drug availability. 
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Fig 1.7 Schematic representation of the flow-through dissolution cell (BP, 2011). 
 
The physiological environment in which drug release from a suppository is achieved can only 
occur in the presence of a small volume of rectal fluid or secretions of approximately 3-5 ml. 
Subsequently, drug that is released is transferred through a highly viscous mucous barrier to the 
rectal membranes and following absorption, into the systemic circulation to exert a therapeutic 
effect.  
The use of a membrane method for the assessment of drug release, potentially avoids surface 
variation effects that may occur between the suppository and a receptor phase, which is one of 
the major causes of poor reproducibility of the methods that do not use membranes to assess drug 
release rates from suppositories. In addition, membrane methods facilitate sampling and analysis 
since a clear filtered solution is sampled for analysis, rather than a complex mixture of 
dissolution medium and suppository base. These models also take into consideration factors such 
as type of excipients used, viscosity of molten bases and water solubility of the drug, which 
might influence the availability of drugs for dissolution and subsequent absorption in vivo, in 
particular when a drug is administered in combination with lipophilic excipients in the form of 
suppositories (Loyed, 2007), (Happiness, 2006). 
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1.7 Mathematical Modeling of Dissolution Rate Profile 
In vitro dissolution has been recognized as an important element in drug development. Under 
certain conditions it can be used as a surrogate for the assessment of Bio- equivalence. Several 
theories /kinetics models describe drug dissolution from immediate and modiﬁed release dosage 
forms. There are several models to represent the drug dissolution proﬁles where ƒt is a function 
of t (time) related to the amount of drug dissolved from the pharmaceutical dosage system. The 
quantitative interpretation of the values obtained in the dissolution assay is facilitated by the 
usage of a generic equation that mathematically translates the dissolution curve in function of 
some parameters related with the pharmaceutical dosage forms. (Paulo C., et al, 2001) 
The kind of drug, its polymorphic form, cristallinity, particle size, solubility and amount in the 
pharmaceutical dosage form can inﬂuence the kinetics of release. A water-soluble drug 
incorporated in a matrix is mainly released by diffusion, while for a low water-soluble drug the 
self-erosion of the matrix will be the principal release mechanism. To compare dissolution 
proﬁles between two drug products model dependent (curve ﬁtting), statistical analysis and 
model independent methods can be used.  
Mathematical models have been used extensively for the parametric representation of drug 
release kinetics from suppository formulations. Models that have been used include, the zero 
order, first order, Higuchi, Korsmeyer-Peppas and Weibull models. (Paulo C., et al, 2001) 
The major objectives of mathematical modeling are as listed below:  
1.  Designing the new drug delivery system based on general release expression.  
2.  Prediction of the exact behavior of drug or drug release rates from and drug diffusion 
behavior through polymers, thus avoid excessive experimentation.  
3.  Optimization of the release kinetics.  
4.  Elucidation of the physical mechanism of drug transport by simply comparing the release data 
to mathematical models. 
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1.7.1 Zero order models 
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and release the drug 
slowly (assuming that area does not change and no equilibrium conditions are obtained) can be 
represented by the following equation: (Paulo C., et al, 2001) 
Qt = Q0 + K0 t …………. (1.3)  
Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution and K is the zero order release constant.  
Ermiş et al, have reported that the zero order release kinetic process from systems such as water-
soluble suppository formulations containing polyethylene glycol, in which the drug is released in 
a controlled manner, is independent of drug concentration (Ermiş, Tarimci, 1995).  
1.7.2 First order model 
This model was first proposed by Gibald & Feldman (1967) later by Wagner (1969). The 
pharmaceutical dosage forms containing water-soluble drugs in porous matrices follow first 
order release kinetics, and can be expressed by the equation: 
Qt = Q0     …………… (1.4) 
Where Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in the 
solution and k is the 1st order release constant. The above equation in decimal logarithm will 
take the form, 
ln Qt = ln Q0 + kt  ……… (1.5) 
This equation implies that a graphic of the decimal logarithm of the amount of drug versus time 
will be linear. The dosage forms that follow this dissolution profile release the drug in a way that 
is proportional to the amount remaining in the interior of the dosage form, in such a way that the 
amount of drug released by unit of time diminishes. Thus any system obeying this model releases 
the drug in such a way that the remaining amount in the system governs the rate of release of 
drugs (Paulo C., et al, 2001). 
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1.7.3 Higuchi Model   
In 1961 Higuchi introduced the most famous and often used mathematical equation to describe 
the release rate of drugs from matrix system initially; it was valid only for planar systems. It was 
later modified and extended to consider different Geometries and matrix characteristics including 
porous structure. Higuchi developed an equation for the release of a drug from an ointment base 
and later applied it to diffusion of solid drugs dispersed in homogeneous and granular matrix 
dosage system. In this model, it is assumed that solid drug dissolves from the surface layer of the 
device first; when this layer becomes exhausted of drug, the next layer begins to be depleted by 
dissolution through the matrix to the external solution. In this way the interface between the 
regions containing dissolved drug and that containing dispersed drug moves into the interior as a 
front (Paulo C., et al, 2001).  
  In a general way it is possible to resume the Higuchi model to the following expression 
(generally known as the simpliﬁed Higuchi model): 
Qt = KHt
0.5
 …………… (1.6)   
Where, KH is the Higuchi dissolution constant. Higuchi describes drug release as a diffusion 
process based on the Fick’s law, square root time dependent. This relation can be used to 
describe the drug dissolution from several types of modiﬁed release pharmaceutical dosage 
forms, as in the case of some transdermal systems and matrix tablets with water soluble drugs. 
This modified Higuchi relationship has been used to describe drug release from various types of 
modified release pharmaceutical dosage forms and for lipophilic suppository formulations 
containing the sparingly soluble drug acetaminophen (Paulo C., et al, 2001), (Toshihito, et al, 
2004). 
1.7.5 Korsmeyer- Peppas Model (The Power Law) 
Power law equation is more comprehensive very simple and semi-empirical equation developed 
by Korsmeyer- Peppas which can be used to analyse data of drug release from polymers. The 
equation implies that; the fractional release of drug is exponentially related to release time. 
  ………………….. (1.7) 
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Where, Mt & M∞ are the absolute cumulative amounts of drug released at time t and infinity 
respectively, k is a constant incorporating structural and geometrical characteristics of the device, 
the k value is experimentally determined, and n is the exponent, indicative of the mechanism of 
drug release. The numerical value of the release exponent, n, is characteristic of the mechanism 
of diffusion release from delivery system. Peppas used the n value to characterise different 
release mechanisms from non-eroding polymers and the data are summarised in Table (1.4) 
(Paulo C., et al, 2001). 
Table 1.4 Exponent n of the power law and drug release mechanism from polymeric controlled 
delivery systems of cylindrical and spherical geometry.  
Exponent, n 
Thin Film                Cylinder                         Sphere                              Drug Release Mechanism 
0.5                            0.45                                0.43                                 Fickian diffusion 
0.5<n<1.0                0.45<n<0.89                  0.43<n<0.85                   Anomalous transport 
1.0                            0.89                                0.85                                 Case II transport                             
 
When the release mechanism is not well known or when more than one type of release 
phenomena could be involved, this model can be used to analyze the release of poly-metric 
dosage form. This equation was later modified to accommodate the lag time (L) in the beginning 
of the drug release from the pharmaceutical dosage form: 
  ……………. (1.8) 
And when there is possibility of burst effect (b), 
  …………… (1.9) 
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Whenever there is absence of lag time and burst effect 1 and b value would be zero and only Kt
n
 
is used. This mathematical model has been frequently used to describe the drug release from 
different modified release dosage forms (Paulo C., et al, 2001). The Korsmeyer-Peppas model 
has been used to characterise diclofenac sodium release from poloxomer based solid 
suppositories and the dissolution rate of the API was found to be independent of the time, the 
exponent n approached 1.0 (Yong , et al, 2005) . 
1.7.6 Weibull Model  
Weibull introduced a general empirical equation which is highly applied to drug dissolution or 
release from pharmaceutical dosage forms (Paulo C., et al, 2001). The accumulated fraction of 
the drug m in solution at time t is given by Weibull equation: 
  ………. (1.10) 
In this equation a, defines the time scale of the process. The location parameter, Ti, represents 
the lag time before the onset of the dissolution or release process and in most cases will be zero. 
The shape parameter, b, characterizes the curve as either exponential (b = 1), sigmoid, S- shaped, 
with upward curvature followed by a turning point (b>1). This equation may be rearranged into: 
 ………. (1.11) 
From this equation a linear relation can be obtained for a log-log plot of – Ln (1 – m) versus time 
t. the shape parameter (b) is obtained from the ordinate value (1/a) at time t = 1.  The parameter a 
can be replaced by the more informative dissolution time Td that is defined by a = (Td) 
b
 and is 
read from the graph as the time value corresponding to the ordinate – In (1 – m) = 1.  
Since –In (1 – m) =1 is equivalent to m = 0.632, Td represents the time interval necessary to 
dissolve or release 63.2% of the drug present. In the pharmaceuticals systems following this 
model, the logarithm of the dissolved amount of drug versus the logarithm of time plot will be 
linear (Paulo C., et al, 2001). 
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Limitations:- 
i. There is not any kinetic fundament and could only describe, but doesn’t adequately 
characterize, the dissolution kinetic properties of the drug.  
ii. There is not any single parameter related with the intrinsic dissolution rate of the drug 
and  
iii. It is of limited use for establishing in vivo/in vitro correlation.   
Drug release from lipophilic suppository formulations is often accompanied by a more or less 
long-lasting lag phase that occurs as a result of the need for the base to melt prior to drug release 
and therefore the melting rate of the base is a factor that contributes to the lag time (Loth, 
Bosche, 1996).  
1.7.7 Selection of Best Model: 
The selection of the appropriate model in the drug release studies is critical to ensure the 
effectiveness of the study.  There are various criteria for the selection of the mathematical 
models which are based on the statistical treatments. The most widely used method employs the 
coefficient of determination, R
2
, to assess the fit of the model equation. This method can be used 
when the parameters of the model equations are similar. But when the parameters of the 
comparing equations increased; a modification is incorporated in this technique where an 
adjusted coefficient of determination (R
2
 adjusted) given by:   
                        ……………….. (1.12) 
Where n is the number of dissolution data points and p is the number of parameters in the model. 
Hence, the best model is the one with the highest adjusted coefficient of determination. A value 
for R
2
 adjusted > 0.950 is considered acceptable for the purposes of comparison of modeling 
dissolution profiles generated. 
Similarly other statistical tools like correlation coefficient (R), Analysis of Variance (ANOVA) 
and Multivariate analysis of variance (MANOVA) are used for the comparison and selection of 
the models (Paulo C., et al, 2001).   
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1.8 Background Information on Cefuroxime Axetil   
1.8.1 Description: 
Structural formula: 
 
                            
 
Chemical name: (1RS)-1-(acetyloxy) ethyl (6R,7R)-3-[(carbamoyloxy)methyl]-7-[[(Z)-2-(furan-
2-yl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
Molecular formula:    C20H22N4O10S 
Relative molecular mass:   510.48        CAS: 64544-07-6 
Content:  
It contains not less than 96.0 per cent and not more than the equivalent of 102.0 per cent of a 
mixture of the 2 diastereoisomers of Cefuroxime Axetil, calculated with reference to the 
anhydrous and acetone-free substance. It contains the equivalent of not less than 745 μg and not 
more than 875 μg of cefuroxime (C16H16N4O8S) per mg, calculated on the anhydrous basis. 
(USP32, 2010) 
1.8.2 General properties:  
Appearance:       White to cream powder 
Melting point:      Cefuroxime Axetil decomposes below its melting point 
Solubility at 20 
0
C:  Cefuroxime Axetil is soluble in dimethyl sulphoxide, dimethylformamide, 
1,4-dioxan, chloroform, acetone, glacial acetic acid, ethyl acetate and methanol, soluble with 
decomposition in alkali and slightly soluble in diethyl ether, 95% ethanol and toluene. It is 
insoluble (i.e. less than 0.1 % w/v soluble) in 2M hydrochloric acid. 
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The solubility of the amorphous material in aqueous solution at 20
o
C is approximately 0.12% 
that on standing converts to mainly crystalline material which has solubility in aqueous solution 
of about 0.03 %. (BP 2011, USP32, 2010) 
1.8.3 Impurities:  
Specified impurities: A, B, E.  
Other detectable impurities: C, D. 
                 Chemical Structure 
A. 1-(acetyloxy) ethyl (6R, 7R)-3-[(carbamoyloxy) 
methyl] - 7-[[(Z)-2-(furan-2-yl)-2-(methoxyimino) acetyl] 
amino]-8- oxo-5-thia-1-azabicyclo [4.2.0] oct-3-ene-2-
carboxylate (∆3-isomers). 
 
B. (1RS)-1-(acetyloxy) ethyl (6R, 7R)-3-[(carbamoyloxy) 
methyl]-7-[[(E)-2-(furan-2-yl)-2-(methoxyimino) acetyl] 
amino]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-
carboxylate (E-isomers), 
 
C. R = CO-CCl3 :( 6R, 7R)-7-[[(Z)-2-(furan-2-yl)-2-
(methoxyimino) acetyl] amino]-8-oxo-3-
[[[(trichloroacetyl) carbamoyl] oxy] methyl]-5-thia-1-
azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 
 
D. R = H: cefuroxime  
E. (5aR,6R)-6-[[(2Z)-2-(furan-2-yl)-2-(methoxy- 
imino)acetyl]amino]-5a,6-dihydro-3H,7H- 
azeto[2,1-b]furo[3,4-d][1,3]thiazine-1,7(4H)-dione 
(descarbamoylcefuroxime lactone). (EuroP., 2002) 
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1.8.4 Pharmacokinetics 
Absorption and Metabolism:    Cefuroxime axetil is a broad spectrum second-generation 
cephalosporin antibiotic active against β-lactamase producing strains. It belongs to class IV drug 
according to Biopharmaceutical Classification (BPC). It is an ester prodrug of cefuroxime. Its 
activity depends upon in-vivo hydrolysis by nonspecific esterases in the intestinal mucosa and 
blood and release of cefuroxime. Cefuroxime is rendered more lipophilic by esterification of the 
C4 carboxyl group of the molecule by the racemic 1-acetoxyethyl bromides, thus enhancing oral 
absorption.  
Cefuroxime axetil is an orally active drug though its absorption is incomplete. Its bioavailability 
ranges between 25 to 52%. It is the axetil form of cefuroxime that is absorbed but when it is 
hydrolysed to cefuroxime its permeation is low. The axetil moiety is metabolized to acetaldehyde 
and acetic acid (Sambhakar, et al, 2011). 
Peak plasma concentration is reported about 2 to 3 hours after an oral dose. Up to 50% of 
cefuroxime in the circulation is bound to plasma proteins. The plasma half life is about 70 
minutes and is prolonged in patients with renal impairments and in neonates. Cefuroxime axetil 
is widely distributed in the body including plural fluid, sputum bone synovial fluid, and aqueous 
humour, but only achieves therapeutic concentration in the CSF when the meninges are 
inflamed. It crosses the placenta and has been detected in breast milk. Cefuroxime is excreted 
unchanged, by glomerular filtration and renal tubular secretion, and high concentration is 
achieved in urine. Probenecid competes for renal tubular secretion with cefuroxime resulting in 
higher and more prolonged plasma concentration of cefuroxime. Small amounts of cefuroxime 
are excreted in bile (Zinat
®
 Tablets, 2011), (Cefuroxime Axetil monograph, 2009), (Cefuroxime 
Axetil information, 2012). 
1.8.5 Indications and Clinical Uses: 
It is used for the treatment of patients with mild to moderately severe infections caused by 
susceptible strains of the designated organisms in the following diseases: (Cefuroxime Axetil 
monograph, 2009) 
 Upper Respiratory Tract Infections: Pharyngitis and tonsillitis caused by S. pyogenes. 
Otitis Media caused by S. pneumoniae, S. pyogenes (group A beta-hemolytic 
 39 
streptococci), H. influenzae (beta-lactamase negative and beta-lactamase positive strains) 
or M. catarrhalis.  
 Sinusitis caused by M. catarrhalis, S. pneumoniae or H. influenzae (including ampicillin-
resistant strains).  
 Lower Respiratory Tract Infections: Pneumonia or bronchitis caused by S. pneumoniae, 
H. influenzae (including ampicillin-resistant strains), H. parainfluenzae, K. pneumoniae 
or M. catarrhalis.  
 Skin Structure Infections: Skin structure infections caused by S. aureus, S. pyogenes or S. 
agalactiae.  
 Gonorrhea: Acute uncomplicated urethritis and cervicitis caused by N. gonorrhea.  
1.8.6 Stability 
The effect of temperature and relative air humidity on the degradation of diastereomers A and B 
of CFA was estimated by studying the stability of CFA in solid state. Changes in the 
concentration of the two diastereomers (A and B) of CFA were recorded by means of HPLC with 
UV detection. It was concluded that the kinetic mechanism of CFA decomposition depends on 
the storage conditions of the respective substance. In a dry ambient atmosphere the 
decomposition is the result of a reversible process and follows the kinetics of a pseudo-first order 
reaction. When stored in a humid environment (RH/50%), the degradation of CFA is of an 
autocatalytic nature. Environmental humidity is a paramount factor determining the 
decomposition of CFA, especially at high temperatures. The B diastereomer of CFA is more 
stable than the A one, both in a dry and in a humid ambient atmosphere (Marianna, 2003).  
The degradation of amorphous CFA yields three main products: Δ3-isomers, E-isomers of 
cefuroxime axetil and cefuroxime regardless of relative humidity. All three products except 
cefuroxime at RH= 0% underwent further decomposition in the consecutive reactions (Fig1.8) 
(Anna, 2006). 
  The hydrolysis kinetics follows a first-order reaction in a pH range 1-9. The pH-rate profile for 
the total isomeric mixture shows a maximum stability in the pH range 3.5-5.5 and different 
hydrolysis rate constants for the two isomers.  Isomer A is always more reactive than isomer B 
with a maximum difference in reactivity about 27% being observed at pH=1. Acetate or 
phosphate buffer catalyzes the degradation, but ionic strength does not have a significant effect 
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on the kinetics. The hydrolysis proceeds through different routes, yielding the Δ2-isomer, 
cefuroxime, and small quantities of sulfoxides (Fabre, 1994). The photoisomerization kinetics of 
cefuroxime axetil revealed competition between the isomerization and photolysis of the β-lactam 
ring, with the two diastereoisomers reacting at different rates. The fact that photoisomerisation 
occurs on exposure to UV radiation at 254 nm confirms the need for photo protection from light 
(Glass, 2004).  
 
 
Figure 1.8 Degradation products of the amorphous form of cefuroxime axetil in solid state 
(Anna, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part Two: 
Objectives 
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2.1 Needs for the study 
The rectal route is commonly used as an alternative when oral administration is inconvenient 
because of inability to swallow or because of gastro - intestinal side effects such as nausea, 
vomiting and irritation.  
 More important, rectal drug administration has the advantage of minimizing or avoiding hepatic 
first pass metabolism.     
It’s well known that the rectal route can deliver 60-70% of the administered drug directly into 
systemic circulation. The lymphatic circulation helps also in absorbing a rectally administered 
drug from liver. The most common dosage form used for drug administration via rectal route is 
solid suppositories (Saritha, 2005).  
Antibiotics are usually administered either orally or by a parenteral route, the latter being used 
for drugs that are poorly or not bioavailable by the oral route or when clinical situations require 
rapid or higher antibiotic concentrations to be achieved in the body.  
In humans the rectum comprises the last 12–19 cm of the large intestine and the rectal epithelium 
is formed by a single layer of columnar or cubical cells and goblet cells; its surface area is about 
200–400 cm2. The absorbing surface area of the rectum is considerably smaller than that of the 
small intestine, as the former lacks villi and microvilli. However, the epithelia in the rectum and 
the upper intestinal tract are histologically similar, giving them comparable abilities to absorb 
drugs. 
The rectal mucosa is richly vascularized: this important blood supply comprises the inferior and 
middle veins, which are directly connected to the systemic circulation, and the superior rectal 
vein, which is connected to the portal system. This ensures that drugs in suppository form which 
are absorbed in the upper rectum will not by-pass the hepatic ‘ﬁrst-pass’ elimination, responsible 
for the metabolism and rapid clearance of many orally administered drugs. 
 Cefuroxime axetil (CFA) is abroad spectrum ß-lactamase cephalosporin that has well defined 
pharmacokinetics after intramuscular and intravenous administration in the form of sodium salt 
(Kar, et al, 2010). CFA is a Biopharmaceutics Classification System (BCS) Class IV drug due to 
its poor aqueous solubility (Sambhakar, et al, 2011).  
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It is available for oral administration as tablet dosage form in 250mg and 500mg strengths, and 
as powder for suspension dosage form in 125mg/5ml and 250mg/5ml strengths. In humans, 
gastrointestinal absorption of cefuroxime is negligible. Cefuroxime (Cefuroxime axetil) an oral 
prodrug shows a bioavailablity of 30% to 40% when taken on fasting and 5% to 60% when taken 
after food (Kar, et al, 2010).  
The in vivo bactericidal activity of Cefuroxime Axetil is due to cefuroxime binding to essential 
target proteins and the resultant inhibition of cell wall synthesis. Cefuroxime has bactericidal 
activity against a wide range of common pathogens, including many beta-lactamase-producing 
strains. Cefuroxime is stable to many bacterial beta-lactamases, especially plasmid-mediated 
enzymes that are commonly found in enterobacteriaceae. Cefuroxime has been demonstrated to 
be active against gram-positive (Staphylococcus aureus, Streptococcus pneumoniae, and 
Streptococcus pyogenes) and gram-negative (Moraxella catarrhalis, Escherichia coli, 
Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, and Neisseria 
gonorrhea) organisms (Ceftin
®
, 2010).  
Vomiting, abdominal pain, and gastrointestinal irritation are often reported adverse reactions for 
Cefuroxime Axetil tablet and powder for suspension dosage forms. 
Cefuroxime Axetil has very bitter taste, and problems are encountered in patient acceptability, 
especially for children and pediatrics.  
The advent of Cefuroxime Axetil suppository dosage form may be the solution for the above 
mentioned problems. Since suppositories avoid any gastrointestinal irritation, and can be used in 
unconscious patients, for systemic absorption to avoid first-pass metabolism, for babies or old 
people who cannot swallow oral medication and for people suffering from severe nausea or 
vomiting.  
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2.2 Objectives of the study: 
 To develop a 125 mg Cefuroxime Axetil pediatric suppositories in both water soluble and 
fatty bases. 
 To assess and evaluate the rate and extent of Cefuroxime Axetil release from the 
suppositories, using an appropriate dissolution method. 
 To develop and validate a suitable method of analysis to measure Cefuroxime Axetil in 
suppository dosage forms. 
 To determine the effects of aging of selected suppository formulations on Cefuroxime 
Axetil release. 
 To study the dissolution kinetics and release mechanism for selected Cefuroxime Axetil 
suppository formulations manufactured using fatty bases. 
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Part Three: 
Experimental part 
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3.1 Work Strategy 
 Choosing the API and the excipients with suitable properties for formulation of the 
different types of suppositories  
 Preformulation trials and evaluation 
 Formulation of CFA Suppositories with the selected base(s) and additives  
 Test methods development and analytical test method validation 
 Studying the stability of CFA suppositories 
 Analyzing data and dissolution profile modeling of CFA suppositories 
3.2 Materials and Reagents 
All materials used in the formulation of CFA suppositories are of Pharmacopoeia grade, the 
materials and reagents used in the preparation of CFA suppositories are listed in tables 3.1 &3.2. 
 
Table 3.1: Reagents used in the study 
No. Item Grade 
1. Monobasic ammonium phosphate HPLC grade 
2. Methanol HPLC grade 
3. Sodium dihydrogen phosphate AR 
4. Disodium hydrogen phosphate AR 
5. Distilled water HPLC grade 
6. Acetonitrile HPLC grade 
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Table 3.2: Materials used in the study 
No. Item Manufacturer Donated by 
1. Cefuroxime Axetil Orchid Chemicals & pharm., India  Bir Zeit Pharm. Co 
2. Witepsol H15  Jerusalem Pharm. Co 
3. Novata A Cognis Gmbh, dusseldorf, Germany Bir Zeit Pharm. Co 
4. Novata BCF Cognis Gmbh, dusseldorf, Germany Bir Zeit Pharm. Co 
5. Paraffin Oil Sonneborn Refined product.  Bir Zeit Pharm. Co 
6. Sodium Lauryl 
Sulfate 
Samkeal Pharmachem Ltd. Bir Zeit Pharm. Co 
7. Tween 80 Sabo Jerusalem Pharm. Co 
8. Tween 85 Seppic Bir Zeit Pharm. Co 
9. Tween 20 Polaquim, S.A. DE C.V. /Mexico Bir Zeit Pharm. Co 
10. Polaxomer 188 Croda Pharmacare Pharm. Co 
11. Lecithin  Sinokrot foods Co 
12. Lanolin anhydrous Stella Jerusalem Pharm. Co 
13. Aerosil Evorik Degussa Jerusalem Pharm. Co 
14. BHT Lanxess AG, Leverkusen, Germany Al Raed Cosmetics Co 
15. Cremophor A6 BASF Jerusalem Pharm. Co 
16. Span 80 Polaquim, S.A. DE C.V. /Mexico Jerusalem Pharm. Co 
17. PEG 4000 BASF Jerusalem Pharm. Co 
18. PEG 400 BASF Jerusalem Pharm. Co 
19. PEG 6000 BASF Jerusalem Pharm. Co 
20. PEG 1500 BASF Jerusalem Pharm. Co 
21 Empty PVC 
Suppository Shells 
Sarong s.p.a Bir Zeit Pharm. Co 
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3.3 Tools and Equipment 
Syringes, vials, pipette, glassware, stands and tubes were supplied by Jerusalem pharmaceuticals 
Table 3.3 illustrates the tools and equipment used in the study. 
Table 3.3 Tools and Equipment used in the study. 
Equipment Source/Model 
HPLC 1 (method validation) Lachrom Elite, HPLC system equipped with: L2130, 
4 channels gradient pump, L2200 auto sampler, 
L2300 column oven and L2400 U.V detector.  
HPLC 2 (Stability studies) Ultimate 3000, HPLC system equipped with: ultimate 
3000 variable wave length detector, column 
compartment, auto sampler, 4 channel gradient pump. 
U.V. Spectrophotometer  Merck Hitachi: U2900, U.V visible 
spectrophotometer. 
pH meter Metrohm 
Balance XT 220 A, Percisia analytical Balance  
Magnetic Stirrer Fried Electronic 
Incubator 25C° Advantec CL-310 
Incubator 30C° WTB binder 
 Submersible water pump Minjiang, NS 160 
Water bath Tuttnauer Co. LTD 
Sonicator Elmasonic 
Refrigerator L.G. 
Dissolution tester, apparatus 1, 
Modified Teflon Basket 
Erweka, Type DT 820 
Suppository disintegration tester Erweka, model ST 30, Serial NO. 1086191069 
Melting point tester Mettler Toledo, type: FP 62, Serial No. 5117084333 
Aluminum Metal Suppository Mold - 
Flow through Cell Home-made  
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3.4 Methodology:  
3.4.1 Choosing the API and the excipients: 
Cefuroxime is an optically active molecule containing two chiral centers. The biological origin 
of 7-aminocephalosporanic acid (7-ACA) (the origin of the cephalosporin nucleus) ensures that 
only one optical isomer is produced.  
Cefuroxime as sodium salt is not appreciably absorbed from the GI tract. The esterification of 
cefuroxime with 1-acetoxyethyl bromide to produce cefuroxime axetil results in the addition of 
another chiral center to the molecule and results in two diastereoisomers of cefuroxime axetil 
about this optically active center in the ester group.  
The 1-acetoxyethyl ester group in position 4 of CFA ensures its lipophilicity and promotes the 
intestinal absorption of cefuroxime. 
For the preparation of pharmaceutical formulations only the amorphous form is used. It has 
better physicochemical and biological properties than the crystalline form, e.g. significantly 
higher solubility and bulk density as well as higher degree of absorption after oral administration 
(Ceftin
®
 prescribing information, 2010).  
Accordingly, amorphous CFA will be used during the course of this study. 
3.4.2 Formulation of Cefuroxime Axetil Suppositories: 
3.4.2.1 Suppository bases: 
The suppository formulations in this study were prepared from either water –soluble bases or 
semisynthetic fatty bases. Polyethylene glycol (PEG) in different grades was used for the 
preparation of water-soluble base suppositories, while, witepsol
®
 and Novata
®
 were used as fatty 
bases, for their characteristics and availability. The characteristics of the fatty and water- soluble 
bases are shown in tables 3.4 and 3.5 respectively. 
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 Table 3.4 Characteristics of Fatty bases used (Lachman, 1986) 
Parameters Novata A Novata BCF Witepsol H15 
Iodine value < 3 < 3 < 7 
Melting range 
o
C 33.5-35.5 35-37 33.5-35.5 
Saponification  value 225-240 225-240 230-240 
Solidification point 
o
C  29-31 30-32 32.5-34.5 
Hydroxyl value 20-40 20-40 5-15 
 
 
Table 3.5: Characteristics of the water-soluble bases (Raymond, 2006)   
PEG  Mean Molecular weight   Melting ranges (°C) Hydroxyl value 
400  400  < 10 264-300 
1000 1000  33.3-33.4 107-118 
1540 1450  43.1-43.3 70-86 
4000 3400  57.4-57.6 30-36 
6000 6750  60.7-61.0 - 
 
3.4.2.2 Determination of Displacement Value  
The volume of the suppository shells where the melt is filled in is uniform, but the weight of the 
suppository may vary, due to the difference in densities between the APIS, adjuvants and the 
base. Therefore, in order to prepare products accurately, allowance was made for the differences 
in density of the suppository base, owing to the presence of the added API and other adjuvants. 
The factor used to account for these differences is termed the displacement value (D.V.), which 
is the amount of API by weight that displaces one part by weight of a specific base being used 
for the manufacture of the suppositories. 
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To determine the Displacement Value the suppository shells are calibrated with the specific base 
alone to obtain an accurate weight for each no medicated suppository; after that ten suppositories 
containing 12.5% w/w of CFA are prepared by the fusion method of manufacture and weighed.  
The D.V. is then calculated using the following Equation: 
  
        
      
    
Where E=weight of pure base suppositories, G=Weight of suppositories with X% active 
ingredient. The appropriate mass of suppository base to be used for a specific batch of product is 
calculated using the following Equation: 
        
  
 
 
Where, 
              P = the amount of base required                    D = the amount of drug that is required 
             N = the number of prepared suppositories      f = displacement value  
             S = the size of the mould used 
 
3.4.2.3 Method of Preparation: 
The fusion or melting method was used for the manufacture of the CFA suppositories.  Each 
suppository was manufactured so as to contain an equivalent amount of 125mg of CFA in each 
suppository. The quantity of bases was weighed accurately. The suppository base is melted at 45-
50°C, by using a water bath. Any other additive is added at this stage of preparation. The molten 
mixture was cooled to approximately 40
o
C, and then the CFA powder was incorporated into the 
melted base while mixing.  The mixture was filled manually into an appropriate suppository 
shells using a-20 ml syringe and left to cool at room temperature. The filled suppository shells 
are finally sealed thermally.  
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3.4.2.4 Development of the formulation: 
To decide on the best and suitable combinations of the CFA, the bases, and the modifying 
additives, some preformulations as illustrated in tables 3.6, 3.7, and 3.8 were prepared in small 
quantities (i.e. 20 suppositories/ formulation), using different combinations of the bases and 
additives. The quality attributes, including colour, appearance, surface texture, melting range, 
dissolution rate, and CFA content and impurities of the formulations were assessed. From the 
assessment results of the preformulations, Witepsol
®
 fatty base was found to be the best base; 
therefore it was selected for the final study formulations along with the additives shown in table 
3.9. Sixteen formulations in larger quantities (i.e. 200 suppositories/ formulation) were prepared 
from the selected Witepsol
®
 H15 fatty-base with the additives in different combinations and 
different percentages as illustrated in table 3.10.The quality attributes, including colour, 
appearance, surface texture, melting range, dissolution rate, disintegration time, and CFA content 
and impurities of the formulations were assessed. The stability of the formulations was evaluated 
at three storage conditions (30
o
C, 25
o
C, and (2-8
O
C)) for a period of three months. 
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                 Table 3.6: Summary of preformulations using Witepsol H15 trials  
 
 
                                                               Formula B.N (quantities in grams for 20 suppositories) 
 
Ingredients PW1 PW2 PW3 PW4 PW5 PW6 PW7 PW8 PW9 PW10 PW11 PW12 PW13 PW14 
CFA 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Witepsol H15 21 17.4 18.43 18.31 18.37 18 18.64 18.65 20.87 18 20.76 20.64 20.52 20.52 
Paraffin oil 0 2.4 2.4 2.4 0.24 0.24 0.24 0.24 0 0 0 0 0 0 
Lanolin anh. 0 0 0 0 0 0 0 0 0 0 0.24 0.24 0.24 0.24 
Aerosil 0 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0 0 0 0 0 0 
Tween 20 0 0 0 0 0 0 0 0 0 0 0 0.12 0.12 0 
Tween 80 0 0 0 0 0 0 0 0 0 0 0 0 0 0.24 
Polaxomer 188 0 1.2 0 0 0 0 0 0 0 0 0 0 0 0 
SLS 0 0 0 0.24 0 0 0.024 0.05 0 0 0 0 0 0 
Cremophor A6 0 0 0.12 0 0.33 0.66 0 0 0 0 0 0 0 0 
Cremophor RH40 0 0 0 0 0 0 0 0 0.11 0 0 0 0 0 
Span 80 0 0 0 0 0 0 0 0 0 0 0 0 0.12 0 
Lecithin (soya bean) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
BHT 0 0 0 0 0.024 0.024 0.024 0.024 0 0 0 0 0 0 
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Table 3.6: Summary of preformulations using Witepsol H15 trials (continued) 
 
 
 
 Formula B.N(quantities in grams for 20 suppositories) 
  
Ingredients PW15 PW16 PW17 PW18 PW19 PW20 PW21 PW22 PW23 
CFA 3 3 3 3 3 3 3 3 3 
Witepsol H15 20.28 18.1 17.35 18.55 20.76 19.56 20.52 18.6 20.28 
Parraffin oil 0 2.4 2.4 2.4 0 0 0 0 0 
Lanolin anh. 0.24 0 0 0 0.24 0.24 0.24 0 0 
Aerosil 0 0 0.05 0.05 0.05 0 0 0 0 
Tween 20 0.48 0.48 0 0 0 0 0 0 0 
Tween 80 0.24 0 0 0 0 0 0 0 0 
SLS 0 0 0 0 0 0 0.24 0 0 
Cremophor A6 0 0 1.2 0 0 1.2 0 0 0 
Lecithin (soya bean) 0 0 0 0 0 0 0 2.4 0.24 
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Table 3.7: Summary of preformulations trials using Novata A & BCF  
                                                               Formula B.N (quantities in grams for 20 suppositories) 
 
Ingredients  PN1 PN2 PN3 PN4 PN5 PN6 PN7 PN8 PN9 PN10 PN11 PN12 PN13 PN14 PN15 
CFA  3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Novata A  0 20.76 20.76 20.28 20.52 19.56 6.3 6 5.22 5.22 5.42 5.22 5.22 5.41 5.41 
Novata BCF  21 0 0 0 0 0 14.7 14 12.18 12.18 12.58 12.18 12.18 12.63 12.63 
Paraffin oil  0 0.24 0 0 0 0 0 0 2.4 2.4 2.4 2.4 2.4 0.24 0.24 
Lanolin anh.  0 0 0.24 0.24 0.24 0.24 0 0 0 0 0 0 0 0 0 
Aerosil  0 0 0 0 0 0 0 0 0.05 0.05 0.05 0.05 0 0.05 0.05 
Tween 20  0 0 0 0.48 0 0 0 0 0 0 0 0 0 0 0 
Polaxomer 188  0 0 0 0 0 0 0 0.5 1.2 0 0 0 0 0 0 
SLS  0 0 0 0 0.24 0 0 0 0 0 0 0.24 0 0 0 
Cremophor A6  0 0 0 0 0 1.2 0 0 0 1.2 0.48 0 0 0.33 0.66 
Span 80  0 0 0 0 0 0 0 0 0 0 0 0 0.5 0 0 
BHT  0 0 0 0 0 0 0 0 0 0 0 0 0 0.024 0.024 
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Table 3.8: Summary of preformulations trials using PEG bases 
 
Batch No. (quantities in gm for 20 suppositories) 
Ingredients PEG 1 PEG 2 
CFA 3 3 
PEG 400 4.2 0 
PEG 1500 7.35 13.65 
PEG 6000 9.45 0 
PEG 4000 0 7.35 
  
  
Table 3.9 Composition and functions of materials used in formulation  
Ingredients % (w/w) Function 
CFA 12.5 Active Ingredient 
Witepsol H15 Q.S Suppository Base 
Paraffin Oil 5.0 Melting point modifier 
Lanolin anhydrous 2.0 Emulsifying agent 
Lecithin soya bean 1.0 Emulsifying and solubilizing agent 
Tween 20 1.0 & 2.0 Emulsifying and solubilizing agent 
SLS 0.5 & 1.0 Emulsifying and solubilizing agent 
BHT 0.02 Anti oxidant 
Tween 85 1.0 Emulsifying and solubilizing agent 
Aerosil 0.1 Emulsion stabilizer and suspending agent 
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Table 3.10: Summary of selected study formulation 
Quantities required in grams per 200 suppositories 
Ingred. 
B. N 
CFA WH15 Paraf. 
Oil 
Lanolin 
Anhyd. 
Aerosil Lecithin Tween
®
 
20 
SLS BHT Tween
®
 
85 
F01 30 209.7 0 0 0.24 0 0 0 0.048 0 
F02 30 196.8 12 0 0.24 0 0 1.2 0.048 0 
F03 30 195.7 12 0 0.24 0 0 2.4 0.048 0 
F04 30 195.7 12 0 0.25 0 2.4 0 0.048 0 
F05 30 193.2 12 0 0.24 0 4.8 0 0.048 0 
F06 30 203.9 0 4.8 0 0 0 1.2 0.048 0 
F07 30 202.8 0 4.8 0 0 0 2.4 0.048 0 
F08 30 202.8 0 4.8 0 0 2.4 0 0.048 0 
F09 30 200.4 0 4.8 0 0 4.8 0 0.048 0 
F10 30 206.4 0 0 0 2.4 0 1.2 0.048 0 
F11 30 205.2 0 0 0 2.4 0 2.4 0.048 0 
F12 30 205.2 0 0 0 2.4 2.4 0 0.048 0 
F13 30 202.8 0 0 0 2.4 4.8 0 0.048 0 
F14 30 207.6 0 0 0 0 0 0 0 2.4 
F15 30 205.2 0 2.4 0 0 0 0 0 2.4 
F16 30 205.2 0 0 0 2.4 0 0 0 2.4 
 
Anhyd: Anhydrous 
Ingred: Ingredient 
Paraf: Paraffin 
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3.4.3 Test methods development  
3.4.3.1 Assay test method of CFA suppositories: 
The assay test method was adapted from the USP 34
th
 edition monograph for Cefuroxime Axetil 
tablets, and validated for testing the amount of CFA present in suppository dosage form. 
Reagents used: 0.2 M Monobasic ammonium phosphate (Dissolve 23.0 g of monobasic 
ammonium phosphate in water to obtain 1000 ml of solution, methanol and distilled water). All 
reagents are of HPLC grade. 
Equipment: Analytical balance, sonicator, hot plate magnetic stirrer and HPLC (EZ Chrom Elite). 
Mobile phase: A filtered and degassed mixture of 0.2 M Monobasic ammonium phosphate and 
methanol (620: 380).  
Standard preparation: A quantity of CFA working standard accurately weighed (equivalent to 
250 mg Cefuroxime base) is transferred to a 100-ml volumetric flask, dissolved in methanol, 
diluted with methanol to volume, and mixed. Promptly 5.0 ml of this solution is transferred to a 
50-mL volumetric flask, 3.8 ml of methanol is added, and the volume is completed with 0.2 M 
Monobasic ammonium phosphate and mixed.  
Assay preparation: Tow suppositories are transferred to a 100-ml volumetric flask, dissolved in 
methanol with the aid of gentle heat, the volume is completed with methanol, and mixed. 5-ml of 
this solution is transferred to a 50-mL volumetric flask, 3.8 ml of methanol are added, and the 
volume is completed with 0.2 M Monobasic ammonium phosphate and mixed. 
 Note: All solutions containing CFA shall be used promptly, or stored in a refrigerator and used 
in the same day. 
Chromatographic system: 
 Detection wavelength: 278 nm 
 Column: 25 cm length and 4.6 mm internal diameter, packed with Octylsilane chemically 
bonded to porous silica. 
 Flow rate: 1.0 ml/min 
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Procedure: Equal volumes (10 µL) from both the standard preparation and the assay preparation 
are injected into the Liquid chromatography. The chromatograms are recorded and the responses 
are measured for the major peaks. 
The percentage of Cefuroxime in the product is calculated using the following formula: 
 
                       
                      
                        
            
                  The average areas are taken as the sum of the peak responses of the cefuroxime axetil 
diastereoisomers A and B for both standard preparation and sample preparation. 
System suitability: 
 The relative retention times: are about 0.8 for cefuroxime axetil diastereoisomer B, 0.9 
for cefuroxime axetil diastereoisomer A, and 1.0 for cefuroxime axetil delta-3 isomers. 
 The resolution, R, between cefuroxime axetil diastereoisomer A and B is not less than 
1.5; and the resolution, R, between cefuroxime axetil diastereoisomer A and cefuroxime 
axetil delta-3 isomers is not less than 1.5.  
 The column efficiency: not less than 3000 theoretical plates when measured using the 
cefuroxime axetil diastereoisomer “A” peak. 
 The relative standard deviation for replicate injections is not more than 2.0%. 
3.4.3.2 Dissolution Test method using (USP apparatus 1): 
Medium: 0.07 M pH 7.0 phosphate buffer, prepared by dissolving 3.7 g of monobasic sodium 
phosphate and 5.7 g of anhydrous dibasic sodium phosphate in 1000 ml of water. Dissolution 
vessels are filled with 900 ml.  
Tools: 100-mL volumetric flask, seven 50- ml volumetric flask, 1-ml volumetric pipette, 5-ml 
volumetric pipette, 1-Lt graduated cylinder, six 20-ml test tubes and 0.2 micron filters. 
Equipment: Dissolution tester (Erweka, Type DT 820), USP apparatus I, with modified baskets, 
UV-Visible spectrophotometer and analytical balance.  
Standard preparation: An amount of CFA, equivalent to 138 mg Cefuroxime base is weighed and 
transferred into a 100-ml volumetric flask and dissolved in methanol, the volume is completed 
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with methanol, a 1.0-ml from the prepared solution is transferred into a 100-mlvolumetric flask 
and the volume is completed with the dissolution media.  
Test conditions: 
Dissolution apparatus:                                 USP apparatus I  
Dissolution medium:                                  0.07 M pH 7.0 phosphate buffer   
 Temperature:                                             37+ 0.5
o
C 
Initial volume:                                            900 ml 
Basket speed:                                             100 rpm 
Filter size:                                                   0.2 µm 
Volume withdrawn:                                   10 ml 
Volume replaced:                                       5 ml 
Sampling times:                                          0, 15, 30, 45, 60, 120, 180 minutes 
Test preparation: Using a 10-ml syringe a 10- ml portion from each dissolution vessel is 
withdrawn into six separate test tubes. A 5-ml portion from each test tube is transferred into a 50-
ml volumetric flask and the volume is completed with the dissolution media. The remaining 
portions in the test tubes are returned to the vessels and 5-ml from dissolution media is added to 
each vessel. 
Procedure: The absorbance at λ = 278 nm of the standard preparation and the test preparations is 
determined for all different bathes of the product. 
The percentage of Cefuroxime released at each time interval is calculated using the following 
equation: 
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3.4.3.3 Dissolution Test method using (Flow through cell): 
In order to study the drug release from the CFA suppositories using the flow through cell device 
as recommended by the US and the European Pharmacopoeias, a flow through cell was proposed 
and designed by us and was shaped in Bir Zeit University as a generous donation. The design of 
the cell was derived from a release cell for ointments (Wen-Di Ma, et al, 2008). It was different 
from the design of both USP apparatus IV and the EurP. 
                    
         
          Figure 3.1:  schematic drawing of the modified flow-through cell apparatus  
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 The modified apparatus is made of glass and it is consisted of the following parts as shown 
in figure 3.1 
 A spherical compartment having a capacity of approximately 25cm3with an inlet and 
outlet I.D 6.77 mm and O.D 10.03 mm. 
 Three tube channels connected to the compartment; two of them are used as inlet and 
outlet channels with an I.D 7.3 mm. The third channel is used to insert the suppositories 
into the compartment. It is 13.9  mm I.D 
 A low flow rate pump. 
 Water bath maintained at 37.5oC 
 One liter glass or plastic vessel 
 A # 40 mesh screen fixed at the outlet of the cell to retain disintegrated portions from the 
suppositories 
Standard preparation: An amount of CFA, equivalent to 138 mg Cefuroxime base is weighed and 
transferred into a 100-ml volumetric flask and dissolved in methanol, the volume is completed 
with methanol, a 1.0-ml from the prepared solution is transferred into a 100-ml volumetric flask 
and the volume is completed with the dissolution media.  
Test conditions: 
Dissolution apparatus:                                 Flow through cell 
Dissolution medium:                                   0.07 M pH 7.0 phosphate buffer 
Temperature:                                              37+ 0.5
o
C 
Initial volume:                                             900 ml 
Pump flow rate:                                           30 ml/min 
Filter size:                                                    0.2 µm 
Volume withdrawn:                                    5 ml 
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Volume replaced:                                        5 ml 
Sampling times:                                           5, 10, 15, 30, 45, 60 minutes 
Procedure: The system was connected as shown in figure 2.1, the pump was operated; using a 
10-ml syringe 10- ml portions were withdrawn into a test tube. A 5-mL portion from the test tube 
is transferred into a 50-ml volumetric flask and the volume is completed with the dissolution 
media. The remaining portion in the test tube was returned to the vessels and 5-mL from 
dissolution media was added to each vessel. The absorbance at λ = 278 nm of the standard 
preparation and the test preparations was determined for all different bathes of the product. 
The percentage of Cefuroxime released at each time interval is calculated using the following 
equation: 
              
                              
                                  
      
3.4.3.4 Weight variation 
Twenty suppositories are individually weighed using an analytical balance and the average 
weight is determined.  
Acceptance criteria: 
The maximum percentage deviation from the average is 5%. 
 
3.4.3.5 Disintegration test: 
The apparatus used for conducting the test is similar to the one described previously in method I 
and figure 1.4 with the difference that the disintegration is determined for three suppositories 
simultaneously instead of one (Erweka, model ST 30, Serial NO. 1086191069).   
Procedure: 
Water maintained at a temperature of 36-37°C was used as the immersion fluid. The samples 
were placed on the lower disc of the metal device and then inserted into the cylinder. The 
apparatus was placed into the beaker and inverted every 10 minutes without removing it from the 
liquid. The time required for the disintegration of the suppositories was recorded.  
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Acceptance criteria: 
The state of each of the three suppositories shall be examined after 30 minutes for fat-based 
suppositories. 
Disintegration is considered to be achieved when: 
 Dissolution is complete 
 The components of the suppositories have separated. 
 There is softening of the test sample, usually accompanied by an appreciable change of 
shape without complete separation of the components. The softening process is such that 
a solid core no longer exists when pressure is applied with a glass rod. 
3.4.3.6 Melting range:    
The ascending melting point method was used for the determination of the melting point of all 
formulations. Capillary tubes of approximately 10 cm in length were sealed at one end and were 
filled with the formulation.  
Procedure: Tow suppositories from each batch were crushed into small pieces and mixed; the 
tubes were filled to a height of 3-6 mm. Following filling, the tubes were placed in an automated 
melting point test apparatus (Mettler Toledo, type: FP 62, Serial No. 5117084333).  
The start and end temperature of the apparatus were set at 32
o
C and 40
o
C respectively, the 
heating rate was set at 2.0 
o
C/min, the tube was observed every minute after the apparatus 
reached the start temperature and the melting temperature was recorded after melting was 
observed. 
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3.4.4 Test methods validation  
3.4.4.1 HPLC Method validation  
3.4.4.1.1 Introduction 
“The object of validation of an analytical procedure is to demonstrate that it is suitable for its 
intended purpose” determined by means of well-documented experimental studies. Accuracy and 
reliability of the analytical results is crucial for ensuring quality, safety and efficacy of 
pharmaceuticals.  
The International Conference on the Harmonisation of Technical Requirements for the 
Registration of Pharmaceuticals for Human Use (ICH) was initiated in 1990, as a forum for a 
constructive dialogue between regulatory authorities and industry, in order to harmonize the 
submission requirements for new pharmaceuticals between Europe, the United States of America 
and Japan. One of the first topics within the Quality section was analytical validation and the 
ICH was very helpful in harmonizing terms and definitions as well as determining the basic 
requirements.  
The ICH guidelines require that accuracy, precision, specificity; linearity, range, limit of 
quantitation (LOQ) and limit of detection (LOD) are assessed for assay and impurities 
determination analytical methods. The efficiency and long term reliability of an analytical 
method is dependent on establishing whether or not the analyte of interest is stable in an aqueous 
solution during the entire period of sample collection, processing, storage and analysis. 
Therefore, the stability of CFA in the mobile phase solution was also determined (USP32, 2010), 
(ICH Q2 (R1), 2005).  
   3.4.4.1.2 Linearity 
Linearity is the ability of the method to elicit test results that are directly proportional to analyte 
concentration within a given range. Linearity is generally reported as the variance of the slope of 
the regression line. Range is the interval between the upper and lower levels of analyte 
(inclusive) that have been demonstrated to be determined with precision, accuracy and linearity 
using the method as written. The range is normally expressed in the same units as the test results 
obtained by the method. A minimum of five concentration levels, along with certain minimum 
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specified ranges are done. For assay, the minimum specified range is from 80-120% of the target 
concentration. For content uniformity testing, the minimum range is from 70-130% of the test or 
target concentration. 
Acceptance Criteria: The correlation coefficient (R
2
) is not less than 0.999 for the least squares 
method of analysis of the line.  
Procedure: 
 A standard stock solution with concentration of 2.5 mg/ml was prepared by dissolving an 
amount of CFA standard material equivalent to 250 mg cefuroxim base in 100.0 ml methanol, 
then ten separate standards with different concentrations were prepared by diluting proportions 
from the stock solution according to the following table 3.11, the standards were analysed in 
according to the HPLC analytical method.  
 Data Analysis: 
The response of each concentration was plot versus standard concentrations prepared for 
linearity and Range. The least squares linear regression analysis, the slope, and Y-intercept of the 
data were performed. The results are shown in the results section.  
Table 3.11: Standard solutions preparation for linearity determination 
Solution 
No. 
Conc. 
% 
Conc. 
(mg/ml) 
Volume Pipetted from Stock St 
Solution (ml) 
Final 
Volume 
(ml) 1 10 0.025 1.0 100.0 
2 20 0.05 1.0 50.0 
3 30 0.075 3.0 100.0 
4 40 0.1 2.0 50.0 
5 60 0.15 3.0 50.0 
6 80 0.2 2.0 25.0 
7 100 0.25 5.0 50.0 
8 120 0.3 3.0 25.0 
9 140 0.35 7.0 50.0 
10 160 0.4 4.0 25.0 
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3.4.4.1.3 Range 
The range is the interval between the upper and lower concentrations of analyte in the sample 
that have been demonstrated to have a suitable level of precision, accuracy, and linearity. The 
specified range is normally derived from linearity studies and depends on the intended 
application of the procedure. It is established by confirming that the analytical procedure 
provides an acceptable degree of linearity, accuracy and precision when applied to samples 
containing amounts of analyte within or at the extremes of the specified range of the analytical 
procedure.   
The following minimum specified ranges should be considered:  
 For the assay of an active substance or a finished product: normally from 80 to 120 
percent of the test concentration;  
 For content uniformity testing, the minimum range is from 70-130% of the test or target 
concentration. 
3.4.4.1.4 Accuracy: 
The accuracy of an analytical procedure measures the closeness of agreement between the value, 
which is accepted either as a conventional true value or an accepted reference value and value 
found (i.e. accuracy is a measure of exactness of an analytical method). Accuracy is evaluated by 
analyzing synthetic mixtures spiked with known quantities of active pharmaceutical ingredient. 
Accuracy should be assessed using a minimum of 9 determinations over a minimum of 3 
concentration levels covering the specified range (e.g., 3 concentrations /3 replicates each of the 
total analytical procedure).  
Accuracy should be reported as percent recovery by the assay of known added amount of analyte 
in the sample or as the difference between the mean and the accepted true value together with the 
confidence intervals. 
Acceptance Criteria: The mean recovery of the assay should be within 100±2.0% at each 
concentration over the range of 80 – 120% of nominal concentration. 
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Procedure:  
A placebo formulation of cefuroxime axetil suppositories was prepared according to the 
formulation procedure of the CFA suppositories. The weight of tow suppositories was 
transferred to a 100-ml volumetric flask and dissolved with methanol with the aid of gentle heat, 
the volume was completed to mark with methanol, then three separate samples with different 
concentrations were prepared by diluting proportions from the stock solution according to table 
3.12, the samples were analysed according to the HPLC analytical method 
 
Table 3.12 Accuracy determination standard solution  
Conc. 
(%) 
Concentration 
(mg/ml) 
Pipetted 
Volume of 
sample (ml) 
Flask 
Volume 
(ml) 
80 0.2 2.0 25.0 
100 0.25 5.0 50.0 
120 0.3 3.0 25.0 
 
 Data Analysis:  
 Calculate the recovery data for each determination; calculate the average of recovery data 
and the RSD for each level. 
 Verify that the mean recovery of the assay should be within 100±2.0% at each 
concentration over the range of 80 – 120% of nominal concentration. 
3.4.4.1.5 Specificity/ Selectivity 
Specificity is the ability to assess unequivocally the analyte in the presence of components which 
are expected to be present. Typically these might include impurities, degradants, matrix, etc. It is 
a measure of the degree of interference from such things and is measured and documented in a 
separation by the resolution, plate count (efficiency), and tailing factor.  
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Procedure: 
A. No interference from excipients:  
This was conducted by preparing synthetic mixture of the product excipients, prepared as sample 
preparation and measured. Standard of 100 % nominal concentration (0.25 mg/ ml) and Sample 
of 100 % nominal concentration were injected in triplicate and measured. 
B. No interference from degradation products: 
A stock solution was prepared by dissolving an amount of cefuroxime axetil equivalent to 250 
mg cefuroxime base in methanol, and then a-100% standard solution of a final concentration of 
0.25 mg/ml was prepared for forced degradation conditions as follows: 
 Alkali degradation studies (0.5 N NaOH):  
From the stock solution, 5.0 ml solution was transferred into a-50.0 ml volumetric flask, a 
quantity of the mobile phase approximately equivalent to 25 ml was added to the flask, a-5.0 ml 
of 0.5 N NaOH was added to the mixture and volume was completed with mobile phase. The 
solution was allowed to stand for three hours and measured in triplicates. 
Acid degradation studies (0.5 N HCl): 
It was preceded as in alkali degradation except with the HCL solution was added instead of 
NaOH solution.  
Oxidation with Hydrogen Peroxide (10% H2O2): 
It was preceded as in alkali degradation except with the H2O2 solution was added instead of 
NaOH solution. 
Light: 
 From the stock solution 5.0 ml solution was transferred into a-50.0 ml volumetric flask, the 
volume was completed with mobile phase solution, mixed and left under U.V. light for 24 hours 
and the response was measured in triplicates. 
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Heat (heat on a boiling water bath for one hour):  
It was preceded as in light exposure except that instead of exposure to U.V. light the solution 
was heated in a boiling water bath for one hour and the response was measured in triplicates. 
C. solution Stability: 
Tow nominal concentration (0.25 mg/ ml) solutions were stored in refregirator (2-8
o
C) and at 
room temperature for 24 houres and the responses were measured in triplicates. 
3.4.4.1.6 Precision 
The precision of an analytical procedure expresses the closeness of agreement (degree  
of scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. Precision may be considered at three 
levels: repeatability, intermediate precision and reproducibility. Precision  should be investigated 
using homogeneous, authentic samples. However, if it is not possible to obtain a homogeneous 
sample it may be investigated using artificially prepared samples or a sample solution.  
The precision of an analytical procedure  is usually expressed as the variance, standard deviation 
or coefficient of variation of a series of measurements. 
Procedure:Tow levels of precision were considered for this study, repeatability and intermediate 
preecision. 
a) Repeatability:  
Repeatability expresses the precision under  the same operating conditions over a short interval 
of time. Repeatability is also termed intra-assay precision. 
 Repeatability was assessed using: 
 9 injections covering the specified range for the procedure (3 concentrations (0.2, 
0.25, 0.3 mg/ ml) / 3 replicates each) and 
 6 injections at 100% (0.25 mg/ ml) of the test concentration for both sample and standard 
solutions. All were prepared as mentioned for the accuracy. 
Acceptance Criteria: Relative Standard Deviation shall not be greater than 1.5%. 
b) Intermediate precision:  
Intermediate precision expresses within-laboratories variations: different days, different analysts, 
different equipment, etc. 
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It was assessed by repeating accuracy in different day by different analyst and different 
instrument. 
3.4.4.1.7  Limit of Detection and Limit of Quantitation Test: 
Limit of Detection (LOD):  
The  detection limit of an individual analytical procedure is the lowest amount of analyte in a 
sample which can be detected but not necessarily quantitated as an exact value. 
Several approaches for determining the detection limit are possible, depending on whether the 
procedure is a non-instrumental or instrumental:  
 Based on Visual Evaluation: The detection limit is determined by the analysis of samples 
with known concentrations of analyte and by establishing the minimum level at which the 
analyte can be reliably detected.  
 Based on Signal-to-Noise: Determination of the signal-to-noise ratio is performed by 
comparing measured signals from samples with known low concentrations of analyte 
with those of blank samples and establishing the minimum concentration at which the 
analyte can be reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally 
considered acceptable for estimating the detection limit.  
 Based on the Standard Deviation of the Response and the Slope: The detection limit (DL) 
may be expressed as:  
             DL =    3.3 σ / S 
 
             where  σ = the standard deviation of the response  
                       S = the slope of the calibration curve  
Limit of Quantitation (LOQ): 
The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a 
sample which can be quantitatively determined with suitable precision and accuracy. The 
quantitation limit is a parameter of quantitative assays for low levels of compounds in sample 
matrices, and is used particularly for the determination of impurities and/or degradation products. 
Several approaches for determining the quantitation limit are possible, depending on whether the 
procedure is a non-instrumental or instrumental.  
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 Based on Visual Evaluation: The quantitation limit is generally determined by 
the analysis of samples with known concentrations of analyte and by 
establishing the minimum level at which the analyte can be quantified with 
acceptable accuracy and precision.   
 Based on Signal-to-Noise Approach: This approach can only be applied to 
analytical procedures that exhibit baseline noise. Determination of the signal-
to-noise ratio is performed by comparing measured signals from samples with 
known low concentrations of analyte with those of blank samples and by 
establishing the minimum concentration at which the analyte can be reliably 
quantified. A typical signal-to-noise ratio is 10:1.   
 Based on the Standard Deviation of the Response and the Slope: The 
quantitation limit (QL) may be expressed:     
                               
                                                  QL = 10 σ / S 
 
                  where  σ = the standard deviation of the response 
                  S = the slope of the calibration curve  
          Procedure: 
From the standard solution having the  concentration of 0.25 mg/ ml, 5-ml solution were 
transferred to a-50ml volumetric flask, the volume was completed with buffur solution to get a 
nominal concentration of 0.025mg/ml, and the following dilutions were prepared from this 
solution as shown in the table below by transferring the mentioned volumes and dilution with the 
mobile phase:  
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Table 3.13: standard solutions for LOD & LOQ determination 
 
Solution 
# 
Conc. Of cefuroxime 
(mg/ml) 
Volume Pipetted 
from Stock 
Solution (ml) 
Final Volume 
(ml) 
1 0.01 10.0 25.0 
2 0.001 2.0 50.0 
3               0.0005 1.0 50.0 
4               0.00025 5.0 250.0 
5
* 
              0.0001 5.0 50.0 
 
*5ml from solution 2 were transferred to 50.0 ml vulumetric flask 
 
3.4.4.2 Dissolution Method Validation  
3.4.4.2.1 Introduction: 
Dissolution testing is one of the most common analytical techniques performed in a 
pharmaceutical analytical laboratory. An ideal dissolution test should deliver information in three 
key areas. First, the dissolution test should be able to detect changes in the physicochemical 
properties of the drug product from the effect of these changes on the rate or amount of the drug 
substance released. Second, dissolution testing should be able to distinguish drug products that 
have been manufactured using different processes and/or formulations during the development 
phase. Finally, when in vitro in vivo correlation is established, dissolution should also reflect 
release and absorption rates in humans.  
The role of an analytical method validation is to demonstrate that the method is capable of 
measuring an analyte accurately (accuracy, which includes specificity) and reliably (precision, 
which includes repeatability and reproducibility). In addition, if the analyte is expected to be in a 
wider range e.g. zero to 100 %, which is usually the case in dissolution testing, then it has to be 
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established that concentrations and responses have a linear relationship (linearity), by measuring 
responses at different concentrations. 
For the purpose of drug dissolution testing, it has to demonstrate that the analytical method is 
capable of measuring it accurately and reliably. Therefore, for validation of such methods, one 
needs to add the drug (“spiking”) in solution form to a dissolution testing apparatus i.e. vessel 
containing required volume of medium maintained at 37 ºC and spindle rotating. Samples are 
withdrawn and processed exactly as if these were from a product (filtration, dilution, extraction 
etc) and responses are measured accordingly. If responses and concentrations are as one would 
expect (as explained above), then that dissolution method has been validated. 
3.4.4.2.2 Linearity and Range: 
Linearity and range are typically established by preparing solutions of the drug, ranging in 
concentration from below the lowest expected concentration to above the highest concentration 
during release (USP32, 2010), (ICH Q2(R1), 2005). 
Acceptance criteria: 
Linearity is calculated by using an appropriate least-squares regression program. A square of the 
correlation coefficient (R
2
 0.98) demonstrates linearity. The y-intercept must not be 
significantly different from zero. 
Procedure: 
 A standard stock solution with concentration of 0.1388 mg/ml cefuroxime base was prepared by 
dissolving an amount of CFA standard material equivalent to 138.8 mg cefuroxime base in 100.0 
ml methanol, then ten ml of the solution were transferred to a-100 ml volumetric flask and the 
volume was completed with the dissolution media solution. From this stock solution separate 
standards with different concentrations were prepared by diluting proportions from the stock 
solution according to the following table 3.14 the standards were analysed in according to the 
U.V analytical method.  
 
 
 
 75 
 
 Data Analysis: 
The absorbance of each concentration was plot versus standard concentrations prepared for 
linearity and Range. The least squares linear regression analysis, the slope, and Y-intercept of the 
data were performed. 
Table 3.14: standard solutions preparation for dissolution method linearity determination 
No. Conc. 
% 
Conc. (mg/ml) Volume 
Pipetted from 
Stock St 
Solution (ml) 
Final Volume 
(ml) 
1 25 0.00347 5.0 200.0 
2 50 0.00694 5.0 100 
3 75 0.01041 15.0 200.0 
4 100 0.01388 5.0 50.0 
5 120 0.016656 3.0 25.0 
6 150 0.02082 15.0 100.0 
 
3.4.4.2.3 Accuracy/Recovery 
Accuracy/recovery are typically established by preparing multiple samples containing the drug 
and any other constituents present in the dosage form ranging in concentration from below the 
lowest expected concentration to above the highest concentration during release. 
Acceptance criteria: 
The measured recovery is typically 95% to 105% of the amount added.  
Procedure: 
The formulation F06 was selected for the accuracy study. A placebo containing all the excipients 
in the formulation F06, as shown in table 3.15 was prepared in a quantity equivalent to 10 
suppositories. From the prepared placebo an amount equivalent to the weight of one suppository 
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(1.2gm/supp.) was weighed and completely dissolved in 900 ml dissolution buffer solution at 
37
o
C. An amount of cefuroxime axetil ( approximately 173.32 mg) equivalent to 138.8 mg 
cefuroxime base was weighed, transferred into a 100-ml volumetric flask and dissolved in 
methanol, the volume was completed with methanol, then 10.0.ml from this solution were 
transferred into a-100.0 ml volumetric flask and volume was completed with buffer solution 
(stock solution with  0.1388 mg/ml concentration). From the stock solution, three different 
solutions (50%, 100%, and 150%) were prepared as in table 3.16. The absorbance of these 
solutions was measured in triplicate for each concentration.       
Table 3.15 Placebo suppository preparations (20 supp. Each) 
Excipients Weight 
WH15 23.52gm 
Lanolin 1% 0.24gm 
SLS 1% 0.24gm 
 
Table 3.16 Solution preparations for dissolution method accuracy determination 
No. % Concentration Conc. Mg/ml Volume from 
stock (ml) 
Final volume (ml) 
1 50 0.00694 5.0 100.0 
2 100 0.01388 5.0 50.0 
3 150 0.02082 15.0 100.0 
 
3.4.4.2.4 Precision  
Repeatability is determined by replicate measurements of standard and/or sample solutions. It 
can be measured by calculating the RSD of the multiple spectrophotometric readings for each 
standard solution, or from the accuracy or linearity data. 
Acceptance criteria:  
The relative standard deviation (RSD) of recoveries should be ≤ 4% 
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Procedure: 
The formula F06 was chosen for the study, since it showed the best release rate. The dissolution 
of this batch was repeated six times and samples were withdrawn at two time intervals (30, 60 
min.) and the absorbance was measured. 
3.4.4.2.5 Specificity/Placebo Interference: 
It is the demonstration that the results are not affected by placebo constituents, other active 
drugs, or degradation materials. The placebo consists of all the excipients without the active 
ingredient. 
Acceptance criteria: 
The placebo interference must not exceed 2%.  The % recovery is 100% +5%. 
Procedure: 
Six placebo formulations were prepared without CFA as shown in table 3.17, then the weight 
equivalent to one suppository (1.2 gm) from each formula was dissolved in 900 ml dissolution 
media solution at 37
o
C, from this solution 5.0 ml were transferred into 50.0 ml volumetric flask 
and volume was completed with the media solution, then the absorbance for each of these 
formulations was measured at 278 nm and Scand at the λ range of 240-340 nm. Six suppository 
formulations were prepared as shown in table 3.18, then one suppository from each formulation 
was dissolved in 900 ml dissolution buffer at 37
o
C, from this solution 5.0 ml were transferred 
into a 50.0 ml volumetric flask, a portion was filtered through 0.22µ filter and absorbance was 
measured for each formulation and the percentage recovery was determined.  
 
Calculations: 
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Table 3.17 Placebo formulations for dissolution specificity determination (quantity for 10 supp.) 
Excipients F1 F2 F3 F4 F5 F6 
WH 15 11.88 gm 11.76 gm 11.76 gm 11.88 gm 11.76 gm 11.76 
Lecithin 1 0 0 0.12 gm 0 0 0.12 
Lanolin 0 0.12 gm 0 0 0.12 0 
SLS 0.12 gm 0.12 gm 0.12 0 0 0 
Tween 85 0 0 0 0.12 0.12 0.12 
 
Table 3.18 Sample formulations for dissolution specificity determination (quantity for 10 supp.) 
Ingredients F1 F2 F3 F4 F5 F6 
CFA 1.561 1.561 1.561 1.561 1.561 1.561 
WH 14 10.32 gm 10.2 gm 10.2 gm 10.2 gm 10.2 gm 10.2 gm 
Lecithin 0 0 0.12 gm 0 0 0.12 gm 
Lanolin 0 0.12 gm 0 0 0.12 gm 0 
SLS 0.12 gm 0.12 gm 0.12 gm 0.12 gm 0 0 
Tween 85 0 0 0 0.12 gm 0.12 gm 0.12m 
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3.5 Stability studies of selected formulations 
3.5.1 Introduction:  
To provide an adequate shelf-life for products, active ingredients and dosage forms must show 
chemical and physical stabilities for long periods. The USP description of suppository dosage 
form instability is summarised by excessive softening, although some suppositories may dry out 
and harden or shrivel. Evidence of oil stains on packaging material should warn the pharmacist 
to examine individual suppositories more closely by removing any foil covering. As a general 
rule, the USP recommends storage in a refrigerator, unless otherwise indicated.    
The bioavailability of chemically stable rectal drugs is influenced by the physical stability of 
suppositories during storage. The so-called hardening effect occurs during storage of 
suppositories.  It results in an increase in the melting time of suppositories. Considerable changes 
in melting times arise only with bases of higher melting ranges (e.g. Witepsol H 37, 36-38°C).  
Bases with the lowest melting points (e.g., Witepsol H 32, 31-32 ° C) are subject only to minor 
changes (Hermann, 1995) 
 It was found that any little hardening resulting in little or no suppository melting, can cause local 
irritation, a defecator reflex or bowel obstruction and therefore it is important to consider this 
during formulation development (Cohen, Lordi, 1980). 
Hardening of suppositories in storage may be due to of polymorphic phase transitions, increased 
crystallinity and/or increased transesterification of the bases (Cohen, Lordi, 1980). 
  Long term storage of suppositories manufactured using semi synthetic fatty suppository bases 
may result in a reduction in drug release from these dosage forms (Webster, et al, 1998).   
3.5.2 Procedure: 
From the selected final formulations only six batches (F01, F07, F11, F14, F15 and F16) were 
selected for the stability testing as representative formulations. Samples from these formulations 
were stored at different conditions as required by the ICH Q1A R2 Guidelines for three months  
period. The storage conditions were as follows: 
25°C ± 2°C/60% RH ± 5% RH, 30°C ± 2°C/65% RH ± 5% RH, and 2-8
o
C (refrigerator) 
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The suppositories were evaluated at initial time and every month thereafter. The following 
parameters were subjected for reevaluation, i.e. colour, surface texture, disintegration time, 
dissolution profile, assay, melting range, and degradation products.  
3.5.3 Stability acceptance criteria: 
• 5% significant change in the % assay 
• Physical changes in colour, texture, appearance of sediments 
• Significant change in the dissolution rate 
• Impurities: 
  The sum of the areas for the pair of peaks corresponding to E-isomers is NMT 1.5% by 
normalisation  
 The sum of the areas of any peaks corresponding to delta isomers corresponding to delta 
isomers is NMT 2.0% by normalisation  
 The area of any other secondary peak is NMT 1.0% by normalization 
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Part Four: 
Results and Discussion 
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4.1 Preformulations Studies: 
4.1.1 Displacement Value: 
The calculated displacement value results for the different fatty bases used in preformulations are 
illustrated in table 4.1. From the results it is observed that the values of D.V are less than one 
which indicates very minor effect on the amount of suppository bases to be used for formulation.  
Table 4.1 displacement value of CFA in different suppository bases 
Base Displacement value Weigh of 
base/suppository [g] 
Novata BCF 0.936 1.040 
Novata A 0.811 1.015 
Novata BCF/Novata A 
(30:70%) 
0.935 1.0396 
Novata BCF/Novata A 
(70:30%) 
0.936 1.040 
Whitepsol H15 0.936 1.040 
 
The value for PEG bases was not calculated since these bases were excluded from the study in 
the early stages for their incompatibility with the CFA. 
4.1.2 Organoleptic and melting range test results for preformulations batches: 
The physical appearance results for suppository formulations containing Novata A/BCF    are 
illustrated in table 4.2., while the results for suppository formulations containing Whitepsol H15 
are illustrated in table 4.3.  
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Table 4.2 Physical appearance data for the formulations using Novata A/BCF   
Formulation 
Code 
 
Colour  
 
 
Appearance Surface 
Texture  
 
Melting range 
o
C 
PN1 White  Opaque Smooth 38-39 
PN2 Off White  Opaque Smooth 36.5-37.4 
PN3 White Opaque Smooth 38.4-39 
PN4 White Opaque Smooth 36.8-37.3 
PN5 White Opaque Smooth 38.5-39.2 
PN6 White Opaque Smooth 38.3-39 
PN7 White  Opaque Smooth 37.5-38 
PN8 White  Opaque Smooth 38.2-38.8 
PN9 White  Opaque Smooth 37.4-38 
PN10 White  Opaque Smooth 37.8-39 
PN11  White  Opaque Smooth 38.6-39.3 
PN12  White  Opaque Smooth 37-37.4 
PN13 White  Opaque Smooth 36.7-37.3 
PN14  White  Opaque Smooth 38-38.5 
PN15 White  Opaque Smooth 38.4-39 
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    Table 4.3 Physical appearance results for the formulations using Witepsol H15  
Formulation 
Code 
 
Colour  
 
 
Appearance Surface Texture  
 
Melting range 
o
C 
o
C 
PW1  White  Opaque Smooth 37.7-38.8 
PW2  White  Opaque Smooth 37-37.6 
PW3  White  Opaque Smooth 36.7-38 
PW4 White  Opaque Smooth 38.3-39.1 
PW5  White  Opaque Smooth 37.4-38.1 
PW6 White  Opaque Smooth 37.7-38.4 
PW7  White  Opaque Smooth 36.8-37.5 
PW8  White  Opaque Smooth 37-37.4 
PW9 Yellowish Opaque Smooth 38.3-38.8 
PW10 White Opaque Smooth with precipitates 39-39.4 
PW11 Off White  Opaque Smooth - 
PW12 Off White  Opaque Smooth 36.6-37.3 
PW13 Off White  Opaque Smooth 35.7-36.2 
PW14 Off White  Opaque Smooth 35.4-36.1 
PW15 Off White  Opaque Smooth 36-37 
PW16 White Opaque Smooth 36.2-37.3 
PW17 White Opaque Smooth 35.8-36.8 
PW18 White Opaque Smooth 37.7-38.5 
PW19 White Opaque Smooth 36.8-37.9 
PW20 White Opaque Smooth 37.4-38.2 
PW21 White Opaque Smooth 35.6-36.7 
PW22 Pale yellow Opaque Smooth 35.6-36.8 
PW23 Pale yellow Opaque Smooth 35.2-36.5 
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When Witepsol H15 was used without additives it was found that the melting point of the 
prepared suppositories is above 37.5
o
C, while using Novata BCF instead, the melting point 
exceeded 38
o
C. The addition of melting point modifiers (e.g. paraffin oil, lecithin, and lanolin) to 
Novata bases did not reduce the melting points significantly, while their addition to Witepsol 
H15 base significantly reduced the melting points. 
 It was observed that some additives changed the colour of suppositories to off white/pale 
yellow; the other physical parameters were almost identical for both bases.    
4.1.3 Dissolution results: 
The results of dissolution profile test for the preformulation trials are listed in tables 4.4 and 4.5. 
From the results it clearly observed that the dissolution results of CFA from suppositories 
compounded using Witepsol H15 were found better than those compounded with Novatas, 
although both were relatively low. The addition of surfactants and melting point modifiers had 
improved the dissolution rate significantly. 
Table 4.4 summary of preformulations dissolution results using Novata A/BCF bases indicated 
as percentage release [%] of CFA. 
Formula 15 min 30 min 45 min 60 min 120 min 180 min Diss. 
Cond. PN1 2 5 6 5 8 - D1 
PN2 53 - - - - - D3 
PN3 5 11 11 12 11 17 D2 
PN4 10 15 21 24 38 53 D2 
PN5 5 4 6 7 8 8 D2 
PN6 9 4 9 12 13 17 D2 
PN7 4 8 10 13 - - D1 
PN8 7 10 15 24 41 47 D1 
PN9 11 17 28 29 41 47 D2 
PN10 68 76 79 82 79 - D2 
PN11 44 55 - 42 - - D2 
PN12 42 69 63 65 77 - D2 
PN13 3 6 14 13 16 - D2 
PN14 3 4 5 6 8 10 D2 
PN15 8 11 14 15 20 20 D2 
-: Not measured 
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Table 4.5 Summary of preformulations dissolution results using Witepsol H15 base indicated as 
percentage release [%] of CFA 
Formula 15 min 30 min 45 min 60 min 120 min 180 min Diss. 
Cond. PW1 - 3 - 11 19 - D2 
PW2 - 7 - 18 27 - D2 
PW3 - 5 - 7 - 15 D2 
PW4 - 105 - 100 - 100 D2 
PW5 3 5 4 7 9 - D2 
PW6 8 12 16 21 32 - D2 
PW7 25 42 47 53 63 - D2 
PW8 70 85 87 92 96 - D2 
PW9 16 17 15 34 35 - D2 
PW10 15 19 22 29 37 - D2 
PW11 30 51 - 65 79 - D5 
PW12 9 18 - 30 41 - D2 
PW13 12 20 - 36 45 53 D2 
PW14 13 23 - 35 49 56 D2 
PW18 6 9 13 17 28 35 D2 
PW19 7 10 14 17 28 35 D2 
PW20 7 11 13 17 27 35 D2 
PW21 31 41 45 47 53 61 D2 
PW22 3 8 11 15 18 40 D2 
PW23 17 35 54 65 78 83 D2 
-: Not measured 
Diss. = Dissolution conditions 
D1= paddle, 0.2M phosphate buffer, pH 7.0, speed = 50 rpm 
D2=modified basket, 0.2 M phosphate buffer, pH 7.0, speed = 100 rpm 
D3= modified basket, 0.2M phosphate buffer +1%SLS in media, pH 7, speed = 100 rpm 
D4=modified basket, 0.2M phosphate buffer + 0.1%SLS in media, PH 7, speed = 100rpm 
D5=modified basket, 0.2M phosphate buffer +0.5% Tween 20 in media, PH 7, speed = 100rpm 
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4.1.4 Evaluation of CFA assay and impurities: 
Representative formulations containing most of the additives were analysed for their CFA and 
impurities contents. The results are illustrated in Table 4.6.  
By comparing the analysis results with the proposed specification mentioned in section 4.2.1, it 
is obvious that CFA is compatible with the used fatty bases and with the majority of the used 
additives, i.e. Paraffin oil, Lanolin, Aerosil, SLS, Cremophor A6. However, it was very clear 
from the number and the percentage of impurities that there was an incompatibility between the 
PEG base and CFA.  
Table 4.6 Drug content evaluation data for some preformulation batches  
Formulation 
code 
%Assay %Free 
Cefuroxime 
%Δ3 
Isomer 
%E1 
Enantiomer 
%E2 
Enantiomer 
CFA 100 0.28 N.D N.D N.D 
PW5 97 0.46 1.89 0.09 0.05 
PW6 97.5 0.47 1.54 0.10 0.06 
PW7 103 0.48 0.79 0.10 0.07 
PW8 99 0.63 0.74 0.09 0.06 
PN14 98 0.75 0.96 0.10 0.07 
PN15 99.8 0.97 1.54 0.09 0.06 
PW14 98 0.84 0.73 0.10 0.07 
PW15 98 0.86 0.81 0.11 0.06 
PN7 101 0.75 1.13 0.12 0.09 
PEG+CFA
* 
54 0.27 49 0.13 N.D 
 
* Three more unidentified impurities were observed at RT 2.97, 8.7, and 9.14 min. 
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4.2 Formulation of Cefuroxime Axetil Suppositories: 
4.2.1 Proposed drug product specifications: 
The following specifications are prevailed for the new CFA suppositories dosage form 
depending on the results obtained in this study and on the specifications of the tablets dosage 
form mentioned in the US Pharmacopoeia. 
Table 4.7 Proposed drug product specifications 
Tests Specifications 
Appearance  
 
Smooth, opaque with no precipitates 
Melting range  
 
36-37.5
o
C 
Disintegration Time  
 
Not more than 30 minutes. 
Assay   
 
The CFA content should be 90-110% of the label 
claim 
Related substances: 
     -Delta-3-Isomer:  
     -E Isomers:  
     -Free Cefuroxime:  
     -Total unknown 
impurities:  
 
 
Not more than 2.5%, calculated by normalization 
method  
Not more than 1.5%, calculated by normalization 
method  
Not more than 2.0%, calculated by normalization 
method  
Not more than 1.0%, calculated by normalization 
method 
 
4.2.2 Selected Formulae Evaluations: 
4.2.2.1 Organoleptic test results:  
All the formulated suppositories were evaluated for their shape, color, size and surface texture. 
The physical appearance of the formulations were checked and compared visually. The 
suppositories of all the formulations were all conical or bullet shaped.  
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             Table 4.8 Organoleptic test results for the selected formulations  
Formulation Code Colour  Appearance Surface Texture  
F01 White  Opaque Smooth 
F02 White  Opaque Smooth 
F03 White  Opaque Smooth 
F04 White  Opaque Smooth 
F05 White  Opaque Smooth 
F06 Off White  Opaque Smooth 
F07 Off White  Opaque Smooth 
F08 Off White  Opaque Smooth 
F09 Off White  Opaque Smooth 
F10 Pale yellow  Opaque Smooth 
F11 Pale yellow  Opaque Smooth 
F12 Pale yellow  Opaque Smooth 
F13 Pale yellow  Opaque Smooth 
F14 White  Opaque Smooth 
F15 Off White  Opaque Smooth 
F16 Pale yellow  Opaque Smooth 
 
4.2.3 Uniformity of Weight:  
The results are illustrated in table 4.9. The average weight, standard deviation and relative 
standard deviation were calculated. 
From the results it was found that all the batches comply with the requirements for weight 
uniformity of suppositories, as described in the BP, which recommends a maximum percentage 
deviation of 5.0%.  
 
 
 
 
 
 
 90 
 
Table 4.9 Evaluation of uniformity of weight data (weights are in gram unit) 
No. F01 F02 F03 F04 F05 F06 F07 F08 
1 1.239 1.270 1.340 1.281 1.246 1.240 1.284 1.194 
2 1.168 1.240 1.220 1.230 1.236 1.257 1.290 1.219 
3 1.310 1.262 1.188 1.195 1.207 1.277 1.310 1.199 
4 1.350 1.242 1.183 1.274 1.220 1.245 1.350 1.211 
5 1.290 1.160 1.218 1.232 1.200 1.262 1.274 1.203 
6 1.168 1.170 1.238 1.320 1.198 1.210 1.230 1.204 
7 1.238 1.216 1.220 1.207 1.187 1.270 1.382 1.265 
8 1.175 1.223 1.182 1.183 1.201 1.230 1.318 1.230 
9 1.287 1.224 1.207 1.204 1.239 1.310 1.252 1.244 
10 1.260 1.234 1.220 1.270 1.249 1.279 1.170 1.230 
11 1.310 1.221 1.208 1.242 1.370 1.214 1.320 1.200 
12 1.277 1.227 1.205 1.197 1.286 1.206 1.220 1.216 
13 1.293 1.224 1.197 1.200 1.260 1.216 1.255 1.227 
14 1.263 1.253 1.305 1.179 1.213 1.213 1.270 1.234 
15 1.215 1.188 1.276 1.224 1.205 1.231 1.245 1.256 
16 1.175 1.198 1.228 1.277 1.216 1.241 1.287 1.244 
17 1.385 1.270 1.210 1.232 1.282 1.214 1.343 1.260 
18 1.213 1.246 1.250 1.213 1.257 1.222 1.307 1.187 
19 1.213 1.210 1.236 1.331 1.290 1.192 1.221 1.253 
20 1.221 1.235 1.211 1.220 1.312 1.198 1.218 1.245 
Average 1.253 1.226 1.227 1.236 1.244 1.236 1.277 1.2261 
SD 0.0611 0.0299 0.0399 0.0434 0.0463 0.0312 0.0524 0.0232 
%RSD 4.9 2.4 3.1 3.5 3.7 2.5 4.1 1.9 
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Table 4.9 Evaluation of uniformity of weight data (continued) 
No. F09 F10 F11 F12 F13 F14 F15 F16 
1 1.207 1.186 1.325 1.160 1.254 1.274 1.395 1.272 
2 1.238 1.218 1.235 1.217 1.209 1.212 1.264 1.283 
3 1.165 1.197 1.230 1.210 1.240 1.284 1.239 1.227 
4 1.239 1.221 1.219 1.195 1.158 1.255 1.264 1.263 
5 1.223 1.219 1.220 1.166 1.254 1.279 1.276 1.233 
6 1.221 1.200 1.360 1.177 1.255 1.254 1.250 1.235 
7 1.186 1.205 1.240 1.230 1.230 1.240 1.268 1.237 
8 1.240 1.249 1.220 1.199 1.243 1.234 1.220 1.243 
9 1.212 1.190 1.176 1.201 1.233 1.232 1.254 1.240 
10 1.230 1.270 1.227 1.220 1.202 1.219 1.237 1.266 
11 1.263 1.233 1.290 1.200 1.187 1.239 1.247 1.239 
12 1.229 1.228 1.241 1.197 1.203 1.297 1.245 1.255 
13 1.254 1.192 1.242 1.236 1.189 1.232 1.260 1.201 
14 1.214 1.222 1.249 1.216 1.201 1.212 1.248 1.224 
15 1.236 1.214 1.313 1.218 1.243 1.250 1.243 1.173 
16 1.232 1.242 1.235 1.201 1.231 1.250 1.246 1.268 
17 1.222 1.221 1.259 1.260 1.223 1.200 1.235 1.227 
18 1.201 1.219 1.248 1.188 1.216 1.219 1.194 1.209 
19 1.219 1.276 1.189 1.219 1.204 1.220 1.205 1.210 
20 1.193 1.210 1.221 1.211 1.266 1.240 1.221 1.189 
Average 1.221 1.220 1.247 1.206 1.222 1.242 1.251 1.235 
SD 0.0232 0.0247 0.0445 0.0234 0.0278 0.0262 0.0398 0.0287 
%RSD 1.9 2.0 3.6 1.9 2.3 2.1 3.2 2.3 
 
4.2.4 Disintegration Time and Melting Range:  
The data for the formulated suppository are shown in the Table 4.10. The disintegration time for 
all formulations was found to be within the limits (< 30 min), however the disintegration time 
was lower in the formulations containing emulsifiers and solubilisers. 
The melting points for formulations containing Aerosil as a suspending agent (F01, F02, F03, 
F04, and F05) were found to be higher than the target temperature (NMT 37.5
o
C). All other 
formulations, except formula F09 which contains 2% lanolin and 2% Tween 20, had melting 
points ranging from (35.9-37.8
o
C). Suppositories containing Lecithin, Lanolin and Tween 85 
showed melting disintegration, however others showed softening disintegration. 
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Table 4.10 Disintegration time and melting temperature data for selected formulations 
Formulation B.N Disintegration time (min) Melting range (
o
C) Observation 
F01 10
 
38.5-39 Softened  
F02 10
 
38.3-38.8 Softened 
F03 10
 
38.7-39.2 Softened 
F04 10
 
38.6-39.3 Softened 
F05 10
 
37.7-38.2 Softened 
F06 10
 
37.4-37.8 Softened 
F07 10
 
36.5-37.1 Melted 
F08 10
 
37.2-38 Softened 
F09 10
 
38.1-39.2 Softened 
F10 10 36.3-37.2 Melted 
F11 10 36.5-37 Melted 
F12 10 36.2-36.5 Melted 
F13 10 36.7-37.3 Melted 
F14 7 36.4-37 Melted 
F15 7 36-36.8 Melted 
F16 7 35.9-36.5 Melted 
 
4.2.5 Drug content and impurities evaluation:  
 The amount of drug and the amount of degradation products/impurities present in each 
formulation have been evaluated according to the validated analytical test method.  The 
calculated values are given in the Table 4.11. From the results in the table, the formulations 
containing the surfactant “Tween 20” (F04, F05, F08, F09, F12, and F13) did not conform with 
the proposed product specifications. It was found that CFA content was significantly below the 
acceptable limits due to the hydrolysis effect of Tween 20. The identified degradation materials 
were found to be free cefuroxim and the Δ3Isomer. This could be due to the presence of hydroxyl 
groups in the surfactant, which promoted hydrolysis reactions. 
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Table 4.11 Drug Content Evaluation Data 
Formulation 
Code 
% 
Assay 
% 
Free 
CF 
% 
Δ3Isomer 
% E1 
Enantiomer 
% E2 
Enantiomer 
% Unidentified 
Impurities  
CFA as 
material 
100 0.28 ND ND ND ND 
F01 100.7 0.455 0.84 ND ND ND 
F02 99 0.527 0.852 ND ND ND 
F03 106 0.727 0.981 0.095 0.046 ND 
F04 93  1.625 6.28 ND ND ND 
F05 82 3.06 11.35 ND ND 0.303 
F06 101.4 0.705 0.935 ND ND ND 
F07 103.6 0.747 0.952 ND ND ND 
F08 87 2.717 8.03 ND ND 0.280 
F09 80.4 3.825 10.76 ND ND 0.418 
F10 102 0.897 1.069 ND ND ND 
F11 100.5 0.903 1.00 0.101 0.072 ND 
F12 92.3 2.42 5.21 ND ND 0.367 
F13 80.5 4.34 9.99 ND ND 0.538 
F14 101.2 0.424 1.958 ND ND ND 
F15 101 0.495 2.186 ND ND ND 
F16 101 0.598 2.29 ND ND ND 
ND Not detected. 
 
4.2.6 In vitro release studies of Cefuroxime Axetil from suppositories: 
4.2.6.1 In vitro release using USP apparatus I (modified basket):  
The dissolution profiles of CFA from the selected formulations are illustrated in table 4.12 and 
depicted in figure 4.1. These results represent the average value of 6 suppositories. It is clearly 
evident that the release profile of CFA from the formulation containing the active material and 
the suppository base alone (F01) was found to be very slow (i.e. not more than 8% in 180 
minutes). 
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This result could be due to many factors including: 
 The use of a suppository base (WHI5) with a low hydroxyl value of 13.6. As the 
hydroxyl value of the suppository base increases the water sorption of the suppository 
increases. 
 The melting point of F01 was high (i.e. 39oC), therefore the suppositories melted slowly 
and incompletely during the dissolution testing, since melting plays a great role in release 
rates and a prerequisite for drug liberation..  
 The CFA is a very lipophilic material, so the partitioning of CFA between the aqueous 
dissolution medium and the lipoid suppository base phase, appears to favor the lipid 
phase. 
When surfactants, solubilizers and melting point modifiers were added to the formulations, the 
release rate was increased. From the results illustrated in table 3.12 the following were observed: 
 The CFA release rate in formulations F02 and F03 was not significantly increased, 
although SLS (HLB  40) was added. This could be due to the high melting point of these 
batches (about 39 C). 
 The addition of (1% and 2%) of Tween 20 to batches F04 and F05 didn't reduce the 
melting points significantly, however the percentage release rate was increased 
moderately (i.e. 45% and 49% respectively at 180min). 
 The addition of 1% lanolin anhydrous to the formulations (F06 and F07) containing 0.5% 
and 1% SLS reduced the melting points from 39 to 37
o
C, but surprisingly it increased the 
release rate of F06 which had the lower SLS concentration more than F07. This could be 
a consequence of exceeding the critical micelles concentration (CMC). According to 
published literature, the presence of surfactants in formulations at concentrations higher 
than their CMC value generally retards the drug release, as a result of micelles 
entrapment of the drug (Aulton, 2002). 
 The addition of 2% lanolin to batches containing Tween 20 (F08 and F09) increased the 
release rate to approximately 67% and 51% for F09 and F08 in 180minutes, respectively. 
 The addition of Lecithin in 1% (w/w) to the formulations containing SLS and Tween 20 
(i.e. F10, F11, F12, and F13) reduced the melting points; however the release rate was not 
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improved significantly as was expected. This could be a consequence of micelles 
entrapment of the CFA. 
 Tween 85 1% (w/w) (HLB  11) was used as a nonionic surfactant in the production of 
batches F14, F15, and F16. Lanolin 1% was added to batch no. F15 and lecithin 1% was 
added to batch no. F16. The results showed a significant decrease in the melting point (36 
– 37oC) and a significantly increase in the percentage of CFA release especially in the 
case of batch F15 containing lanolin anhydrous showed the higher release rate (about 
91% at 180min), however the batch containing lecithin didn't show a high release rate as 
was expected although the suppositories were completely melted at the first stages of the 
dissolution testing and micelles were clearly observed at the top of dissolution vessels. 
The inadequacy in the release rate of CFA from this batch could be a consequence of 
micelles entrapment of the CFA. 
Table 4.12 Cumulative percentage release of CFA from all formulations using (USP apparatus I, 
modified basket): 
Formulation 15 min 30 min 45 min 60 min 120 min 180 min 
F01 2 3 3 4 6 8 
F02 4 5 6 7 9 10 
F03 8 11 12 14 16 18 
F04 11 18 24 28 40 45 
F05 19 19 24 29 43 49 
F06 55 71 78 78 82 82 
F07 9 18 22 28 44 48 
F08 15 24 29 33 44 51 
F09 15 30 32 38 58 67 
F10 27 40 45 50 64 75 
F11 29 46 53 56 63 78 
F12 7 12 17 21 31 38 
F13 7 15 26 33 54 64 
F14 20 40 41 52 74 81 
F15 22 54 71 80 91 91 
F16 15 27 35 37 56 68 
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     Figure 4.1 Comparative dissolution profiles of all formulations (USP apparatus I, modified 
basket) 
 
 Figures 4.2 to 4.6 represent comparative dissolution profiles between similar formulations with 
different surfactant concentration.  
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Figure 4.2 Comparative dissolution profiles between F1, F2 and F3  
 
Figure 4.3 Comparative dissolution profiles between F1, F6 and F7  
 
 
Figure 4.4 Comparative dissolution profiles between F1, F10 and F11  
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Figure 4.5 Comparative dissolution profiles between F1, F12 and F13   
 
Figure 4.6 Comparative dissolution profiles between F1, F14 and F15, F16   
4.2.6.2 In-vitro release using flow through cell: 
Six batches (F01, F07, F11, F14, F15, and F16) were tested for dissolution release rate using the 
modified flow through cell for a time period of 60 minutes. The results obtained are illustrated in 
table 4.13 and depicted in figure 4.7. The addition of the surfactants and the solubilizers 
increased the release rate, where it approached the maximum (98% at 60min) in batch F16 with 
Tween 85 and lecithin. All batches showed a significant increase in the percentage release rate. 
These results could be explained as a consequence of the continuous flow of fresh dissolution 
medium through the molten suppository mass as compared to the constant exposure that prevails 
with the modified USP apparatus I. In this case drug exchange at the lipid/water interface 
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over the product maintained a concentration gradient between the saturation solubility 
concentration at the solid/liquid interface and the solute concentration in the bulk of the system, 
therefore there is a potential for mass transfer.  
The objective of the flow through cell design is to expose the product to a homogeneous, non-
turbulent, laminar flow to avoid the problems associated with a stirring mechanism, which are: 
 When the stirring is fast, eddies are formed and hence the dissolved particles resides in 
these eddies and as a result the dissolution rate is low. 
 When stirring is very slow, eddies are not formed; however the dissolved particles are 
not homogeneously distributed in the vessel.  
Table 4.13 Cumulative percentage release of CFA from selected formulations (flow through 
cell): 
Formulation 5 min 10 min 15 min 30 min 45 min 60 min 
F01 23 39 48 59 64 68 
F07 29 51 57 59 65 68 
F11 81 96 93 92 90 85 
F14 5 17 31 68 83 88 
F15 51 63 78 72 85 87 
F16 73 87 92 92 94 98 
 
 
Figure 4.7 Comparative dissolution profiles (flow-through cell) 
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4.3 Mathematical Modeling of dissolution rate profile:  
To determine the mechanism by which CFA is released from suppositories manufactured using 
fatty bases, dissolution data were fitted to selected mathematical models. The Korsmeyer-Peppas 
model was used to characterize drug release behavior from all batches, in the absence and 
presence of additives. The data were also fitted to the Higuchi, Zero order, First order and 
Weibull mathematical models to determine which model best described the release kinetics of 
CFA from these formulations using DD solver program (Yong Zhang, et al, 2010). 
4.3.1 Application of the Korsmeyer-Peppas model:  
An analysis of the fitting of experimental data to the Korsmeyer-Peppas model, as described in 
Equation 1.7, in addition to the interpretation of the corresponding release exponent values (n) 
were used to characterize  and understand the mechanism by which CFA was released from these 
products.  
The best-fit model parameters obtained following fitting of experimental data obtained from 
these formulations are listed in Table 4.14.  
The release exponent n was found to be 0.6000, 0.5840, and 0.5410 for batches F01, F07, and 
F16 indicating that the release mechanism from these dosage forms was controlled by non-
Fickian diffusion, whereas the n value determined for batch F14 was found to be 0.4800, 
suggesting that the release mechanism of CFA from this batch was controlled by Fickian 
diffusion as n ≈ 0.50. The release mechanism elucidated for batches F02, F03, F06, F10, and 
F15, was not able to be explained by the Korsmeyer-Peppas model, since the resultant n values 
(n<0.5) did not fall within the specified range. The inability to ascribe the mechanism of release 
to these batches of suppositories may in part be explained by the change in geometry of the 
suppositories dosage forms on melting, since n is affected by the change in shape of the product. 
It was observed that as the suppositories melt, they acquire the shape of the base of the basket in 
which they are placed during dissolution testing. These suppositories changed from a cone-like 
shape, in the solid state, to a flattened circular-disk shape after melting.  
The kinetic constants (k) calculated are summarized in Table 4.14. Since the Korsmeyer-Peppas 
kinetic constant incorporates the structural and geometric characteristics of dosage forms, the 
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change in matrix geometry, as implicated by the change in n value, affected the k value directly. 
It is clear that there is a direct relationship between the total percentage CFA released and the 
kinetic rate constant in batches F01, F02, and F03, where SLS surfactant was added to 
formulations F02, and F03. However after the addition of Lanolin anhydrous and Lecithin S to 
the formulations containing the SLS and Tween 85, it was clear that there is no relationship 
between the total percentage CFA released and the kinetic rate constant. This implies that the 
melting rate of the formulations affected the structural and geometric characteristics of the 
suppository formulations, which in turn affects the resultant n and k values.  
Table 4.14 Summary of Korsemeyer-Peppas best-fit parameters 
Batch NO. n Kp R
2
Adjusted 
F01 0.6 0.348 0.9890 
F02 0.297 1.451 0.9963 
F03 0.297 3.895 0.9921 
F06 0.13 43.98 0.9711 
F07 0.584 2.446 0.978 
F10 0.379 10.508 0.9968 
F11 0.323 14.4 0.9757 
F14 0.48 6.98 0.9773 
F15 0.361 15.5 0.8842 
F16 0.541 4.14 0.9933 
 
4.3.2 Application of other mathematical models: 
To establish the kinetics of drug release in a more comprehensive way, dissolution data 
generated during the study were fitted to various drug release kinetic models, including the 
Higuchi, Zero order, First order and Weibull models.  
The selection criterion for the best-fit model was based on the adjusted coefficient of 
determination, R
2
 adjusted. The R
2
 adjusted value was used to compare the results of fitting data 
to kinetic models with different numbers of parameters. The results of fitting the dissolution data 
to selected mathematical models are summarized in Table 4.15 
When comparing the results of model fitting using the R
2
 adjusted selection criteria, the Weibull 
model was found as the model that best fitted the dissolution data for CFA release from 
suppository formulations. When model fitting was conducted R
2
 adjusted values for these studies 
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ranged between 0.9830 and 0.9970. This result is in agreement with the nature of drug release 
from lipophilic suppository formulations which is often accompanied by long-lasting lag phase, 
that occurs as a result of the need for the base to melt prior to drug release and therefore the 
melting rate of the base is a factor that contributes to the lag time. The values of α, which is 
considered as the interval necessary for the process to reach 63.2% of the drug present in the 
product to be dissolved or to be released, was observed to be proportional to the percentage 
release of the different batches in the study. 
None of the formulations was observed to fit the Zero Order model. This indicates that the 
release from all formulations is concentration dependent and hence the results came in agreement 
with the lipophilic nature of the drug substance and the suppository base which are not soluble in 
the aqueous media. 
Three formulations (F14, F15, and F16) which contain Tween 85, Lanoline and Lecithin as 
surfactant and solubilisers were observed fitting the First Order model. The result could be a 
consequence to the presence of the surfactant and the solubilisers which helped in making 
emulsion during the dissolution testing. 
Six batches were observed fitting Higuchi model (F01, F02, F07, F10, F14, F16) indicating that 
diffusion was the predominant factor that controlled the CFA release from these bathes. The KH 
values were observed to be a function of the surfactant type and percentage and also to the type 
of solubilisers used. The highest value was observed for the bathes that contained Tween 85.  
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          Table 4.15 Results of model parameters obtained following fitting CFA dissolution data:  
Model Type 
 
Zero Order 
 
First Order 
 
Higuchi Model 
 
Weibull Model 
 
Parameter 
 
R
2
 Adj  
 
K0 R
2
 Adj  
 
K1 R
2
 Adj  
 
KH R
2
 Adj  
 
α β Ti 
Formula  
F01 0.846 0.05 0.859 0.001 0.977 0.552 0.986 298.3 0.614 -0.001 
F02 0.3399 0.071 0.4465 0.001 0.9610 0.822 0.9961 62.97 0.369 9.282 
F03 0.0977 0.131 0.2119 0.001 0.8800 1.549 0.9966 18.67 0.254 9.282 
F06 -0.865 0.668 0.828 0.038 0.4678 8.284 0.997 1.113 0.135 14.85 
F07 0.8109 0.322 0.9298 0.005 0.9711 3.609 0.9886 32.638 0.605 8.825 
F10 0.4129 0.519 0.8542 0.011 0.9635 6.045 0.9965 14.589 0.572 14.589 
F11 0.204 0.545 0.793 0.013 0.899 6.423 0.983 5.31 0.383 10.04 
F14 0.551 0.559 0.965 0.012 0.980 6.382 0.985 24.16 0.719 3.69 
F15 0.267 0.670 0.976 0.025 0.858 8.210 0.993 5.79 0.558 13.13 
F16 0.444 0.770 0.952 0.008 0.992 5.000 0.995 35.7 0.711 2.276 
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4.4 Stability studies of selected formulations  
The stability data for the selected batches (F01, F07, F11, F14, F15, and F16) are illustrated in 
Tables (3.16-3.21). The rest of formulations (F04, F05, F08, F09, F12, and F13) which contain 
Tween 20 as a surfactant were excluded from the study as they were out of specifications at 
initial time. The following discussion is a summary of the stability study observations:  
Formulation batch no.F01: 
 An increase in the disintegration time (10-18 min) which could be a consequence 
to the hardening effect in storage. 
 An assay decrease (≈5%) at the storage conditions (30°C / 60%RH), and a slight 
increase in the degradation materials (free cefuroxime and the Δ3 isomer) 
quantities at both storage conditions (25°C / 60%RH), and (30°C / 60%RH) as a 
consequence of the temperature and humidity effects on CFA which is heat and 
humidity sensitive. 
Formulation batch no. F07 and F11: 
 A slight change in colour and sediments were observed at 30°C during the three 
months storage period, and the third month at 25°C. This could be due to 
polymorphism formation or increased crystallinity of the active ingredient. 
 The suppositories were softened during the disintegration time testing and didn’t 
disintegrate without pressing on them. This could be due to the hardening, 
polymorphism or increased crystallinity of the suppository base and the active 
ingredient.  
 A slight increase in the degradation materials (free cefuroxime and the Δ3 isomer) 
quantities at (30°C / 60%RH) as a consequence of the temperature and humidity 
effects on CFA which is heat and humidity sensitive. 
 A significant decrease in the dissolution release rate at 30°C and slight decrease at 
25°C due to the hardening and polymorphism effects. 
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Formulation batch no. F14, F15 and F16: 
 A clear change in colour and sediments were observed at 30°C during the three 
months storage period. 
 A significant decrease (more than 5%) in the CFA assay at the 25 & 30°C storage 
conditions. 
 A significant increase in degradation materials quantities (free cefuroxime and the 
Δ3 isomer) at 25 & 30°C storage conditions as a consequence of the temperature 
and humidity effects on CFA which is heat and humidity sensitive and also the 
presence of Tween 85 increased this effect. 
 A significant decrease in the dissolution release rate at 25 & 30°C was observed 
in batch no. F14 due to the hardening and polymorphism effects. However, the 
decrease was very minor in batches F15 and F16 at 25°C, which could be due to 
the presence of lanoline and lecithin in the two bathes.  
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Table 4.16 Stability results, batch no. F01 
 
 
 
2 - 8
o
C 30
o
C/60% RH 25
o
C/60% RH Zero Time B.N. F-01 
3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
                        
Time/month       
Test 
No 
change 
No 
change 
No 
change 
No 
change 
No 
change 
No 
change 
No 
change 
No 
change 
No 
change 
White, smooth, no 
sediments. 
Description 
1.180 1.195 1.215 1.159 1.27 1.282 1.280 1.251 1.233 1.234  Av. Wt/gm 
37.5-38.2 37-38 36.5-
37.5 
38-38.7 36.7-38 37.2 – 
39
 
 
37-38
 
 36.7-38
 
 37.1 – 
38 
37 – 39 M.P ( oC ) 
11 min 10 min 18 min 13 min 12 min 13 min 13 min 11 min 14 min 10 min Disintegration 
98 98 99.7 101 95 94 99 100.8 103% 100.67% % Assay 
          Degradation: 
0.39 0.18 0.364 0.71 0.69 0.333 0.59 0.42 0.298 0.455% % Free Cefuroxime 
0.57 0.69 0.807 1.67 1.655 1.02 1.26 1.28 1.106 0.84% % Delta Isomer 
N.D N.D 0.089 N.D N.D 0.071 N.D N.D 0.064 N.D % E1 Enantiomer 
N.D N.D 0.057 N.D N.D 0.049 N.D N.D 0.044 N.D % E2 Enantiomer 
         % Release  Dissolution: 
3 3 4 2 1 2 3 2 2 2 15 min 
3 6 6 3 2 2 3 3 2 3 30 min 
4 8 7 4 2 1 8 4 3 3 45 min 
9 10 8 5 2 1 9 6 4 4 60 min 
11 11 10 7 4 3 11 6 10 6 120 min 
12 13 14 9 5 5 12 8 15 8 180 min 
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   Table 4.17 Stability results, batch no. F07 
2 - 8
o
C 30
o
C/60% RH 25
o
C/60% RH Zero Time B.N. F-07 
3
rd
 
month 
2
nd
 
month 
1
st 
month 
3
rd
 
month 
2
nd
 
month 
1
st
 
month
 
 
3
rd
 
month 
2
nd
 
month 
1
st 
month 
                       Time/month     
Test 
No 
change 
No 
change 
No 
change 
Creamy, 
with 
sediments 
Creamy 
,with 
sediments 
Creamy-
white, 
little 
sediment 
Creamy-
white, 
little 
sediment 
No change No change White, smooth, no 
sediments. 
Description 
1.315 1.265 1.245 1.214 1.246 1.277 1.123 1.189 1.255 1.246 Av. Wt 
37.4
 
 36.9
 
 37.5-38 38.7-39 38-38.5
 
 37.6-38.2 37-37.7
 
 36.6-37.8 36.9-37.2 37-37.5 M.P/
o
C 
10 7 11 13
* 
10
* 
10
*
 10 8 10  10 Disintegration time/min 
97 99.8 100 98 95 102 97 98 101.6 103.6 % Assay 
          Degradation: 
0.59 0.46 0.479 1.34 1.03 0.627 0.90 0.69 0.454 0.747 % Free Cefuroxime 
0.70 0.75 0.888 2.56 2.39 1.96 1.41 1.32 1.14 0.952 % Delta Isomer 
N.D N.D 0.097 N.D N.D 0.099 N.D N.D 0.092 N.D
** 
% E1 Enantiomer 
N.D N.D 0.057 N.D N.D 0.069 N.D N.D 0.056 N.D % E2 Enantiomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % Impurities 
unidentified 
          Dissolution: 
16 15 21 1 3 1 9 10 10 9 15 min 
24 21 30 2 4 1 14 13 15 18 30 min 
28 25 34 2 4 3 15 16 22 22 45 min 
32 30 41 2 5 3 19 18 25 28 60 min 
38 38 47 3 6 9 21 19 48 44 120 min 
38 40 50 4 7 12 23 21 52 48 180 min 
 
*Suppositories softened only. 
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    Table 4.18 Stability results, batch no. F11 
2 - 8
o
C 30
o
C/60% RH 25
o
C/60% RH Zero Time B.N. F-11 
3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
                        Time/month     
Test 
No 
change 
No 
change 
No change Creamy-
white, 
little 
sediment 
No 
change 
No 
change 
No change No 
change 
No change White, smooth, no 
sediments. 
Description 
1.277 1.253 1.23 1.245 1.180 1.24 1.293 1.242 1.237 1.197 Av. Wt 
37.4-38 37.1-37.8 36.8-37.5 38-38.5 37-37.7 36.8-37.2 37.1-37.9 36.9-37.6 37.3-37.8 37-37.5 M.P/
o
C 
10 7 10 11 7 7 10 10 10 10 Disintegration time/min 
100 99.5 101 97.5 96 100 99.3 97 100.8 100.5 % Assay 
          Degradation: 
0.87 0.59 0.627 1.58 1.13 0.667 1.14 1.0616 0.699 0.903 % Free Cefuroxime 
0.77 0.89 0.828 2.16 1.83 0.944 1.06 1.208 1.44 1.00 % Delta Isomer 
N.D N.D 0.117 N.D N.D 0.099 N.D N.D 0.100 0.101
 
% E1 Enantiomer 
N.D N.D 0.066 N.D N.D 0.055 N.D N.D 0.069 0.072 % E2 Enantiomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % Impurities 
unidentified 
          Dissolution: 
25 26 17 5 8 23 17 15 25 29 15 min 
40 38 30 5 18 31 26 29 34 46 30 min 
45 43 40 6 23 34 33 36 37 53 45 min 
52 47 43 8 27 36 35 41 40 56 60 min 
59 56 53 12 33 41 40 50 47 63 120 min 
62 62 57 15 39 43 44 56 50 68 180 min 
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     Table 4.19 Stability results, batch no. F14 
2 - 8
o
C 30
o
C/60% RH 25
o
C/60% RH Zero Time B.N. F-14 
3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
                        Time/month     
Test 
No 
change 
No 
change 
No 
change 
Creamy 
with 
sediments 
Creamy,
with 
sediments 
Creamy-
white, 
little 
sediment 
No change No change No change White, smooth, 
no sediments. 
Description 
1.250 1.233 1.225 1.275 1.268 1.229 1.226 1.219 1.247 1.236 Av. Wt 
37.5-38.6 37-38 37.1-37.7 37.4- 38.3 37.5-38 37.2-37.7 36.8-37.5 37.2-37.8 37-37.5 36.5-37.4 M.P/
o
C 
10 10 7 18
* 
14
* 
12
* 
13 12 8 7 Disintegration time/min 
95 98 100 85 88.6 92 92.5 89.5 93 105 % Assay 
          Degradation: 
1.16 1.65 1.24 7.12 4.06 2.54 5.10 3.10 2.156 0.42 % Free Cefuroxime 
2.47 2.29 2.37 5.91 5.25 4.94 4.46 4.03 4.25 1.96 % Delta Isomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % E1 Enantiomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % E2 Enantiomer 
N.D N.D N.D 0.83 0.50 0.32 0.695 0.41 N.D N.D % Impurities 
unidentified 
          Dissolution: 
12 18 16 2 1 2 2 3 4 20 15 min 
30 29 34 4 2 2 17 10 9 40 30 min 
42 45 51 4 2 3 20 14 13 41 45 min 
62 59 75 4 2 3 21 20 16 52 60 min 
78 77 83 5 3 6 24 27 41 74 120 min 
83 81 85 8 5 7 26 31 54 81 180 min 
*Suppositories softened only. 
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Table 4.20 Stability results, batch no. F15 
2 - 8
o
C 30
o
C/60% RH 25
o
C/60% RH Zero Time B.N. F-15 
3
rd
 month 2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 month 2
nd
 
month 
1
st
                        Time/month     
Test 
No change No 
change 
No 
change 
Creamy 
with 
sediment
s 
Creamy 
with 
sediment
s 
Creamy to 
brown 
with 
sediments 
No change No change No change Creamy,  
smooth,  no 
sediments. 
Description 
1.219 1.219 1.245 1.229 1.207 1.237 1.259 1.226 1.250 1.297 Av. Wt 
38.2- 38.5 37.8-38.2 37.1-38 38.1-38.6 37.5-38 36.7-37.5 37.9 38.2 36.7-37.5 36.7-37.3 36.8-37.6 M.P/
o
C 
9 10 7 13
* 
11
*
 11
* 
10 12 8 7 Disintegration time/min 
95.5 97.7 100.5 90.6 85 86.5 87.8 88 87 101 % Assay 
          Degradation: 
1.22 2.12 1.69 7.67 5.24 2.96 5.77 3.77 2.5 0.495 % Free Cefuroxime 
2.61 2.12 2.51 6.1 5.77 5.27 5.10 4.20 3.93 2.18 % Delta Isomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % E1 Enantiomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % E2 Enantiomer 
N.D 0.18 0.17 0.90 0.64 0.44 0.67 0.44 0.30 N.D % Impurities 
unidentified 
          Dissolution: 
19 21 21 3 16 3 10 24 17 43 15 min 
71 40 52 4 8 4 22 31 40 56 30 min 
75 68 79 4 6 5 23 38 66 78 45 min 
80 80 91 4 3 6 25 54 78 83 60 min 
91 93 99 6 8 12 74 81 95 91 120 min 
95 95 97 8 9 17 92 92 94 91 180 min 
 
*Suppositories softened only. 
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     Table 4.21 Stability results, batch no. F16 
2 - 8
o
C 30
o
C/60% RH 25
o
C/60% RH Zero Time B.N. F-16 
3
rd
 
month 
2
nd
 
month 
1
st
 3
rd
 month 2
nd
 
month 
1
st
 3
rd
 
month 
2
nd
 
month 
1
st
                        Time/month     
Test 
No 
change 
No 
change 
No 
change 
Faint 
brown 
smooth 
with 
sediments. 
Faint 
brown, 
smooth 
with 
sediments. 
Faint 
brown, 
smooth, 
with 
sediments. 
Faint 
brown, 
smooth, no 
sediments. 
Faint 
brown, 
smooth, no 
sediments. 
Faint brown, 
smooth, no 
sediments. 
Faint yellow, 
smooth, no 
sediments. 
Description 
1.197 1.214 1.246 1.233 1.232 1.260 1.237 1.234 1.243 1.230 Av. Wt 
36-37.1 36.3-
37.3 
36-37.2 37.5-38.2 37.5-38 37.3-37.7 35.7-36.5 36.3-37 35.8-36.7 36-36.5 M.P/
o
C 
9 10 6 12 13 10 10 10 7 7 Disintegration time/min 
95 98.7 98.8 84 86 88 90 83 91 100.6 % Assay 
          Degradation: 
2.84 2.37 1.94 10.06 6.93 4.2 7.01 5.26 3.4 0.598 % Free Cefuroxime 
2.44 1.87 2.47 6.85 6.15 5.9 5.45 4.63 4.6 2.3 % Delta Isomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % E1 Enantiomer 
N.D N.D N.D N.D N.D N.D N.D N.D N.D N.D % E2 Enantiomer 
0.24 0.19 0.21 1.09 0.82 0.60 0.76 0.73 0.42 N.D % Impurities 
unidentified 
          Dissolution: 
8 10 24 5 4 10 7 5 8 15 15 min 
12 13 24 6 5 14 12 14 15 27 30 min 
17 19 29 8 4 21 16 26 22 35 45 min 
29 24 37 12 9 18 21 36 30 37 60 min 
48 41 49 8 12 40 36 39 54 56 120 min 
61 63 65 16 15 47 47 54 61 68 180 min 
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Figure 4.8 Comparative dissolution profiles for batch F11 stored at 25
o
C for 3 months 
 
Figure 4.9 Comparative dissolution profiles of batch F11stored at 30
o
C for 3 months 
 
 
Figure 4.10 Comparative dissolution profiles of batch F11 stored at 2-8
o
C for 3 months 
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Figure 4.11 Comparative dissolution profiles of batch F7 stored at 2-8
o
C for 3 months  
 
Figure 4.12 Comparative dissolution profiles of batch F7 stored at 25
o
C for 3 months 
 
Figure 4.13 Comparative dissolution profiles of batch F7 stored at 30
o
C for 3 months  
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Figure 4.14 Comparative dissolution profiles of batch F16 stored at 2-8
o
C for 3 months  
 
Figure 4.15 Comparative dissolution profiles of batch F16 stored at 25
o
C for 3 months 
 
Figure 4.16 Comparative dissolution profiles of batch F16 stored at 30
o
C for 3 months 
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Figure 4.17 Comparative dissolution profiles of batch F15 stored at 2-8
o
C for 3 months 
 
Figure 4.18 Comparative dissolution profiles of batch F15 stored at 25
o
C for 3 months 
 
Figure 4.19 Comparative dissolution profiles of batch F15 stored at 30
o
C for 3 months  
 
0
20
40
60
80
100
120
0 15 30 45 60 120 180
R
e
le
as
e
(%
) 
Time(min) 
F15 at 2-8 oC 
Zero
1st
2nd
3rd
0
20
40
60
80
100
0 15 30 45 60 120 180
R
e
le
as
e
(%
) 
Time(min) 
F15 at 25 oC /60%RH 
Zero
1st
2nd
3rd
0
20
40
60
80
100
0 15 30 45 60 120 180
R
e
le
as
e
(%
) 
Time(min) 
F15 at 30 oC/60%RH 
Zero
1st
2nd
3rd
 116 
 
 
Figure 4.20 Comparative dissolution profiles of batch F14 stored at 2-8
o
C for 3 months 
 
Figure 4.21 Comparative dissolution profiles of batch F14 stored at 25
o
C for 3 months 
 
Figure 4.22 Comparative dissolution profiles of batch F14 stored at 30
o
C for 3 months 
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4.5 Analytical Method validation Results 
4.5.1 Assay method validation: 
The method was validated according to USP category I and the ICH Q2 (R1) guidelines for the 
quantitation of drug substance in dosage forms. As the guidelines require; the accuracy, 
precision, specificity, linearity and range are assessed in order to ensure that the method is 
reliable. In addition the limit of quantitation (LOQ) and limit of detection (LOD) were also 
determined. The stability of the CFA in an aqueous solution was also determined.    The results 
are clarified in the following tables and figures. 
4.5.1.1 Linearity 
Linearity was assessed by analyzing ten standard sample solutions of different concentrations. 
The calibration curve was plotted in order to establish whether a correlation between response 
and analyte concentration existed. A typical calibration curve obtained for these studies is 
depicted in Figure 4.23. The linearity of the method was established from the correlation 
coefficient (R
2
) of the best fit least squares linear regression  curve, which was obtained by 
plotting peak areas versus known CFA concentrations. For these studies, an R
2
 value of > 0.990 
was considered appropriate to demonstrate the linearity of the analytical method. The calibration 
curve was found to be linear over the concentration range stated, with an R
2
 of 0.9999 and the 
equation for the line of y = 4544.3x + 4347.1. 
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Table 4.22 linearity results of HPLC assay method validation  
Conc. % St. Conc. 
mg/ml 
Peak Area 
1 
Peak Area 
2 
Peak Area 
3 
Average %RSD 
10% 0.025 2366472 2353809 2364787 2361689.33 0.29 
20% 0.05 4690796 4688138 4658794 4679242.66 0.38 
30% 0.075 6783518 6820667 6849720 6817968.33 0.49 
40% 0.1 9005470 9035022 9050428 9030306.67 0.25 
60% 0.15 13253757 13270062 13303616 13275811.67 0.19 
80% 0.2 17957105 17824477 18137927 17973169.67 0.88 
100% 0.25 22468536 22503691 22547026 22506417.66 0.17 
120% 0.3 27135946 26984281 27086790 27069005.66 0.29 
140% 0.35 31665006 31532767 31775682 31657818.33 0.38 
160% 0.4 35807222 36016087 35872141 35898483.33 0.30 
 
 
 
Figure 4.23 Linearity graph for HPLC method validation 
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4.5.1.2 Accuracy 
The percentage CFA recovered from spiked placebo samples for three concentrations, i.e. 80, 
100, 120 % respectively was calculated in addition to the % RSD of the three readings of each 
spiked sample. An acceptance criteria for accuracy was considered to be % RSD<2.0% and a 
recovery of 100+2.0%. 
The results obtained are clarified in table 4.23 and figure 4.24. The resultant values for % RSD 
and recovery satisfied the criteria and the plot of peak areas vs. concentration were found linear 
with an R
2
 value of 0.9991.  
Table 4.23 Accuracy results of HPLC method validation 
No. of 
injectio
n 
Target 
Conc. 
(%) 
Theo. Conc. 
(mg / ml) 
Conc. after 
Spiking (mg/ml) 
Spiked Sample 
Response  
Recovery 
(%) 
Mean 
(%) 
RSD 
(%) 
1.1 
80% 
 
 
0.2 
0.2005 18026135 100.25  
100.33 
 
0.06 1.2 0.2008 18047464 100.4 
1.3 
0.2007 18037957 100.35 
2.1 
100% 
 
 
0.25 
0.247 22216157 98.8  
99.2 
 
 
0.41 
 
2.2 0.249 22390118 99.6 
2.3 
0.248 22348501 99.2 
3.1 
120% 
 
 
0.3 
0.3007 27135946 100.2  
99.99 
 
0.29 3.2 
0.2991 26984281 99.7 
3.3 0.3002 27086790 100.06 
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Figure 4.24 HPLC method validation accuracy regression line 
  
4.4.1.3 Precision: 
The precision is the ability of a method to produce precise analytical results from a series of 
measurements of the same homogenous sample under prescribed assay conditions. The standard 
deviation (SD) or percentage relative standard deviation (% RSD) of a series of measurements is 
usually used to assess the precision of an analytical method. The % RSD is calculated using the 
following equation. 
                             
σ
 
 
Where, 
σ = Standard deviation around the mean of a set number of samples (calculated using nonbiased 
or n-1 method)  
X = Mean of the peak height ratio responses for a set number of samples 
The precision of the method was considered at two levels, repeatability and intermediate 
precision.  A value for % RSD of < 1.5% was set as an acceptable limit 
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Repeatability: 
The repeatability was determined by the analysis of six determinations at 100% of the test 
concentration. The repeatability results obtained are shown in Table 4.24.The results reveal that 
% RSD values were within the acceptable limits thus the method is repeatable for the analysis of 
CFA suppositories. 
Intermediate precision: 
Intermediate precision or inter-day variability expresses the within laboratory variation. The 
accuracy testing was repeated by different analyst and using different instrument. The results of 
these studies are listed in Tables 4.25 and 4.26. The results show that all % RSD values fell 
below 1.5%, which is within the limits and therefore the method is precise.                                 
Table 4.24 Repeatability results of HPLC method validation 
 N Concentration 
(mg/ ml) 
Response Average 
Response 
SD of 
Response 
% RSD 
Standard 
1 
0.25 
 
32494885  
 
318687559 
 
 
422009 
 
1.3 
 
2 32089680 
 
3 31988964 
4 31707647 
5 31827885 
6 31103493 
  
Sample 
1 
0.25 
32674912  
33238609 
404851 1.2 
2 32776548 
3 33188534 
4 33666096 
5 33394346 
6 33731217 
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Table 4.25 Intermediate precision results using Elite HPLC Instrument 
No. of 
injectio
n 
Target 
Conc. 
(%) 
Theo. Conc. 
(mg / ml) 
Conc. after 
Spiking (mg/ml) 
Spiked Sample 
Response  
Recovery 
(%) 
Mean 
(%) 
RSD 
(%) 
1.1 
80% 
 
 
0.2 
0.2005 18026135 100.25  
100.33 
 
0.06 1.2 
0.2008 18047464 100.4 
1.3 
0.2007 18037957 100.35 
2.1 
100% 
 
 
0.25 
0.247 22216157 98.8  
99.2 
 
 
0.41 
 
2.2 
0.249 22390118 99.6 
2.3 
0.248 22348501 99.2 
3.1 
120% 
 
 
0.3 
0.3007 27135946 100.2  
99.99 
 
0.29 
3.2 
0.2991 26984281 99.7 
3.3 
0.3002 27086790 100.06 
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Table 4.26 Intermediate precision results using Ultimate 3000 HPLC Instrument 
No. of 
injectio
n 
Target 
Conc. 
(%) 
Theo. Conc. 
(mg / ml) 
Conc. after 
Spiking (mg/ml) 
Spiked Sample 
Response  
Recovery 
(%) 
Mean 
(%) 
RSD 
(%) 
1.1 
80% 
 
 
0.2 
0.202 90.88 101 101.17 0.283 
1.2 0.203 91.51 101.5 
1.3 
0.202 91.12 101 
2.1 
100% 
 
 
0.25 
0.254 114.00 101.6 101.3 0.228 
2.2 0.253 113.91 101.2 
2.3 
0.253 113.89 101.2 
3.1 
120% 
 
 
0.3 
0.303 134.74 101 101.8 0.839 
3.2 
0.305 136.00 101.7 
3.3 
0.308 136.97 102.7 
 
4.5.1.4 Specificity / Selectivity Test: 
It is a measure of the degree of interference from materials other than active material, such as 
excipients, impurities, and degradation products. It should be ensuring that the peak response is 
due to a single component only. To validate for specificity, the interference from excipients and 
the Interference with degradants were determined.  
 The interference with excipients was determined by finding the response of the excipients alone, 
the response of the active material (100%) alone and the response of a spiked sample, and then 
the percentage recovery was calculated. From the results in table 4.25, it is observed that there is 
no interference with the excipients. The interference with degradation products was determined 
by performing forced degradation studies on solutions containing CFA (0.25 mg / ml), and the 
resolution and % recovery of CFA were determined. The results are summarized in table 4.28, 
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from which the resolutions of all degradation products were found to be more than the minimum 
accepted limits (˃ 1.5). The results of the forced degradation studies indicate that the method has 
a high degree of selectivity for the determination of CFA in the presence of degradation 
products.  
Following exposure of CFA API to basic conditions, a golden yellow solution resulted when 
compared to the colorless control solution. The resultant chromatogram following exposure of 
CFA API to basic conditions is depicted in Figure 4.26. It is evident that the degradation of CFA 
API is significant with four degradation products under basic conditions. One of the major 
degradation products reported to be found after base degradation of CFA is the free cefuroxime, 
which is known to be produced after a hydrolysis process.  
CFA was found to be relatively stable when stored under Acidic conditions at room temperature. 
When CFA was treated with a 0.5 M HCl solution, no degradation products were observed after 
three hours storage.  
 Following exposure of CFA to a solution of 10% v/v H2O2 at ambient temperature, it was 
evident as shown in figure 4.27 that the degradation of CFA is significant. Four degradation 
products were observed; from the peaks of these products the free cefuroxime product was 
identified. 
The exposure of CFA solution to heat at 60
o
C for a period of one hour lead to the appearance of 
four degradation products; free cefuroxime, Δ3Isomer, and unidentified two products (degradants 
1 and 2) as shown in figure 4.30. 
The exposure of CFA solution to U.V light for a period of twenty hours lead to the appearance of 
four degradation products; free cefuroxime, Δ3Isomer, and cefuroxime E1 & E2 Enantiomer as 
shown in figure 4.29. 
The CFA solution was kept in the refrigerator (2-8
o
C) for a period of 24 hours and it was 
observed that the quantities of free cefuroxime and of Δ3Isomer were slightly increased.  
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The CFA solution was kept at room temperature for a period of 24 hours and it was observed that 
the quantities of free cefuroxime and of Δ3Isomer were increased and the unidentified 
degradation product (3) appeared.  
Table 4.27: No interference from excipients 
 Average Response 
X 10
3 
Theoretical conc. 
(mg/ml) 
Recovery 
% 
Retention time 
(min.) 
Synthetic 
mixture 
No response 0.00 0.00 N.A 
Diluent No response 0.00 0.00 N.A 
100% TC 
Standard 
22506.4 0.25 100 Isomer B 8.84 
Isomer A 10.19 
100% Sample 22318.3 0.25 99.2 Isomer B 9.14 
Isomer A 10.61 
 
 
 
 
 
 
 
 
. 
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Figure 4.25: typical chromatogram obtained for CFA obtained for CFA at normal conditions.  (1) 
unretained, (2) free cefuroxime, (3) cefuroxime axetil diastereoisomer B, (4) cefuroxime axetil 
diastereoisomer A. 
 
 Figure 4.26 typical chromatogram obtained for CFA following base degradation. (1) unretained, 
(2) free cefuroxime, (3) unidentified degradant1, (4) unidentified degradant 2, (5) cefuroxime 
axetil diastereoisomer B, (6) cefuroxime axetil diastereoisomer A, (7) unidentified degradant 3   
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Figure 4.27: typical chromatogram obtained for CFA following exposure to 10% H2O2. (1) 
unretained , (2) unidentified degradant1, (3) free cefuroxime, (4) unidentified degradant2, (5) 
unidentified degradant3, (6)  unidentified degradant4, (7) cefuroxime axetil diastereoisomer B, 
(8) cefuroxime axetil diastereoisomer A    
 
 
Figure 4.28: typical chromatogram obtained for CFA following exposure to 0.5 M HCl. (1) 
unretained, (2) free cefuroxime, (3) cefuroxime axetil diastereoisomer B, (4) cefuroxime axetil 
diastereoisomer A    
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Figure 4.29: typical chromatogram obtained for CFA obtained following exposure to U.V light. 
(1) Unretained, (2) free cefuroxime, (3) unidentified degradant1, (4) unidentified degradant2, (5) 
cefuroxime axetil diastereoisomer B, (6) cefuroxime axetil diastereoisomer A, (7) cefuroxime 
axetil delta-3 isomer, (8) cefuroxime axetil E1 enantiomer, (9) cefuroxime axetil E2 enantiomer      
 
 
Figure 4.30: typical chromatogram obtained for CFA obtained following exposure to heat at 
60
o
C for 1 hr. (1) unretained, (2) free cefuroxime, (3) unidentified degradant1, (4) unidentified 
degradant2, (5) cefuroxime axetil diastereoisomer B, (6) cefuroxime axetil diastereoisomer A, 
(7) cefuroxime axetil delta-3 isomer. 
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Table 4.28: CFA Interference with degradation products 
 
 
 
 
 
Secondary Peaks Detected 
 Free Cefuroxime Δ3 Isomer E Isomers ( E1+E2) 
Sample Conc. 
Mg/ml 
% 
Recov. 
Area 
A&B 
X10
6 
# of* 
peaks 
Res. 
B&A 
Area 
X10
3 
Rt % RRT Res. Area 
X10
3 
Rt % RRT Res. Area 
X10
5
 
Rt 
E1 
Rt 
E2 
% RRT 
E1 
RRT 
E2 
Res. 
Non-stressed 
standard 
0.25 100.00 23.01 1 2.5 50.06 2.56 0.2 0.24 4.1 ND - - - - ND -  - -  - 
Base 0.25 3.87 0.89 4 2.5 13057 2.5 67 0.25 2.4 ND - - - - ND -  - -  - 
Acid  0.25 99.60 22.92 1 2.5 ND - - - - ND - - - - ND -  - -  - 
Heat 0.25 83.65 19.25 4 2.5 2040 2.24 9.2 0.22 2.1 743 11.6 3.4 1.15 2.1 ND -  - -  - 
Light  0.25 78 18.01 4 2.5 367 2.37 1.6 0.22 2.7 144 12 0.64 1.15 2.2 37.6 17.7 21.6 16.8 1.67 2.05 4.1 
Refrigerator 
24 hrs. 
0.25 101 23.3 2 2.5 220.8 2.4 0.93 0.22 3.8 166.4 12.2 0.7 1.15 2.2 ND - - - - - - 
Hydrogen 
Peroxide 
0.25 20 4.6 4 2.46 1374 2.5 8.7 0.25 3.4 ND - - - - ND - - - - - - 
Room temp. 
24 hrs. 
0.25 96 22.16 2 2.5 729.52 2.37 3.12 0.23 3.6 333 12.1 1.43 1.15 2.2 N.D - - - - - - 
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             Table 4.28: CFA Interference with degradation products (continued)                       
 
*Degradation product 5 
**Degradation product 6 
 
 
 
Secondary Peaks Detected 
 Degradant  1 Degradant  2 Degradant  3 Degradant  4 
Sample Area 
X103 
Rt % RRT Res. Area 
X103 
Rt % RRT Res. Area 
X103 
Rt % RRT Res. Area 
X103 
Rt % RRT Res. 
Base 1249.4 4.3 6.5 0.45 7.2 3541.7 5.42 18.3 0.563 3.16 565.6
** 15 2.9 1.54 8.1 - - - - - 
Acid  ND - - - - ND - - - - ND - - - - ND - - - - 
Heat 118 4.9 0.52 0.48 8.5 162.5 5.57 0.73 0.554 1.78 ND - - - - ND - - - - 
Light  - - - - - - - - - - - - - - - - - - - - 
Refrigerator 
24 hrs. 
ND - - - - ND - - - - ND - - - - ND - - - - 
H2O2 
*4404.4 6.9* 28* 0.7* 2.3* ND - - - - 134 5.3 0.85 0.54 10 4521 6 28.5 0.61 1.95 
Room 
temp. 
24hrs 
N.D - - - - ND - - - - 87.74 4.99 0.37 0.48 8.9 ND - - - - 
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4.5.1.5 Limit of Detection and Limit of Quantitation: 
LOD and LOQ for the analytical method were determined based on finding the Standard 
Deviation of the Response and the Slope and calculating the limits using the following equations: 
LOD =    3.3 σ / S 
LO Q = 10 σ / S 
The SD was found to be 460.81 and the slope was found to be 120375000. The LOD was 
calculated to be 1.3 X 10
-5
 and LOQ was found to be 3.8 X 10
-5
.                                                                                         
Table 4.29: Summary results of dilutions and response for LOD & LOQ determination 
Concentration (mg CFA/ml) Average Peak Area (A & B) S/N (A) S/N (B) 
0.0001 35376 4.2 0.97 
0.00025 29737 5.87 4.15 
0.0005 82006 4.86 5.15 
0.001 149019 14 15.3 
0.01 1221087 117.7 124.3 
SD 460.81 
 
  
Figure 4.31: Calibration curve obtained for LOD & LOQ determination
y = 120375x + 18.156 
R² = 0.9995 
0
200
400
600
800
1000
1200
1400
0 0.005 0.01 0.015
A
re
a
 X
 1
0
3
 
Conc (mg/100ml) 
LOD & LOQ 
 132 
 
4.5.2  Dissolution method validation 
The method was validated according to USP category IV guidelines for. As the guidelines 
require; the accuracy, precision, specificity, and linearity are assessed in order to ensure that the 
method is reliable.  
4.5.2.1 Linearity 
Linearity was assessed by analyzing six standard sample solutions of different concentrations. 
The calibration curve was plotted in order to establish whether a correlation between response 
and analyte concentration existed. A typical calibration curve obtained for these studies is 
depicted in Figure 4.32. The linearity of the method was established from the correlation 
coefficient (R
2
) of the best fit least squares linear regression  curve, which was obtained by 
plotting peak areas versus known CFA concentrations. For these studies, an R
2
 value of > 0.980 
was considered appropriate to demonstrate the linearity of the analytical method. The calibration 
curve was found to be linear over the concentration range stated, with an R
2
 of 0.9993 and the 
equation for the line of y = 156.7x + 2.293. 
Table 4.30: Linearity results of dissolution method validation 
Conc. % St. Conc. 
mg/ml 
Absorbance 
1 
Absorbance2 Absorbance3 Average RSD 
25% 0.00347 
159.1 158.8 158.7 
158.8 
0.11 
50% 0.00694 
314.9 315.2 317.3 
315.8 
0.34 
75% 0.01041 
478 480.1 475.5 
477.8 
0.39 
100% 0.01388 
629.2 629.5 631.3 
630 
0.15 
120% 0.016656 
770.6 773.7 769.9 
771.4 
0.21 
150% 0.02082 
951.5 952.1 950.7 
951.4 
0.06 
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Figure 4.32: Linearity graph for dissolution method validation 
 
4.5.2.2 Accuracy 
The percentage CFA recovered from spiked placebo samples for three concentrations, i.e. 50, 
100, 150 % respectively was calculated in addition to the % RSD of the three readings of each 
spiked sample. An acceptance criterion for accuracy was considered to be a recovery of 
100+5.0% and % RSD ≤2. The results obtained are clarified in table 4.31 and figure 4.33. The 
resultant values for % RSD and recovery satisfied the criteria and the plot of absorbance vs. 
concentration were found linear with an R
2
 value of 0.9999.  
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Table 4.31: Accuracy results of dissolution method validation 
No. of 
injectio
n 
Target 
Conc. 
(%) 
Theo. Conc. 
(mg / ml) 
Conc. after 
Spiking (mg/ml) 
Spiked Sample 
Response  
Recovery 
(%) 
Mean 
(%) 
RSD 
(%) 
1.1 
50% 
 
0.00694 
0.007088 312.4 102  
101.5 
 
0.42 1.2 0.007054 310.9 101.6 
1.3 
0.007157 309.2 101 
2.1 
100% 
 
0.01388 
0.01399 616.7 100.8  
101.3 
 
0.37 2.2 0.01409 621 101.5 
2.3 
0.01411 622.1 101.7 
3.1 
150% 
 
0.02082 
 
0.02127 937.7 102  
102 
 
0.07 3.2 
0.02127 937.7 102 
3.3 0.02131 936.4 102 
 
 
Figure 4.33: Accuracy regression curve for dissolution method validation 
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4.5.2.3 Precision: 
The precision is the ability of a method to produce precise analytical results from a series of 
measurements of the same homogenous sample under prescribed conditions. 
The standard deviation (SD) or percentage relative standard deviation (% RSD) of a series of 
measurements is usually used to assess the precision of an analytical method.  
The precision of the method was considered at repeatability level. A value for % RSD of < 4% 
was set as an acceptable limit 
The repeatability was determined by the analysis batch no. F06 for six times and samples were 
withdrawn at 30 and 60 min. The repeatability results obtained are shown in Table 4.32.The 
results reveal that % RSD values were within the acceptable limits thus the method is repeatable 
for the dissolution analysis of CFA suppositories. 
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Table 4.32: Dissolution method validation repeatability results 
Lot No. F06 
No. Time 
(min) 
% Dissolution Average RSD,% 
 
1 
30 
60 
387 
449 
379 
446 
359 
456 
370 
453 
358 
455 
389 
459 
374 
453 
3.3 
0.9 
 
2 
30 
60 
335 
439 
367 
456 
372 
447 
357 
438 
369 
463 
388 
457 
365 
450 
4.4 
2.0 
 
3 
30 
60 
360 
460 
372 
455 
375 
442 
362 
459 
377 
446 
386 
456 
371 
453 
2.1 
1.5 
 
4 
30 
60 
369 
437 
361 
457 
380 
446 
359 
463 
 
388 
449 
392 
459 
374 
452 
3.4 
1.9 
 
5 
30 
60 
372 
441 
365 
453 
378 
462 
 
387 
445 
367 
470 
358 
448 
371 
453 
2.5 
2.2 
 
6 
30 
60 
356 
432 
382 
457 
360 
443 
364 
442 
353 
450 
370 
461 
364 
448 
2.7 
2.2 
Avg. 30 
60 
 369.8 
451.5 
 
RSD,% 
30 
60 
 3.1 
1.8 
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4.5.2.4 Specificity: 
Six placebo formulations containing all the excipients used in the formulation were prepared, and 
the absorbance of these formulations was scanned over the wave length range 240-340 nm. The 
resultant scanning showed no absorbance for any of the placebo formulations which indicates 
that there isn’t any interference from the excipients in the dissolution results.  
Six sample suppository formulations were prepared, and the absorbance of these formulations 
was measured at λ = 278 nm. The percentage recovery was calculated for each formulation and 
the results were within the acceptable limits (i.e. 100 +5%) as shown in table 4.33.  
Table 4.33 percentage recovery from sample suppositories containing the different excipients 
used in suppository preparations 
Formula Abs. 1 Abs. 2 Abs. 3 Average % 
recovery 
% RSD 
F1 707 704 694 702 100.7 0.79 
F2 668 665 671 668 95.8 0.37 
F3 663 663 665 664 95.2 0.14 
F4 672 680 671 674 97 0.59 
F5 700 698 696 698 100.1 0.23 
F6 675 669 672 696.4 96.4 0.36 
 
Abs = Absorbance 
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Figure (4.34) placebo F1 scanning spectrum: 
 
Figure (4.35) placebo F2 scanning spectrum: 
 
      Figure (4.36) placebo F3 scanning spectrum: 
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Figure (4.37) placebo F4 scanning spectrum: 
 
 
Figure (4.38) placebo F5 scanning spectrum: 
 
 
Figure (4.39) placebo F6 scanning spectrum: 
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Part Five: 
Summary and Conclusions 
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CFA is a broad spectrum second generation cephalosporin antibiotic, active against β-lactamase 
producing bacterial strains. It is demonstrated to be active against gram-positive and gram-
negative organisms. CFA is marketed as a powder for oral suspension in 125mg and 250 mg per 
5ml strengths, and as tablet dosage form in 125mg, 250mg, and 500mg strengths. However CFA 
extreme bitterness limits its use to a wide spectrum of patients. Administration of CFA in a 
suppository dosage form may be a useful alternative for the treatment of the aforementioned 
diseases when patients, especially children are unwilling or unable to take oral medications. 
We attempted to formulate CFA suppositories in two main types of suppository bases, i.e. water 
soluble and fatty bases. PEG bases were used as the water-soluble bases, while Witepsol H15 
and Novata (A and BCF) were used as fatty bases. The suppositories were prepared by the fusion 
method of manufacture and were assessed in terms of their physical appearance, weight 
uniformity, melting range, disintegration time, CFA content, and dissolution behavior. The PEG 
water soluble bases were excluded from the study at the preformulation stage as they showed 
incompatibilities with the CFA active material.  
The displacement values for Witepsol H15 and Novata A and BCF suppository bases were found 
to be less than one (0.811-0.936), therefore the API quantity (125 mg cefuroxim base) has no 
significant effect on the quantity of fatty base required for one suppository. 
For the quantitation of CFA in suppositories dosage form an HPLC method was adapted from 
the USP monograph for CFA tablets and was validated according to USP category I and the ICH 
Q2 (R1) guidelines. The method was found to be linear over the concentration range of 25 μg / 
ml to 400 μg / ml with a correlation coefficient (R2) of 0.9999.  The resultant % RSD values for 
the method precision at the two levels; repeatability and intermediate precision  were found to be 
≤ 1.5% RSD for all concentrations studies. The method was also found to be accurate with 
%RSD values of ≤ 2% and recovery of 100 + 2%. In addition the method was considered 
selective for the detection and quantitation of CFA in the presence of formulation excipients and 
degradation products, thus the method can also be considered as stability indicating.  
In vitro dissolution testing was performed on all batches using USP apparatus I with modified 
baskets. The method was validated according to USP category III guidelines. The method was 
found to be linear over the concentration range of 3.5 μg / ml to 21 μg / ml with a correlation 
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coefficient (R
2
) of 0.9998. The resultant % RSD values for the method repeatability were found 
to be ≤ 4% RSD for all concentrations studied. The method was also found to be accurate with 
%RSD values of ≤ 2% and recovery of 100 + 2%. The method was found to be selective for the 
detection of CFA in the presence of all formulation excipients. 
In the preformulations stage CFA suppositories were compounded with WH15 and Novata 
A/BCF fatty bases alone and with surfactants and physical properties modifiers (i.e. Tween 20, 
Tween 80, Tween 85, SLS, lanolin anhydrous and lecithin S, Poloxamer 188, Cremophore A6, 
Cremophore RH 40, and Span 80). Tween 80, Cremophore A6, Cremophore RH 40 were found 
to be incompatible with CFA. Poloxamer 188 and Span 80 were also excluded as they had no 
significant added value to the performance of CFA suppositories.      
 The fatty base, Witepsol H15 was selected as the base for further studies, since it showed better 
viscosity during compounding, relatively low melting range temperatures and lead to finished 
suppositories with low disintegration times compared to Novata bases..  
The suppository formulations were assessed initially for their performance: Physical appearance, 
weight uniformity, melting ranges, disintegration time, dissolution, and CFA content and 
impurities. All suppositories had a smooth and opaque appearance; however the colour ranged 
between white, off white to pale yellow as per the additive type. The weight uniformity was 
found to comply with the BP requirements for suppositories (i.e. %RSD <5.0).   The melting 
points for formulations containing Aerosil in 0.1% concentration, as a suspending agent were 
found to be higher than the target temperature (NMT 37.5
o
C), while the other additives except 
SLS were found to reduce the melting points below 37
o
C.  
The disintegration times of suppositories complied with BP requirements. The addition of 
Lecithin, Lanolin and/or Tween 85 decreased the melting point and as a result the disintegration 
time decreased accordingly. 
All formulations exhibited an acceptable CFA content except those containing Tween 20 which 
underwent hydrolysis to form free cefuroxim and the Δ3Isomer due to the presence of hydroxyl 
groups in the surfactant. 
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The release rate of CFA from the formulation containing the active material and the suppository 
base alone was found to be very slow (i.e. not more than 10% in 180 minutes). This is due to the 
high lipophilicity of CFA, to the low hydroxyl value of WH 15 base and to the relatively high 
melting point. The CFA release was modified by adding surfactants and physical properties 
modifiers (i.e. Tween 20, SLS, lanolin anhydrous, Aerosil and lecithin S) in different 
concentrations and combinations.   
The use of Flow through Cell for dissolution testing instead of the USP apparatus I modified 
basket, increased the percentage release rate significantly for all formulations tested in 60 
minutes duration time. As a comparison, the maximum release from the formulation containing 
the suppository base (WH 15) only approached 68% in 60 minutes compared to 8% in 180 
minutes using USP apparatus I. These results ascertain that the flow through cell apparatus is 
more suitable for the use in poorly soluble drugs than the conventional static method (Farrugia, 
2002)   
The release data obtained from in vitro release studies were fitted to various mathematical 
models, such as the Zero order, First order, Higuchi, and Weibull models. In addition, the 
mechanism of CFA release from fatty suppositories was evaluated using the Korsmeyer- Peppas 
model. The drug release mechanism can be considered to occur primarily by means of 
anomalous transport kinetics, which is an indication of the presence of more than one type of 
release phenomenon. These findings were not entirely unexpected, due to the complexity of the 
drug release process from suppositories, which involves a series of consecutive steps, such as 
melting, drug partitioning and diffusion through the molten base to the hydrophilic dissolution 
medium. For most of the formulations tested, the data were best fitted to the Weibull model, This 
result is in agreement with the nature of drug release from lipophilic suppository formulations 
which is often accompanied by long-lasting lag phase, that occurs as a result of the need for the 
base to melt prior to drug release and therefore the melting rate of the base is a factor that 
contributes to the lag time. Six formulations fitted to the Higuchi model indicating that diffusion 
is one of the primary mechanisms governing drug release from the lipophilic suppository 
formulations tested. 
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The results from the preliminary stability studies for the selected formulations revealed that there 
was a significant decrease in the dissolution at 30
o
C/60%RH. All formulations containing Tween 
20 failed the stability acceptance criteria for assay and degradation impurities. The Δ3Isomer 
increased significantly at 30
o
C/60%RH and slightly at 25
o
C/60%RH. Change in color was 
observed at 30
o
C/60%RH and slightly changed at 25
o
C/60%RH. Sediments were observed at 
30
o
C/60%RH and at 25
o
C/60%RH for formulations containing Tween85. Storage at 2-8
o
C 
revealed a stability of all parameters for three months. Long-term stability studies are crucial to 
ensure that effective antimicrobial activity is retained in such products when stored under 
specified storage conditions. Therefore, CFA suppositories should be stored in refrigerator.  
Despite the apparent complexity of suppository formulations, these studies have shown the 
applicability of using fatty bases for the formulation of CFA suppository dosage forms for 
pediatric use. It has been observed that the use of surfactant in combination with fatty base can 
improve the release of CFA from such suppositories.  Further studies should be conducted to 
elucidate any potential interactions between CFA and the specific excipients used. Analytical 
methods, such as DSC, can be used to investigate drug/excipient incompatibility and would be of 
value when undertaking these investigations. Also further studies must be conducted on the basis 
of determining drug partitioning in the presence of suppository base-rectal fluid systems, to 
further elucidate and/or predict the process of drug release. It would be necessary to determine 
the in vivo bioavailability of CFA, of the suppository dosage forms prior to determining whether 
an in vitro-in vivo correlation exists for CFA following administration of a rectal suppository 
formulation.   
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6. Excipients profile 
6.1 Witepsol H15 (Raymond C., et al, 2006), (EurP., 2002) 
Definition: 
Hard Fats are mixture of triglycerides, diglycerides and monoglycerides, which may be obtained 
either by esterification of fatty acids of natural origin with glycerol or by transesterification of 
natural fats. It contains no added substances. 
Empirical Formula and Molecular Weight: 
Hard fat suppository bases consist mainly of mixtures of the triglyceride esters of the higher 
saturated fatty acids (C8H17COOH to C18H37COOH) along with varying proportions of mono- 
and diglycerides. Special grades may contain additives such as beeswax, lecithin, polysorbates, 
ethoxylated fatty alcohols, and ethoxylated partial fatty glycerides. 
Structural Formula: 
 
 
Where R = H or OC- (CH2)n-CH3; n = 7–17 
Not all Rs can be H at the same time. 
Applications in Pharmaceutical Formulation: 
The primary application of hard fat suppository bases, or semisynthetic glycerides, is as a vehicle 
for the rectal or vaginal administration of a variety of drugs, either to exert local effects or to 
achieve systemic absorption. 
Characters: 
Appearance: white or almost white, waxy, brittle mass. 
Solubility: practically insoluble in water, slightly soluble in anhydrous ethanol. 
When heated to 50 °C, it melts giving a colourless or slightly yellowish liquid. 
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Typical properties: 
Characteristic values Limits 
Ascending melting point 
o
C 33.5-35.5 
Hydroxyl value mg KoH/g 5-15 
Acid value mg KoH/g <0.2 
Iodine value g I2/100g <3.0 
Peroxide value meq./kg <1.0 
Saponification value mg KoH/g 230-245 
Alkaline impurities ml HCL/2g <0.15 
Heavy metals ppm <10 
Ash <0.05 
Unsaponifiable matter <0.3 
 
Safety 
Suppository bases are generally regarded as nontoxic and nonirritant materials when used in 
rectal formulations. However, animal studies have suggested that some bases, particularly those 
types with a high hydroxyl value, may be irritant to the rectal mucosa. 
Handling and Storage:  
Dry, protected from light, in original containers and at temperatures below 25°C, shelf life is at 
least three years. 
6.2 Lecithin (Raymond C., et al, 2006), (BP, 2011)  
Lecithin is a complex mixture of acetone-insoluble phosphatides, which consist chiefly of 
phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, and phosphatidyl inositol, 
combined with various amounts of other substances such as triglycerides, fatty acids, and 
carbohydrates, as separated from the crude vegetable oil source. It contains not less than 50.0 
percent of acetone-insoluble matter. 
Empirical Formula:  
The composition of lecithin (and hence also its physical properties) varies enormously depending 
upon the source of the lecithin and the degree of purification. Egg lecithin, for example, contains 
 69% phosphatidylcholine and 24% phosphatidylethanolamine, while soybean lecithin contains 
21% phosphatidylcholine, 22% phosphatidylethanolamine, and19% phosphatidylinositol, along 
with other components. 
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Structural Formula: 
 
 
R
1
 and R
2
 are fatty acids, which may be different or identical. 
The structure above shows phosphatidylcholine, the principal component of egg lecithin, in its a-
form. In the b-form, the phosphorus-containing group and the R
2
 group exchange positions. 
Functional Category: 
Lecithin is mainly used as emollient, emulsifying agent and solubilizing agent. 
Description: 
Lecithins vary greatly in their physical form, from viscous semi liquids to powders, depending 
upon the free fatty acid content. They may also vary in color from brown to light yellow, 
depending upon whether they are bleached or unbleached or on the degree of purity. When they 
are exposed to air, rapid oxidation occurs, also resulting in a dark yellow or brown color. 
Lecithins have practically no odor. Those derived from vegetable sources have a bland or nutlike 
taste, similar to that of soybean oil. 
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 Pharmacopoeia Specifications: 
 
 
Incompatibilities: 
Lecithin is incompatible with esterases owing to hydrolysis.  
Applications in Pharmaceutical Formulation: 
 Lecithins are used in a wide variety of pharmaceutical applications. They are also used in 
cosmetics and food products. 
 Lecithins are mainly used in pharmaceutical products as dispersing, emulsifying, and 
stabilizing agents and are included in intramuscular and intravenous injections, parenteral 
nutrition formulations, and topical products such as creams and ointments. 
 Lecithins are also used in suppository bases, to reduce the brittleness of suppositories, 
and have been investigated for their absorption-enhancing properties in an intranasal 
insulin formulation. 
 Lecithins are also commonly used as a component of enteral and parenteral nutrition 
formulations. 
 Liposomes in which lecithin is included as a component of the bilayer have been used to 
encapsulate drug substances; their potential as novel delivery systems has been 
investigated. 
 Therapeutically, lecithin and derivatives have been used as a pulmonary surfactant in the 
treatment of neonatal respiratory distress syndrome. 
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Stability and Storage Conditions: 
Lecithins decompose at extreme pH. They are also hygroscopic and subject to microbial 
degradation. When heated, lecithins oxidize, darken, and decompose. Temperatures of 160–1808 
o
C will cause degradation within 24 hours. 
 
Packaging and storage: Preserve in well-closed, light-resistant containers. Store at the 
temperature indicated on the label. Protect from excess heat and moisture.  
6.3 Lanolin (EurP., 2002), (Raymond C., et al, 2006), (USP34, 2010)  
Definition: 
Purified, anhydrous, waxy substance obtained from the wool of sheep (Ovis Aries). It may 
contain no more than 200 ppm of butylhydroxytoluene. 
Characteristics: 
Appearance: yellow, unctuous substance. When melted, it is a clear or almost clear, yellow 
liquid. A solution in light petroleum is opalescent. 
Solubility: freely soluble in benzene, chloroform, ether, and petroleum spirit; sparingly soluble in 
cold ethanol (95%), more soluble in boiling ethanol (95%); practically insoluble in water. 
It has a characteristic odour.  
Empirical Formula:  
It contains not more than 0.25% w/w of water and may contain up to 0.02% w/w of a suitable 
antioxidant; the PhEur 2005 specifies up to 200 ppm of butylated hydroxytoluene as an 
antioxidant. 
Functional Category: 
Lanolin is used as emulsifying agent; ointment base. 
 Applications in Pharmaceutical Formulation: 
 
 Lanolin is widely used in topical pharmaceutical formulations and cosmetics. 
 Lanolin may be used as a hydrophobic vehicle and in the preparation of water-in-oil 
creams and ointments. 
 When mixed with suitable vegetable oils or with soft paraffin, it produces emollient 
creams that penetrate the skin and hence facilitate the absorption of drugs.  
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 Lanolin mixes with about twice its own weight of water, without separation, to produce 
stable emulsions that do not readily become rancid on storage. 
 
 
 Pharmacopoeia Specifications: 
Test Specifications 
Melting range  
Loss on drying 
Sulfated ash  
Chloride 
Acid value 
Iodine value  
Peroxide value  
Saponification value  
Paraffin  
 
Butylated hydroxytoluene 
38-44
o
C 
≤0.5% 
≤0.15% 
≤150 ppm 
≤1.0 
18-36 
≤20 
90-105 
≤1.0 
≤200 ppm 
 
Stability and Storage Conditions: 
Lanolin may gradually undergo autoxidation during storage. To inhibit this process, the inclusion 
of butylated hydroxytoluene is permitted as an antioxidant. Exposure to excessive or prolonged 
heating may cause anhydrous lanolin to darken in color and develop a strong rancid like odor. 
However, lanolin may be sterilized by dry heat at 1508
o
C. Ophthalmic ointments containing 
lanolin may be sterilized by filtration or by exposure to gamma irradiation. 
Lanolin should be stored in a well-filled, well-closed container protected from light, in a cool, 
dry place. Normal storage life is 2 years. 
Incompatibilities: 
Lanolin may contain prooxidants, which may affect the stability of certain active drugs. 
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6.4 Polysorbate 85 (Tween 85) (EurP., 2002), (Raymond C., et al, 2006) 
Chemical name: Polyoxyethylene 20 sorbitan trioleate. CAS number [9005-5-70-3] 
Definition: 
Mixture of partial esters of fatty acids, mainly Oleic acid (0799), with sorbitol and its anhydrides 
ethoxylated with approximately 20 moles of ethylene oxide for each mole of sorbitol and sorbitol 
anhydrides. 
Characters: 
Appearance: oily, yellowish or brownish-yellow, clear or slightly opalescent liquid. 
Solubility: dispersible in water, in anhydrous ethanol, in ethyl acetate and in methanol, 
practically insoluble in fatty oils and in liquid paraffin. 
Empirical Formula and Molecular Weight: 
Polysorbate 85, Formula C100H188O28, Molecular weight= 1839 
Structural Formula: 
 
 
                       Polyoxyethylene sorbitan triester 
w + x + y + z = 20 (Polysorbates 20, 40, 60, 65, 80, and 85) 
R = fatty acid 
Functional Category: 
 Polysorbate 85 is used as emulsifying agent; nonionic surfactant; solubilizing agent; wetting, 
dispersing/suspending agent. 
 Applications in Pharmaceutical Formulation: 
Polysorbates containing 20 units of oxyethylene are hydrophilic nonionic surfactants that are 
used widely as emulsifying agents in the preparation of stable oil-in-water pharmaceutical 
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emulsions. Polysorbate 85 is used as an emulsifier in combination with a variety of oil in water, 
and water in oil emulsion systems. 
Individually, it is an excellent solubilizer of vegetable oils and fragrances, a wetting agent, 
viscosity modifier, stabilizer and dispersing agent. It is useful for oil-in-water emulsions and to 
make anhydrous ointments water soluble washable. 
Polysorbates are also widely used in cosmetics and food products.  
Typical properties: 
Physical form at 25
o
C:       Yellow liquid   
HLB:                                  11 
Solubility:                          Vegetable oil, water and mineral oils 
Specific Gravity at 25
o
C:   1.03 
Specifications: 
Saponification value:                     80-90 
Hydroxyl value:                             39-52 
Acid value:                                    <2.0 
Water:                                           <0.5% 
Surface tension at 208C (mN/m): 41.0 
Incompatibilities: 
Discoloration and/or precipitation occur with various substances, especially phenols, tannins, 
tars, and tarlike materials. The antimicrobial activity of paraben preservatives is reduced in the 
presence of polysorbates. 
Stability and Storage Conditions: 
Polysorbates are stable to electrolytes and weak acids and bases; gradual saponification occurs 
with strong acids and bases. The oleic acid esters are sensitive to oxidation. Polysorbates are 
hygroscopic and should be examined for water content prior to use and dried if necessary. Also, 
in common with other polyoxyethylene surfactants, prolonged storage can lead to the formation 
of peroxides. Polysorbates should be stored in a well-closed container, protected from light, in a 
cool, dry place. 
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6.5 Sodium Lauryl Sulfate (Raymond C., et al, 2006) 
Chemical Name and CAS Registry Number: 
Sulfuric acid monododecyl ester sodium salt [151-21-3] 
 Empirical Formula and Molecular Weight: C12H25NaO4S,               288.38 
The USPNF describes sodium lauryl sulfate as a mixture of sodium alkyl sulfates consisting 
chiefly of sodium lauryl sulfate (C12H25NaO4S). The PhEur states that sodium lauryl sulfate 
should contain not less than 85%of sodium alkyl sulfates calculated as C12H25NaO4S. 
 
 
 
 Structural Formula: 
 
 
Functional Category: 
 Used as anionic surfactant; detergent; emulsifying agent; skin penetrant; tablet and capsule 
lubricant; wetting agent. 
 Applications in Pharmaceutical Formulation: 
Sodium lauryl sulfate is an anionic surfactant employed in a wide range of nonparenteral 
pharmaceutical formulations and cosmetics. It is a detergent and wetting agent effective in both 
alkaline and acidic conditions. In recent years it has found application in analytical 
electrophoretic techniques: SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresis is 
one of the more widely used techniques for the analysis of proteins; and sodium lauryl sulfate 
has been used to enhance the selectivity of micellar electrokinetic chromatography. 
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Uses of sodium lauryl sulfate: (Raymond, 2006) 
 
Use Concentration % 
Anionic emulsifier, forms self-emulsifying bases with 
fatty alcohols 
0.5–2.5 
Detergent in medicated shampoos ≈ 10 
Skin cleanser in topical applications 1 
Solubilizer in concentrations greater than critical 
micelle concentration 
˃ 0.0025 
Tablet lubricant  
 
1.0-2.0 
Wetting agent in dentifrices 1.0-2.0 
 
Description: 
Sodium lauryl sulfate consists of white or cream to pale yellow colored crystals, flakes, or 
powder having a smooth feel, a soapy, bitter taste, and a faint odor of fatty substances. 
Typical Properties: 
Acidity/alkalinity: pH = 7.0–9.5 (1% w/v aqueous solution) 
Acid value: 0 
Antimicrobial activity: sodium lauryl sulfate has some bacteriostatic action against Gram-
positive bacteria but is ineffective against many Gram-negative microorganisms. It potentiates 
the fungicidal activity of certain substances such as sulfanilamide and sulfathiazole. 
Critical micelle concentration: 8.2mmol/L (0.23 g/L) at 20
o
C 
Density: 1.07 g/cm3 at 20 
o
C 
HLB value: ≈ 40 
Interfacial tension: 11.8mN/m (11.8 dynes/cm) for a 0.05% w/v solution (unspecified non 
aqueous liquid) at 30
o
C. 
Melting point: 204–207oC (for pure substance) 
Moisture content: 45%; sodium lauryl sulfate is not hygroscopic. 
Solubility: freely soluble in water, giving an opalescent solution; practically insoluble in 
chloroform and ether. 
Surface tension: 25.2mN/m (25.2 dynes/cm) for a 0.05% w/v aqueous solution at 30
o
C 
 
 156 
 
Stability and Storage Conditions: 
Sodium lauryl sulfate is stable under normal storage conditions. However, in solution, under 
extreme conditions, i.e., pH 2.5 or below, it undergoes hydrolysis to lauryl alcohol and sodium 
bisulfate. 
The bulk material should be stored in a well-closed container away from strong oxidizing agents 
in a cool, dry place. 
Safety: 
Sodium lauryl sulfate is widely used in cosmetics and oral and topical pharmaceutical 
formulations. It is a moderately toxic material with acute toxic effects including irritation to the 
skin, eyes, mucous membranes, upper respiratory tract, and stomach. Repeated, prolonged 
exposure to dilute solutions may cause drying and cracking of the skin; contact dermatitis may 
develop. 
Prolonged inhalation of sodium lauryl sulfate will damage the lungs. Pulmonary sensitization is 
possible, resulting in hyperactive airway dysfunction and pulmonary allergy. 
Sodium lauryl sulfate should not be used in intravenous preparations for humans. The probable 
human lethal oral dose is 0.5–5.0 g/kg. 
Incompatibilities: 
Sodium lauryl sulfate reacts with cationic surfactants, causing loss of activity even in 
concentrations too low to cause precipitation. Unlike soaps, it is compatible with dilute acids and 
calcium and magnesium ions. 
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 تطوير وتقييم مخبري لمستحضر السيفيوروكسيم آكسيتل على شكل تحاميل شرجية للاطفال
 إعداد: محمد المحاريق
 المشرف: د. نعمان مالكية
 المشرف المشارك: د. طارق الجعبة
 
 الملخص
 
 
سيفوروكسيم آكسيتل مضاد حيوي واسع الطيف من الجيل الثاني من السيفالوسبورينات، فعال ضد طائفة واسعة من مسببات 
دواء على شكل مسحوق صلب معلق واقراص تعطى الامراض الشائعة، بما في ذلك منتجات "البيتالاكتميز". يتم تسويق ال
من قبل مجموعة واسعة من  اللمرضى عن طريق الفم. مادة السيفوروكسيم آكسيتل شديدة المرارة مما يحد من استخدامه
المرضى وعليه فان إعطاء الدواء على شكل تحاميل قد يكون بديًلا مقبوًلا لدى المرضى أكثر من الاشكال الصيدلانيه عن 
طريق الفم خصوصًا لدى الاطفال وكبار السن الذين يجدون صعوبة في ابتلاع الاقراص او تذوق المرارة الشديدة عن 
 على شكل معلق.طريق تناول المستحضر 
لقد تم تشكيل تحاميل سيفوروكسيم أكسيتل باستخدام طريقة الانصهار، حيث استخدم في ذلك نوعان من قواعد تشكيل 
التحاميل أحدهما تذوب في الماء والاخرى دهنية لا تذوب في الماء. حيث تم استخدام مادة "البولي أيثيلين جلايكول" 
تم  " كقواعد دهنية.FCBونوفاتا  A" و "نوفاتا 51Hاء واستخدمت مادتي " وايتبسول بتدرجات مختلفة كقاعدة تذوب في الم
استبعاد مادة البولي ايثيلين جلايكول منذ بداية الدراسة وذلك لظهور تعارض بينها وبين مادة السيفوروكسيم آكسيتل. 
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" 51Hوجود أفضلية لمادة "وايتبسول وكنتيجة للفحوصات التي اجريت للمستحضر في المراحل الاوليه من الدراسة تبين 
" في الدراسة 51Hعلى مادة نوفاتا من حيث درجة الانصهار ومعدل تحرر المادة الفعالة, لذا استخدمت مادة "وايتبسول 
تم تقييم التحاميل المصنعة من خلال عدة فحوصات تم اجراؤها على هذه  كقاعدة لتشكيل التحاميل بتراكيبها المختلفة.
حيث اشتملت على الفحص الحسي، فحص تجانس الوزن، فحص زمن التفتت، تركيز المادة الفعالة، دراسة  التحاميل,
لقد وجد من نتائج الفحوصات بأن معدل تحرر المادة الفعالة من المستحضر تتأثر بشكل  الذوبان الرطب ودراسة الثباتية.
لقلة ذائبية المستحضر في المحاليل المائية  وميله للطبقة مباشر بالخواص الفيزيوكيميائية مثل درجة انصهار التحاميل. و
الزيتية فإن توزعه بين الجزء المائي والزيتي كان يميل بشكل كبير وواضح نحو الطبقة الزيتية مما كان له الاثر الكبير 
 على تأخير تحرر المادة الفعالة من المستحضر الى الجزء المائي.
لاجراء الدراسة عليها، حيث تم استخدام مخفضات التوتر السطحي ومحسنات  تم تحضير ستة عشر تركيبة مختلفة
، صوديوم لوريل سلفات، لانولين وليسيتين الصويا) بنسب مختلفة وكنتيجة لذلك طرأ 58، توين  02الانصهار (مثل توين 
%  من 8لم تتعدى  نسبة التحرر , علما بأن فيها استخدمتزيادة بشكل ملحوظ على تحرر المادة الفعالة من التراكيب التي 
تم دراسة وتقييم آلية تحرر المادة الفعالة من المستحضر باستخدام نماذج رياضية عدة منها،  دون استخدام هذه الاضافات.
باباس، معادلة من الدرجة الصفرية، معادلة من الدرجة الاولى ونموذج ويبول. لوحظ من هذا -ايرمهيجونشي، كورس 
فعالة من المستحضر تخضع بشكل واضح ومميز الى نموذج ويبل، كورسماير باباس لة تحرر المادة االتطبيق بأن آلي
كان نتاجًا لخاصية الانتشار ولمعدل انصهار  تفيد بأن تحرر الدواء التي تم حسابها "n" ونموذج هيجوتشي، وأن قيم
 المستحضر ولتجزأة المادة الفعالة بين الوجه الزيتي والوجه المائي، وعليه فإن تحرر المادة الفعالة يمكن ان يوصف بالشاذ 
وهي هور، حيث وضع عدد مختار من التشغيلات في ثلاثة ظروف تخزين (شتم اجراء دراسة ثباتية للمستحض لمدة ثلاثة 
م). أفادت النتائج بأن غالبية o8 - 5% رطوبة نسبية، 60م/o60% رطوبة نسبية، درجة حرارة 60م/o25درجة حرارة 
م) ومعظمها كان غير ثابتًا على درجة حرارة o8 - 5التركيبات من المستحضر وجدت ثابتة على درجة حرارة الثلاجة (
 .مo60م و o25
